PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 10411607-4 1999 5)decane-1,3-dione] hydrochloride (RS86) and the cholinesterase inhibitor physostigmine all decreased the percentage of avoidance responses at doses that produced less than approximately 30% response failures. Physostigmine 74-87 butyrylcholinesterase Rattus norvegicus 49-63 10370104-7 1999 An inhibitor of AChE, physostigmine, had no significant effect on the relaxations caused by EFS, while both the muscarinic receptor antagonist, atropine, and the muscarinic M2-receptor antagonist, AFDX 116, enhanced these responses. Physostigmine 22-35 acetylcholinesterase Ovis aries 16-20 10403635-14 1999 Both the phosphotriesterase and physostigmine treatments protected the brain AChE activities measured 24 h after sarin exposure. Physostigmine 32-45 acetylcholinesterase Mus musculus 77-81 10403635-15 1999 In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher sarin dose, respectively, was needed to cause a 50% inhibition of brain AChE activity. Physostigmine 26-39 acetylcholinesterase Mus musculus 149-153 10214735-8 1999 RESULTS: In an intent-to-treat population, the last observation carried forward analysis revealed a 2.9-point ADAS-Cog (p = 0.002) difference between physostigmine and placebo-treated patients for both dosages, and a 0.26 to 0.31-point difference on the CIBIC+ (p = 0.048). Physostigmine 150-163 alkylglycerone phosphate synthase Homo sapiens 110-114 10192824-2 1999 Physostigmine (PHYSO), a reversible cholinesterase inhibitor, was administered to normal women and men at a dose that elevated plasma ACTH1-39, cortisol, and arginine vasopressin (AVP) concentrations but produced few or no side effects. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 36-50 10192824-2 1999 Physostigmine (PHYSO), a reversible cholinesterase inhibitor, was administered to normal women and men at a dose that elevated plasma ACTH1-39, cortisol, and arginine vasopressin (AVP) concentrations but produced few or no side effects. Physostigmine 0-13 arginine vasopressin Homo sapiens 167-178 10372954-1 1999 We have reported that physostigmine, a reversible cholinesterase inhibitor, enhances verbal memory in patients with Alzheimer disease (AD). Physostigmine 22-35 butyrylcholinesterase Homo sapiens 50-64 10372954-6 1999 High-dose physostigmine infusion that produced noxious side effects resulted in significant elevation above baseline in plasma levels of adrenocorticotrophic hormone (ACTH) (p = 0.0001), cortisol (p = 0.0001), and beta-endorphin (p = 0.0001). Physostigmine 10-23 proopiomelanocortin Homo sapiens 167-171 10372954-6 1999 High-dose physostigmine infusion that produced noxious side effects resulted in significant elevation above baseline in plasma levels of adrenocorticotrophic hormone (ACTH) (p = 0.0001), cortisol (p = 0.0001), and beta-endorphin (p = 0.0001). Physostigmine 10-23 proopiomelanocortin Homo sapiens 214-228 10221754-4 1999 This increase is completely blocked by the specific AChE inhibitors propidium, physostigmine, DFP and BW 284C51. Physostigmine 79-92 acetylcholinesterase Rattus norvegicus 52-56 10366013-7 1999 Furthermore, the acetylcholinesterase inhibitor, physostigmine (50 microM), decreased the amplitude of the excitatory synaptic potentials, indicating that ambient acetylcholine can depress this potential. Physostigmine 49-62 acetylcholinesterase Rattus norvegicus 17-37 9887183-5 1999 Pretreatment with the nonspecific cholinesterase inhibitors physostigmine (0.1-0.2 mg/kg) or neostigmine (0.1 mg/kg) reduced the pressor response by diminishing the increase in systemic vascular resistance. Physostigmine 60-73 butyrylcholinesterase Rattus norvegicus 34-48 10637939-9 1999 Cholinergic drugs including cholinesterase inhibitors such as physostigmine, tacrine, velnacrine as well as the acetylcholine releaser linopiridine have been reported to increase the cerebral blood flow in AD patients both after acute and fairly short period of treatment. Physostigmine 62-75 butyrylcholinesterase Homo sapiens 28-42 9880090-6 1998 Other cholinesterase inhibitors, such as galantamine (galanthamine), metrifonate, physostigmine, eptastigmine, are currently under clinical evaluation. Physostigmine 82-95 butyrylcholinesterase Homo sapiens 6-20 9742217-1 1998 The role of the functional architecture of the human acetylcholinesterase (HuAChE) active centre in accommodating the non-covalent inhibitors tacrine and huperzine A, or the carbamates pyridostigmine and physostigmine, was analysed using 16 mutants of residues lining the active-centre gorge. Physostigmine 204-217 acetylcholinesterase (Cartwright blood group) Homo sapiens 53-73 10073483-2 1999 The present study determined whether systemically administered physostigmine, a cholinesterase inhibitor, alters the rat"s ability to discern among odorant mixtures. Physostigmine 63-76 butyrylcholinesterase Rattus norvegicus 80-94 9863767-5 1998 The relative blocking potency of the different AChE inhibitors was the same in all cell types, and followed the order parathion > physostigmine > PSP > paraoxon. Physostigmine 133-146 acetylcholinesterase Mus musculus 47-51 9863767-8 1998 Human nAChR in SH-SY5Y cells appeared more sensitive to block by physostigmine, PSP and paraoxon, while these AChE inhibitors similarly inhibited nicotinic currents in insect cells and in mouse neuroblastoma cells. Physostigmine 65-78 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 6-11 9863767-10 1998 Only in locust cells physostigmine induced a non-desensitizing inward current, that appeared to originate from nAChR activation. Physostigmine 21-34 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 111-116 10049139-2 1998 We investigated whether change in neuronal activity in cholinergic pathways mediates the anesthetic effect of the alpha2 agonist, dexmedetomidine, by determining whether physostigmine, a cholinesterase inhibitor, could antagonize the hypnotic response to dexmedetomidine in the rat and whether dexmedetomidine decreases the release of acetylcholine (ACh) in the thalamus in vivo. Physostigmine 170-183 butyrylcholinesterase Rattus norvegicus 187-201 11189211-9 1998 Physostigmine (0.2 mg/kg, s.c.), as a cholinesterase inhibitor significantly increased the ACh levels and reversed the anisodine-induced ACh decrease. Physostigmine 0-13 butyrylcholinesterase Mus musculus 38-52 9774528-2 1998 The present study examined the impact of the centrally active cholinesterase inhibitor physostigmine, which enhances memory and central cholinergic activity, on brief shock-induced hypoalgesia on the tail-flick test using Sprague-Dawley rats. Physostigmine 87-100 butyrylcholinesterase Rattus norvegicus 62-76 9642034-6 1998 On the other hand, the anticholinesterase, physostigmine, potentiated both the vasopressin-induced tonic and spontaneous contractions. Physostigmine 43-56 arginine vasopressin Homo sapiens 79-90 9767635-5 1998 Some of the newly synthesized derivatives, when tested on isolated and/or AChE-enriched rat brain cortex fraction, displayed a selective inhibitory activity and were more active than physostigmine. Physostigmine 183-196 acetylcholinesterase Rattus norvegicus 74-78 9778190-5 1998 Third, the sensitivity of [18F]FP-TZTP binding to changes in brain acetylcholine (ACh) was assessed by administering physostigmine, an acetylcholinesterase (AChE) inhibitor, by intravenous infusion (100 to 200 microg x kg(-1) x h(-1)) beginning 30 minutes before tracer injection (n = 7). Physostigmine 117-130 acetylcholinesterase Macaca mulatta 157-161 9675107-0 1998 Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine. Physostigmine 87-100 acetylcholinesterase (Cartwright blood group) Homo sapiens 30-50 9595284-14 1998 Both the GABAA and GABAB receptor antagonists reduced the learning improvement induced by physostigmine. Physostigmine 90-103 gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1 Mus musculus 9-14 9595284-22 1998 It is concluded that both GABAA and GABAB activation inhibit improvement of acquisition induced by physostigmine. Physostigmine 99-112 gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1 Mus musculus 26-31 9697967-5 1998 Three cholinesterase inhibitors, physostigmine, neostigmine, and edrophonium, suppressed the activity of the leading edges of the extending axons (the nerve growth cones) dose dependently. Physostigmine 33-46 butyrylcholinesterase Gallus gallus 6-20 9689457-4 1998 The rCBF response abolished by scopolamine was recovered by the administration of physostigmine, a cholinesterase inhibitor in a dose-dependent manner. Physostigmine 82-95 butyrylcholinesterase Homo sapiens 99-113 9447863-2 1998 Cholinergic stimulation of the hypothalamic-pituitary-adrenal axis and adrenal medulla by physostigmine enhances secretion of arginine vasopressin, epinephrine, and norepinephrine. Physostigmine 90-103 arginine vasopressin Homo sapiens 135-146 9568379-0 1998 Effects of hexamethonium, phenothiazines, propranolol and ephedrine on acetylcholinesterase carbamylation by physostigmine, aldicarb and carbaryl: interaction between the active site and the functionally distinct peripheral sites in acetylcholinesterase. Physostigmine 109-122 acetylcholinesterase (Cartwright blood group) Homo sapiens 71-91 9568379-0 1998 Effects of hexamethonium, phenothiazines, propranolol and ephedrine on acetylcholinesterase carbamylation by physostigmine, aldicarb and carbaryl: interaction between the active site and the functionally distinct peripheral sites in acetylcholinesterase. Physostigmine 109-122 acetylcholinesterase (Cartwright blood group) Homo sapiens 233-253 9568379-1 1998 Physostigmine, aldicarb and carbaryl were potent inhibitors of acetylcholinesterase (AChE). Physostigmine 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 63-83 9568379-1 1998 Physostigmine, aldicarb and carbaryl were potent inhibitors of acetylcholinesterase (AChE). Physostigmine 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 85-89 9568379-2 1998 The physostigmine-inhibited AChE fluoresced at 300 nm excitation and 500 nm emission wavelengths, but the aldicarb and carbaryl inhibited enzyme did not. Physostigmine 4-17 acetylcholinesterase (Cartwright blood group) Homo sapiens 28-32 9568379-4 1998 The fluorescence intensity of physostigmine-inhibited AChE decreased with increasing the substrate (acetylthiocholine) concentration, thus indicating that physostigmine binding to the active site is essential for the development of fluorescence. Physostigmine 30-43 acetylcholinesterase (Cartwright blood group) Homo sapiens 54-58 9568379-4 1998 The fluorescence intensity of physostigmine-inhibited AChE decreased with increasing the substrate (acetylthiocholine) concentration, thus indicating that physostigmine binding to the active site is essential for the development of fluorescence. Physostigmine 155-168 acetylcholinesterase (Cartwright blood group) Homo sapiens 54-58 9568379-5 1998 Thus, the physostigmine-inhibited AChE fluoresces due to the binding of trimethylpyrrolo[2,3-b]indol (TMPI) moiety, formed by the hydrolysis of physostigmine, to a peripheral site in AChE. Physostigmine 10-23 acetylcholinesterase (Cartwright blood group) Homo sapiens 34-38 9568379-5 1998 Thus, the physostigmine-inhibited AChE fluoresces due to the binding of trimethylpyrrolo[2,3-b]indol (TMPI) moiety, formed by the hydrolysis of physostigmine, to a peripheral site in AChE. Physostigmine 10-23 acetylcholinesterase (Cartwright blood group) Homo sapiens 183-187 9568379-5 1998 Thus, the physostigmine-inhibited AChE fluoresces due to the binding of trimethylpyrrolo[2,3-b]indol (TMPI) moiety, formed by the hydrolysis of physostigmine, to a peripheral site in AChE. Physostigmine 144-157 acetylcholinesterase (Cartwright blood group) Homo sapiens 34-38 9568379-5 1998 Thus, the physostigmine-inhibited AChE fluoresces due to the binding of trimethylpyrrolo[2,3-b]indol (TMPI) moiety, formed by the hydrolysis of physostigmine, to a peripheral site in AChE. Physostigmine 144-157 acetylcholinesterase (Cartwright blood group) Homo sapiens 183-187 9568379-12 1998 Hexamethonium protected AChE from inhibition by carbamates and decreased the fluorescence intensity of the physostigmine-inhibited AChE. Physostigmine 107-120 acetylcholinesterase (Cartwright blood group) Homo sapiens 131-135 21781849-3 1998 Centrally-active physostigmine was more toxic than centrally-inactive pyridostigmine and the toxic signs of carbamates appeared to be closely related to the level of inhibition of brain cholinesterase activity. Physostigmine 17-30 butyrylcholinesterase Mus musculus 186-200 9680262-8 1998 All of the compounds tested were at least several hundred times less potent than physostigmine as AChE inhibitors. Physostigmine 81-94 acetylcholinesterase Rattus norvegicus 98-102 10322906-0 1997 Physostigmine blocked nicotinic acetylcholine receptors in rat sympathetic ganglion neurons. Physostigmine 0-13 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 22-55 9429048-1 1997 PURPOSE: The bradycardia produced by pyridostigmine and physostigmine in an animal model of acute cardiac denervation was examined according to its relation to cholinesterase inhibition and sensitivity to block by cholinergic receptor antagonists. Physostigmine 56-69 butyrylcholinesterase Felis catus 160-174 9429048-7 1997 RESULTS: With pyridostigmine and physostigmine the dose-response relationship for the decrease in heart rate (ED50 1.05 +/- 0.25 and 0.198 +/- 0.03 mg.kg-1, respectively) was shifted to the right of that for the inhibition of cholinesterase activity (ED50 0.094 +/- 0.03 and 0.032 +/- 0.01 mg.kg-1, respectively). Physostigmine 33-46 butyrylcholinesterase Felis catus 226-240 9405519-4 1997 The effects of the afferent stimulus were greatly enhanced in CA1 neurons exposed to the catalytic AChE inhibitors neostigmine, physostigmine, or 9-amino-1,2,3, 4-tetrahydro-acridine. Physostigmine 128-141 carbonic anhydrase 1 Rattus norvegicus 62-65 9405519-4 1997 The effects of the afferent stimulus were greatly enhanced in CA1 neurons exposed to the catalytic AChE inhibitors neostigmine, physostigmine, or 9-amino-1,2,3, 4-tetrahydro-acridine. Physostigmine 128-141 acetylcholinesterase Rattus norvegicus 99-103 9399975-7 1997 When tested in animals pretreated with both omeprazole and physostigmine (a drug able to prevent the enzymatic breakdown of vagally released ACh through the blockade of acetylcholinesterase), 2-deoxy-D-glucose or electrical vagal stimulation significantly increased pepsinogen secretion without affecting acid secretion. Physostigmine 59-72 acetylcholinesterase Rattus norvegicus 169-189 9428657-0 1997 Long chain analogs of physostigmine as potential drugs for Alzheimer"s disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase. Physostigmine 22-35 acetylcholinesterase (Cartwright blood group) Homo sapiens 143-163 9500121-0 1997 Effects of BN-50730 (PAF receptor antagonist) and physostigmine (AChE inhibitor) on learning and memory in mice. Physostigmine 50-63 acetylcholinesterase Mus musculus 65-69 9500121-6 1997 These results suggest that BN-50730, a PAF receptor antagonist, produced retrograde amnesia and physostigmine attenuated BN-50730-induced amnesia possibly through increased concentration of cerebral acetylcholine and a consequent increase in PAF release. Physostigmine 96-109 platelet-activating factor receptor Mus musculus 39-51 10322906-1 1997 AIM: To study the blocking mechanism of physostigmine (Phy) on nicotinic acetylcholine receptors (NAChR) in sympathetic neurons. Physostigmine 40-53 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 63-96 10322906-1 1997 AIM: To study the blocking mechanism of physostigmine (Phy) on nicotinic acetylcholine receptors (NAChR) in sympathetic neurons. Physostigmine 40-53 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 98-103 10322906-1 1997 AIM: To study the blocking mechanism of physostigmine (Phy) on nicotinic acetylcholine receptors (NAChR) in sympathetic neurons. Physostigmine 55-58 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 63-96 10322906-1 1997 AIM: To study the blocking mechanism of physostigmine (Phy) on nicotinic acetylcholine receptors (NAChR) in sympathetic neurons. Physostigmine 55-58 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 98-103 20654340-3 1997 The nitromethylene heterocyclic insecticide WL145004 and physostigmine selectively agonize the insect type nAChR. Physostigmine 57-70 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 107-112 9267778-5 1997 Pretreatment of 0.1 mg/kg physostigmine, the cholinesterase inhibitor, changed neither the incidence (90%) nor latency to the onset of scopolamine-induced convulsions. Physostigmine 26-39 butyrylcholinesterase Mus musculus 45-59 9279214-7 1997 Physostigmine (0.1 mumol/L), an acetylcholinesterase inhibitor, reduced A23187-evoked histamine release by 58%. Physostigmine 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 32-52 9057895-2 1997 Physostigmine and N-methylcarbamate insecticides (BPMC = 2-sec-butylphenyl methylcarbamate and PHC = propoxur = 2-isopropoxyphenyl methylcarbamate) were employed as ChE inhibitors. Physostigmine 0-13 cholinesterase Oryctolagus cuniculus 165-168 9278976-10 1997 An additive blocking effect on partly curarized preparations was observed and cholinesterase inhibition by physostigmine (eserine) transiently augmented the muscle twitch contraction in preparations partly blocked by the extract. Physostigmine 107-120 butyrylcholinesterase Mus musculus 78-92 9249577-1 1997 The effects of intracerebroventricular administration of physostigmine, a cholinesterase inhibitor, on the cardiovascular responses evoked by static voluntary exercise were investigated using conscious cats. Physostigmine 57-70 butyrylcholinesterase Felis catus 74-88 9249577-5 1997 Administration of physostigmine did not alter the resting MAP and HR but attenuated the MAP and HR responses to exercise (5-30 min postphysostigmine: MAP = 8 +/- 3 mmHg, HR = 25 +/- 7 beats/min; 30-60 min postphysostigmine: MAP = 4 +/- 3 mmHg, HR = 19 +/- 8 beats/min). Physostigmine 18-31 microtubule associated protein 4 Felis catus 224-231 9246076-5 1997 Physostigmine, an acetylcholinesterase inhibitor, 0.7 mg/kg i.v., suppressed the amplitude of the responses more at V1 (suppression ratio: mean +/- SD, 85.4 +/- 9.3%) than at LGNd (32.4 +/- 30.7%) (P < 0.05). Physostigmine 0-13 acetylcholinesterase Felis catus 18-38 9190877-4 1997 The rCBF response abolished by pretreatment with scopolamine was recovered by administration of physostigmine (1 or 10 microg/kg), E2020 (10 or 100 microg/kg) or tacrine (100 or 1000 microg/kg), in a dose-dependent manner. Physostigmine 96-109 CCAAT/enhancer binding protein zeta Rattus norvegicus 4-8 9189894-4 1997 The increase in working memory errors induced by intrahippocampal administration of 0.32 microgram/side scopolamine to rats treated with 10 mg/kg propranolol was decreased by concurrent injection of the cholinesterase inhibitor physostigmine (3.2 micrograms/side). Physostigmine 228-241 butyrylcholinesterase Rattus norvegicus 203-217 9299207-6 1997 Diltiazem and nifedipine blocked the amphetamine induced facilitation of FSA, while verapamil blocked both amphetamine as well as physostigmine induced facilitation of FSA. Physostigmine 130-143 RIKEN cDNA 4932438A13 gene Mus musculus 168-171 9070622-1 1997 The effects of scopolamine, a muscarinic cholinergic receptor antagonist and physostigmine, a cholinesterase inhibitor, on the regional cerebral blood flow (rCBF) response to vibrotactile stimulation of the forepaw were studied in the brain of unanesthetized monkeys using 15O-labeled water and high resolution positron emission tomography. Physostigmine 77-90 CCAAT/enhancer binding protein zeta Rattus norvegicus 157-161 9070622-4 1997 The rCBF response abolished by scopolamine (50 microg/kg) was recovered by administration of physostigmine (10 microg/kg). Physostigmine 93-106 CCAAT/enhancer binding protein zeta Rattus norvegicus 4-8 9030907-4 1997 Acetylcholinesterase activity of adrenal homogenates was inhibited by tacrine and physostigmine in a concentration-dependent manner. Physostigmine 82-95 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 9062656-2 1997 AChE inhibitors, including physostigmine, E-2020, amiridin, tetrahydroaminoacridine (THA) and Nicergoline had a poor effect on AChE present in the senile plaque-rich fraction isolated from Alzheimer brain than that either in the soluble fraction of Alzheimer brain or in the control brain. Physostigmine 27-40 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-4 9035256-6 1997 Physostigmine, an acetylcholinesterase (AChE) inhibitor, alleviated the scopolamine-induced memory impairment in all these drug administration schedules. Physostigmine 0-13 acetylcholinesterase Mus musculus 18-38 9035256-6 1997 Physostigmine, an acetylcholinesterase (AChE) inhibitor, alleviated the scopolamine-induced memory impairment in all these drug administration schedules. Physostigmine 0-13 acetylcholinesterase Mus musculus 40-44 8737906-1 1996 Flinders Sensitive Line hypercholinergic rats, which exhibit augmented hypothermic responses to the cholinesterase inhibitor physostigmine and to the muscarinic agonist oxotremorine, have been proposed to represent a useful animal model for some aspects of human depression. Physostigmine 125-138 butyrylcholinesterase Rattus norvegicus 100-114 9365431-3 1997 She improved with a combination of benzodiazepines and the acetylcholinesterase inhibitor physostigmine. Physostigmine 90-103 acetylcholinesterase (Cartwright blood group) Homo sapiens 59-79 9170171-6 1997 The selected software systems were employed in separate scientific GLP studies conducted in dogs, rats, and mini-pigs to demonstrate the ability to detect cholinesterase effects due to multiple infusions of physostigmine, based on parallel measurement of cholinesterase biomarkers. Physostigmine 207-220 cholinesterase Sus scrofa 155-169 9170171-6 1997 The selected software systems were employed in separate scientific GLP studies conducted in dogs, rats, and mini-pigs to demonstrate the ability to detect cholinesterase effects due to multiple infusions of physostigmine, based on parallel measurement of cholinesterase biomarkers. Physostigmine 207-220 cholinesterase Sus scrofa 255-269 8905730-2 1996 The increase in working memory errors induced by intrahippocampal 3.2 micrograms/side scopolamine was reduced by concurrent injection of the cholinesterase inhibitor physostigmine (1.0 and 3.2 micrograms/side. Physostigmine 166-179 butyrylcholinesterase Rattus norvegicus 141-155 8764619-2 1996 The study was carried out in eight healthy human volunteers using as a tracer [11C]-physostigmine ([11C]PHY), an inhibitor of AChE. Physostigmine 84-97 acetylcholinesterase (Cartwright blood group) Homo sapiens 126-130 8780856-3 1996 To address this question, we measured the plasma adrenocorticotropic hormone (ACTH), beta-endorphin-like immunoreactivity (beta E-LI), and cortisol responses to the cholinesterase inhibitor physostigmine in 10 healthy normal older subjects (age = 71 +/- 2 years) and 11 outpatients with probable AD (age = 72 +/- 2 years; Mini Mental State Exam score = 19 +/- 2). Physostigmine 190-203 butyrylcholinesterase Homo sapiens 165-179 8856831-3 1996 In addition, we evaluated whether the cholinesterase inhibitor, physostigmine, would prevent delta 9-THC-induced impairment of spatial memory. Physostigmine 64-77 butyrylcholinesterase Homo sapiens 38-52 8784921-1 1996 A method for preparing various forms of acetylcholinesterase (AChE) from human erythrocyte has been established and they have been characterized in terms of kinetic parameters such as K(m), rate constant (k), turnover number (kcat), specificity constant (ksp), Vmax, half-life (t1/2), IC50 and Ki for tetrabutylammonium hydroxide, procaine and physostigmine in the present study. Physostigmine 344-357 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-60 8784921-1 1996 A method for preparing various forms of acetylcholinesterase (AChE) from human erythrocyte has been established and they have been characterized in terms of kinetic parameters such as K(m), rate constant (k), turnover number (kcat), specificity constant (ksp), Vmax, half-life (t1/2), IC50 and Ki for tetrabutylammonium hydroxide, procaine and physostigmine in the present study. Physostigmine 344-357 acetylcholinesterase (Cartwright blood group) Homo sapiens 62-66 9812738-4 1996 RESULTS: Sub 1.9, Sub-DU 3.0, or physostigmine (Phys) 0.15 mg.kg-1 obviously lengthened the SDL by 195%, 271%, and 210%, and shortened the EL by 56%, 61%, and 33%, and the two formers inhibited the brain AChE activities by 17% and 19%, respectively in aging (3-4 months) mice. Physostigmine 33-46 acetylcholinesterase Mus musculus 204-208 9812738-4 1996 RESULTS: Sub 1.9, Sub-DU 3.0, or physostigmine (Phys) 0.15 mg.kg-1 obviously lengthened the SDL by 195%, 271%, and 210%, and shortened the EL by 56%, 61%, and 33%, and the two formers inhibited the brain AChE activities by 17% and 19%, respectively in aging (3-4 months) mice. Physostigmine 48-52 acetylcholinesterase Mus musculus 204-208 8890920-2 1996 In conscious rats, the dose-response curves of muscarinic agonists arecoline and pilocarpine, cholinesterase inhibitors soman and physostigmine rather than GABA receptor antagonist pentylenetetrazol or glycine receptor antagonist strychnine for producing EEG seizures were shifted leftwards by acutely repeated injections of nicotine. Physostigmine 130-143 butyrylcholinesterase Rattus norvegicus 94-108 8835781-0 1996 Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. Physostigmine 35-48 amyloid beta precursor protein Homo sapiens 73-103 9139239-7 1996 However, the physostigmine-induced inhibition of ChE could be readily reversed by further substrate addition. Physostigmine 13-26 butyrylcholinesterase Rattus norvegicus 49-52 8825739-3 1996 For this study, physostigmine was administered ip at doses of 0.05, 0.2 or 1.0 mg/kg, resulting in average cholinesterase inhibition in plasma (28, 38 and 70%), erythrocytes (19, 24 and 36%), and brain (2, 10 and 31%) which correlated well with increased total power and amplitude changes. Physostigmine 16-29 butyrylcholinesterase Rattus norvegicus 107-121 9033122-2 1996 The cholinesterase inhibitor eserine (10 microM) decreased field responses by 20 +/- 2%. Physostigmine 29-36 butyrylcholinesterase Rattus norvegicus 4-18 7636741-5 1995 The purpose of this study was to determine the selectivity of physostigmine, metrifonate, methanesulfonyl fluoride and tetrahydroaminoacridine (tacrine) toward AChE as compared with butyrylcholinesterase (BChE) in human cortex. Physostigmine 62-75 acetylcholinesterase (Cartwright blood group) Homo sapiens 160-164 8846227-4 1995 AChE inhibitors, physostigmine and Tacrine can slow the decline of cognitive function and memory in some patients with mild or moderate AD, if given for at least 3-6 months in sufficient doses to inhibit brain AChE. Physostigmine 17-30 acetylcholinesterase (Cartwright blood group) Homo sapiens 210-214 8846227-6 1995 Newer, less toxic AChE inhibitors, with selective central activity, formulations of physostigmine, selective Ml and nicotinic agonists are becoming available with improved bioavailability and pharmacokinetics. Physostigmine 84-97 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-22 8819182-5 1995 Inhibition of acetylcholinesterase by physostigmine or neostigmine potentiated contractile responses elicited by 5-HT and alpha-Me-5-HT. Physostigmine 38-51 acetylcholinesterase Rattus norvegicus 14-34 8588286-3 1995 For this study, physostigmine was administered ip at doses of 0.05, 0.2 or 1.0 mg/kg, resulting in average cholinesterase inhibition in plasma (28, 38 and 70%), erythrocytes (19, 24 and 36%), and brain (2, 10 and 31%) which correlated well with increased total power and amplitude changes. Physostigmine 16-29 butyrylcholinesterase Rattus norvegicus 107-121 8562665-0 1995 Oral physostigmine in Alzheimer"s disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma. Physostigmine 5-18 arginine vasopressin Homo sapiens 73-84 8562665-2 1995 In this study, we explored in persons with Alzheimer"s disease (AD) the effects of an acute dose of physostigmine in patients receiving chronic physostigmine treatment on the activity of the cholinergically regulated noradrenergic and arginine vasopressin (AVP) systems. Physostigmine 100-113 arginine vasopressin Homo sapiens 244-255 8562665-2 1995 In this study, we explored in persons with Alzheimer"s disease (AD) the effects of an acute dose of physostigmine in patients receiving chronic physostigmine treatment on the activity of the cholinergically regulated noradrenergic and arginine vasopressin (AVP) systems. Physostigmine 144-157 arginine vasopressin Homo sapiens 244-255 7562554-1 1995 In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex. Physostigmine 88-101 butyrylcholinesterase Rattus norvegicus 54-68 7562554-1 1995 In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex. Physostigmine 103-106 butyrylcholinesterase Rattus norvegicus 54-68 7554703-10 1995 CONCLUSIONS: These results showed that, in cognitive responders, memory enhancement by physostigmine in Alzheimer"s disease is correlated directly to the magnitude of plasma cholinesterase inhibition. Physostigmine 87-100 butyrylcholinesterase Homo sapiens 174-188 7589215-1 1995 The acetylcholine esterase inhibitor (-)-physostigmine has been shown to act as agonist on nicotinic acetylcholine receptors from muscle and brain, by binding to sites on the alpha-polypeptide that are distinct from those for the natural transmitter acetylcholine (Schroder et al., 1994). Physostigmine 37-54 Fc epsilon receptor Ia Rattus norvegicus 175-192 7543947-8 1995 Acute treatments with physostigmine, which inhibit cerebral cortical AChE, had no effect on galanin concentrations. Physostigmine 22-35 acetylcholinesterase Rattus norvegicus 69-73 7636741-5 1995 The purpose of this study was to determine the selectivity of physostigmine, metrifonate, methanesulfonyl fluoride and tetrahydroaminoacridine (tacrine) toward AChE as compared with butyrylcholinesterase (BChE) in human cortex. Physostigmine 62-75 butyrylcholinesterase Homo sapiens 205-209 7636741-7 1995 Physostigmine inhibited AChE more than BChE. Physostigmine 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 24-28 7670367-0 1995 Oxime effects on the rate constants of carbamylation and decarbamylation of acetylcholinesterase for pyridostigmine, physostigmine and insecticidal carbamates. Physostigmine 117-130 acetylcholinesterase Bos taurus 76-96 8539321-2 1995 Specifically, we compared the activity of ondansetron to that of the cholinesterase inhibitor physostigmine in attenuating two distinct cognitive deficits in the Morris water maze. Physostigmine 94-107 butyrylcholinesterase Rattus norvegicus 69-83 7646566-1 1995 Inhibition of acetylcholinesterase (AChE) in the whole brain, cerebellum, pons, frontal cortex, basal ganglia and medulla oblongata of rat brain by physostigmine (CAS 57-47-6) in vitro was studied. Physostigmine 148-161 acetylcholinesterase Rattus norvegicus 14-34 7646566-1 1995 Inhibition of acetylcholinesterase (AChE) in the whole brain, cerebellum, pons, frontal cortex, basal ganglia and medulla oblongata of rat brain by physostigmine (CAS 57-47-6) in vitro was studied. Physostigmine 148-161 acetylcholinesterase Rattus norvegicus 36-40 8749612-1 1995 Physostigmine, a reversible and nonselective cholinesterase inhibitor, administered by steady-state, continuous intravenous infusion to carefully selected subjects with mild-moderate Alzheimer disease, produced significant but modest improvement in memory in five of nine subjects. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 45-59 7874590-1 1995 BACKGROUND: The purpose of this study was to determine the effects of normal human aging on the hypothalamic-pituitary-adrenocortical (HPA) axis response to the centrally active cholinesterase inhibitor physostigmine. Physostigmine 203-216 butyrylcholinesterase Homo sapiens 178-192 7760120-9 1995 Ionophoresis of ACh into the neuropil depolarized FETi, as did the application of the cholinesterase inhibitor physostigmine. Physostigmine 111-124 butyrylcholinesterase Homo sapiens 86-100 8749612-4 1995 Steady-state cholinesterase inhibition by physostigmine appears to produce sustained cognitive improvement in some subjects with Alzheimer disease without substantially altering its therapeutic index. Physostigmine 42-55 butyrylcholinesterase Homo sapiens 13-27 8545252-4 1995 Physostigmine (0.2 mg/kg), a cholinesterase inhibitor, and oxotremorine (0.01 and 0.03 mg/kg), a cholinergic agonist, significantly inhibited the shortening of step-down latency induced by GAL (0.3 microgram) administered 15 min before retention tests, indicating the involvement of cholinergic dysfunction in the GAL (0.3 microgram)-induced shortening of step-down latency. Physostigmine 0-13 galanin and GMAP prepropeptide Mus musculus 189-192 8545252-4 1995 Physostigmine (0.2 mg/kg), a cholinesterase inhibitor, and oxotremorine (0.01 and 0.03 mg/kg), a cholinergic agonist, significantly inhibited the shortening of step-down latency induced by GAL (0.3 microgram) administered 15 min before retention tests, indicating the involvement of cholinergic dysfunction in the GAL (0.3 microgram)-induced shortening of step-down latency. Physostigmine 0-13 galanin and GMAP prepropeptide Mus musculus 314-317 7898122-9 1994 (-)-Huperzine-A and (+/-)-huperzine-A were shown to be more potent than physostigmine as inhibitors of acetylcholinesterase in vitro (IC50 = 6 x 10(-7) M). Physostigmine 72-85 acetylcholinesterase Rattus norvegicus 103-123 8848515-8 1995 In a second experiment, we evaluated the effects of scopolamine and mecamylamine on the AVP and NE responses to physostigmine, a cholinesterase inhibitor which stimulates AVP release into plasma through a non-osmolar central nervous system cholinergic mechanism. Physostigmine 112-125 butyrylcholinesterase Homo sapiens 129-143 7645197-2 1995 The anticholinesterase compound physostigmine was administered at various steady-state intravenous infusion rates based on pharmacokinetic estimates of plasma and red blood cell cholinesterase inhibition. Physostigmine 32-45 butyrylcholinesterase Canis lupus familiaris 8-22 7714714-2 1994 Physostigmine, in combination with hyoscine, inhibited plasma cholinesterase, and red blood cell and brain acetylcholinesterase, in a concentration-dependent manner, did not affect the normal growth rate of guinea-pigs, and produced no obvious signs of poisoning. Physostigmine 0-13 acetylcholinesterase Cavia porcellus 107-127 7714714-3 1994 A dose rate of 4.85 micrograms h-1 physostigmine and 1.94 micrograms h-1 hyoscine was required to inhibit red cell acetylcholinesterase by 30% and brain acetylcholinesterase by 5-15%, with an accompanying plasma hyoscine concentration of 700-850 pg mL-1. Physostigmine 35-48 acetylcholinesterase Cavia porcellus 115-135 7714714-3 1994 A dose rate of 4.85 micrograms h-1 physostigmine and 1.94 micrograms h-1 hyoscine was required to inhibit red cell acetylcholinesterase by 30% and brain acetylcholinesterase by 5-15%, with an accompanying plasma hyoscine concentration of 700-850 pg mL-1. Physostigmine 35-48 acetylcholinesterase Cavia porcellus 153-173 7714714-8 1994 Red cell acetylcholinesterase activity, 24 h after soman poisoning, was higher following continuous pretreatment with physostigmine and hyoscine than after acute treatment with atropine. Physostigmine 118-131 acetylcholinesterase Cavia porcellus 9-29 7974514-2 1994 Physostigmine and carbamate insecticides (2-s-butylphenyl methylcarbamate (BPMC); isoprocarb, 2-isopropylphenyl methylcarbamate (MIPC); and propoxur, 2-isopropoxyphenyl methylcarbamate (PHC)) were employed as ChE inhibitors. Physostigmine 0-13 cholinesterase Oryctolagus cuniculus 209-212 7870192-8 1994 produced significant, prolonged and dose-dependent increases (4 and 12 times the control value, respectively), the peak effect occurring within 1 h. Perfusion with 10 mumol/l physostigmine produced an about 30-fold increase of ACh output, suggesting that the basal extracellular ACh concentration is highly dependent on ChE activity. Physostigmine 175-188 butyrylcholinesterase Rattus norvegicus 320-323 7870192-9 1994 When ChE was inhibited locally by perfusion with physostigmine, THA (5 mg/kg) produced a transient and, at its maximum, a 1.42-fold increase in extracellular ACh concentration. Physostigmine 49-62 butyrylcholinesterase Rattus norvegicus 5-8 7990271-3 1994 On the other hand, in the presence of physostigmine (50 microM; under this condition, cholinesterase activity was inhibited), tacrine did not enhance the basal ACh release. Physostigmine 38-51 butyrylcholinesterase Rattus norvegicus 86-100 7536306-5 1994 The acetylcholinesterase inhibitor, physostigmine, exerts a similar modulatory influence on the ACh current and on its extinction, and also prevents the manifestation of the effects of amiridin and tacrine. Physostigmine 36-49 acetylcholinesterase (Cartwright blood group) Homo sapiens 4-24 7861669-2 1994 The Ch/ACh ratio in CSF perfused with Ringer"s solution (30 microliters/30 min) containing 10(-5) M physostigmine, a centrally active cholinesterase inhibitor, was significantly lower than that in unprocessed CSF due to significantly higher ACh levels in the former. Physostigmine 100-113 butyrylcholinesterase Rattus norvegicus 134-148 7816881-5 1994 The cholinesterase inhibitors tacrine (THA) and, to a lesser extent, physostigmine (PHYSO) and amodiaquine (AMDQ), caused an upward shift in the frequency of the resting electrocortical activity, although scopolamine significantly slowed the activity below baseline levels. Physostigmine 69-82 butyrylcholinesterase Homo sapiens 4-18 7816881-5 1994 The cholinesterase inhibitors tacrine (THA) and, to a lesser extent, physostigmine (PHYSO) and amodiaquine (AMDQ), caused an upward shift in the frequency of the resting electrocortical activity, although scopolamine significantly slowed the activity below baseline levels. Physostigmine 84-89 butyrylcholinesterase Homo sapiens 4-18 7975932-9 1994 The impairment of working and reference memories in OB lesioned rats, which was assessed using a 3-panel-runway apparatus, was reduced by cholinesterase inhibitor physostigmine and NIK-247. Physostigmine 163-176 butyrylcholinesterase Rattus norvegicus 138-152 7958721-9 1994 This inhibition caused by ketamine seems to be associated with the protection of acetylcholinesterase against the inhibition by ranitidine and physostigmine. Physostigmine 143-156 acetylcholinesterase Cavia porcellus 81-101 7913496-1 1994 A microdialysis technique was used to investigate the effect of physostigmine (PHY) and heptylphysostigmine (HEP), administered systemically or locally, on the extracellular levels of acetyl-choline (ACh), norepinephrine, dopamine and 5-hydroxytryptamine in the cerebral cortex of the rat. Physostigmine 64-77 acyl-CoA thioesterase 12 Rattus norvegicus 200-203 7913496-5 1994 Systemic administration of two doses of cholinesterase inhibitor [PHY (30 and 300 micrograms/kg) and HEP (2 and 5 mg/kg)] produced a dose-dependent increase in ACh levels. Physostigmine 66-69 butyrylcholinesterase Rattus norvegicus 40-54 7913496-5 1994 Systemic administration of two doses of cholinesterase inhibitor [PHY (30 and 300 micrograms/kg) and HEP (2 and 5 mg/kg)] produced a dose-dependent increase in ACh levels. Physostigmine 66-69 acyl-CoA thioesterase 12 Rattus norvegicus 160-163 7970904-6 1994 Dose-response curves to locally applied Ach were obtained before and after the intravenous administration of the AChE inhibitor physostigmine (Phys). Physostigmine 128-141 acetylcholinesterase (Cartwright blood group) Homo sapiens 113-117 8014847-9 1994 The muscarinic agonists, oxotremorine and arecoline, and the cholinesterase inhibitor, physostigmine, were also antinociceptive, ranging from 7 times less to 100 times more potent than morphine. Physostigmine 87-100 butyrylcholinesterase Mus musculus 61-75 7934317-1 1994 Heptylphysostigmine (HP) is a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer inhibitory action than the parent compound, physostigmine (Phy). Physostigmine 6-19 butyrylcholinesterase Homo sapiens 41-55 7934317-1 1994 Heptylphysostigmine (HP) is a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer inhibitory action than the parent compound, physostigmine (Phy). Physostigmine 6-19 butyrylcholinesterase Homo sapiens 57-60 7981642-5 1994 From these results, it appears that perfusion of physostigmine at a variety of concentrations, changes not only the basal level of acetylcholine induced by the inhibition of acetylcholinesterase but also the relative acetylcholine output induced by systemic treatment with scopolamine. Physostigmine 49-62 acetylcholinesterase Rattus norvegicus 174-194 9343568-1 1994 Physostigmine, a powerful cholinesterase inhibitor, has recently been labelled with 11C in view of its potential application for in vivo imaging of cerebral acetylcholinesterase (AChE) using positron emission tomography. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 157-177 9343568-1 1994 Physostigmine, a powerful cholinesterase inhibitor, has recently been labelled with 11C in view of its potential application for in vivo imaging of cerebral acetylcholinesterase (AChE) using positron emission tomography. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 179-183 9343568-5 1994 The distributions of 11C label and of AChE activity were found to be essentially super-imposable, both after in vivo injection of and after in vitro incubation with [11C]physostigmine. Physostigmine 170-183 acetylcholinesterase Rattus norvegicus 38-42 9343568-7 1994 The fixation of [11C]physostigmine to cerebral tissue was abolished after incubation of the rat brain sections with BW 284C51, a specific AChE inhibitor, but not after incubation with iso-OMPA, a specific inhibitor of butyrylcholinesterase. Physostigmine 21-34 acetylcholinesterase Rattus norvegicus 138-142 9343568-9 1994 These results indicate that autoradiographic images of the rat brain obtained with [11C]physostigmine reflect AChE distribution, thus supporting the use of this radioligand to trace cerebral AChE activity in humans with positron emission tomography. Physostigmine 88-101 acetylcholinesterase Rattus norvegicus 110-114 8090809-1 1994 Previous evidence indicated that physostigmine, an acetylcholinesterase inhibitor, facilitated lordosis behavior when administered intraventricularly to cycling female rats on proestrus prior to the onset of natural sexual receptivity, but not when administered to rats on mid-diestrus or diestrus II. Physostigmine 33-46 acetylcholinesterase Rattus norvegicus 51-71 8064320-10 1994 Maximum tolerated doses of the anti-cholinesterase, physostigmine, rather than tending to normalize abnormalities in these patients, further reduced cerebral metabolism (p < 0.01) and increased metabolism in thalamus in a pattern inversely correlated (p < 0.001) with that produced by scopolamine. Physostigmine 52-65 butyrylcholinesterase Homo sapiens 36-50 8185877-5 1994 Physostigmine plasma concentrations were relatively stable (0.56 +/- 0.10 ng/ml) and correlated well with blood acetylcholinesterase inhibition. Physostigmine 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 112-132 8206111-6 1994 Pyridostigmine, neostigmine and physostigmine induced a significant GH increase (peak vs. basal levels, mean +/- S.E. Physostigmine 32-45 growth hormone 1 Homo sapiens 68-70 8019748-19 1994 Physostigmine, neostigmine, tacrine and DFP (all at 30 microM) each produced near-total (> 96%) inhibition of AChE activity. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 113-117 8161944-0 1994 Rate constants of carbamylation and decarbamylation of acetylcholinesterase for physostigmine and carbaryl in the presence of an oxime. Physostigmine 80-93 acetylcholinesterase Bos taurus 55-75 8161944-1 1994 Membrane-bound bovine erythrocyte acetylcholinesterase was inhibited with physostigmine or carbaryl, and the rate constants of carbamylation and decarbamylation were determined from the proportion of inhibited acetylcholinesterase in the steady state, and the rate of approach to the steady state. Physostigmine 74-87 acetylcholinesterase Bos taurus 34-54 8293309-4 1994 Again, inhibition of CA1 pyramidal cells firing was significantly more pronounced after Px injection than after physostigmine. Physostigmine 112-125 carbonic anhydrase 1 Oryctolagus cuniculus 21-24 7915961-3 1994 When the acetylcholinesterase (AChE) blocker physostigmine was present, the well-established muscarinic receptor-mediated autoinhibition was operative, i.e., the release was significantly reduced. Physostigmine 45-58 acetylcholinesterase Cavia porcellus 9-29 7915961-3 1994 When the acetylcholinesterase (AChE) blocker physostigmine was present, the well-established muscarinic receptor-mediated autoinhibition was operative, i.e., the release was significantly reduced. Physostigmine 45-58 acetylcholinesterase Cavia porcellus 31-35 7890023-8 1994 Meal intake stimulated ACTH and cortisol secretion which was significantly enhanced when physostigmine was administered (p < 0.05). Physostigmine 89-102 proopiomelanocortin Homo sapiens 23-27 8399826-0 1993 A peptide enhancement strategy in Alzheimer"s disease: pilot study with TRH-physostigmine infusions. Physostigmine 76-89 thyrotropin releasing hormone Homo sapiens 72-75 8309962-1 1993 This study reports the modulatory effects of physostigmine (Phy) and concurrent acute exercise on the time course of cholinesterase (ChE) activity, the rate of decarbamylation (Kd), and half-time of recovery of ChE in red blood cells (RBC) and various tissues of rats. Physostigmine 45-58 butyrylcholinesterase Rattus norvegicus 117-131 8309962-1 1993 This study reports the modulatory effects of physostigmine (Phy) and concurrent acute exercise on the time course of cholinesterase (ChE) activity, the rate of decarbamylation (Kd), and half-time of recovery of ChE in red blood cells (RBC) and various tissues of rats. Physostigmine 45-58 butyrylcholinesterase Rattus norvegicus 133-136 8309962-1 1993 This study reports the modulatory effects of physostigmine (Phy) and concurrent acute exercise on the time course of cholinesterase (ChE) activity, the rate of decarbamylation (Kd), and half-time of recovery of ChE in red blood cells (RBC) and various tissues of rats. Physostigmine 45-58 butyrylcholinesterase Rattus norvegicus 211-214 8332628-0 1993 Effect of physostigmine and exercise on choline acetyltransferase and acetylcholinesterase activities in fast and slow muscles of rat. Physostigmine 10-23 acetylcholinesterase Rattus norvegicus 70-90 7681755-4 1993 Intravenous administration of physostigmine, an acetylcholinesterase inhibitor, evoked a spatial frequency-dependent change in VEP amplitude. Physostigmine 30-43 acetylcholinesterase (Cartwright blood group) Homo sapiens 48-68 8395146-1 1993 Single channel studies carried out in cultured rat myoballs and cultured hippocampal neurons, and ion flux studies performed on Torpedo electrocyte membrane vesicles, showed that physostigmine (Phy), a well-established acetylcholinesterase inhibitor, interacts directly with nicotinic acetylcholine receptors (nAChR). Physostigmine 179-192 acetylcholinesterase Rattus norvegicus 219-239 8395146-1 1993 Single channel studies carried out in cultured rat myoballs and cultured hippocampal neurons, and ion flux studies performed on Torpedo electrocyte membrane vesicles, showed that physostigmine (Phy), a well-established acetylcholinesterase inhibitor, interacts directly with nicotinic acetylcholine receptors (nAChR). Physostigmine 179-192 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 275-308 8395146-1 1993 Single channel studies carried out in cultured rat myoballs and cultured hippocampal neurons, and ion flux studies performed on Torpedo electrocyte membrane vesicles, showed that physostigmine (Phy), a well-established acetylcholinesterase inhibitor, interacts directly with nicotinic acetylcholine receptors (nAChR). Physostigmine 179-192 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 310-315 8496822-5 1993 In the presence of THA, atropine induced a smaller increase in extracellular ACh concentrations than it did in the presence of physostigmine, under experimental conditions in which THA (100 microM) and physostigmine (10 microM) produced an equivalent effect on ChE activity. Physostigmine 202-215 butyrylcholinesterase Rattus norvegicus 261-264 8496822-7 1993 THA (100 microM) and physostigmine (10 microM) produced an additive effect on the extracellular concentration of ACh, and the addition of THA (10 microM) to physostigmine (1 microM) produced further inhibition of in vitro ChE activity. Physostigmine 21-34 butyrylcholinesterase Rattus norvegicus 222-225 8474626-3 1993 However, local administration of the cholinesterase inhibitors neostigmine, physostigmine or heptyl-physostigmine through the dialysis probe elevated acetylcholine above the detection limit. Physostigmine 76-89 butyrylcholinesterase Rattus norvegicus 37-51 8446666-1 1993 Continuous administration of the carbamate physostigmine, producing approximately 40% serum cholinesterase (ChE) inhibition, provides significant protection against the lethal effects of the organophosphorous nerve agent pinacolyl methylphosphonofluoridate (soman). Physostigmine 43-56 butyrylcholinesterase Rattus norvegicus 92-106 8446666-1 1993 Continuous administration of the carbamate physostigmine, producing approximately 40% serum cholinesterase (ChE) inhibition, provides significant protection against the lethal effects of the organophosphorous nerve agent pinacolyl methylphosphonofluoridate (soman). Physostigmine 43-56 butyrylcholinesterase Rattus norvegicus 108-111 8446666-3 1993 Soman and physostigmine both inhibit ChE, yet animals pretreated with physostigmine exhibited less ChE inhibition in serum and brain than did animals exposed to soman alone. Physostigmine 10-23 butyrylcholinesterase Rattus norvegicus 37-40 8446666-3 1993 Soman and physostigmine both inhibit ChE, yet animals pretreated with physostigmine exhibited less ChE inhibition in serum and brain than did animals exposed to soman alone. Physostigmine 70-83 butyrylcholinesterase Rattus norvegicus 37-40 8446666-3 1993 Soman and physostigmine both inhibit ChE, yet animals pretreated with physostigmine exhibited less ChE inhibition in serum and brain than did animals exposed to soman alone. Physostigmine 70-83 butyrylcholinesterase Rattus norvegicus 99-102 8421706-2 1993 We previously reported that traditional acetylcholinesterase inhibitors such as BW284C51, tacrine, and physostigmine were more potent inhibitors of the acetylcholinesterase in normal axons and cell bodies than of the acetylcholinesterase in plaques and tangles. Physostigmine 103-116 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-60 8421706-2 1993 We previously reported that traditional acetylcholinesterase inhibitors such as BW284C51, tacrine, and physostigmine were more potent inhibitors of the acetylcholinesterase in normal axons and cell bodies than of the acetylcholinesterase in plaques and tangles. Physostigmine 103-116 acetylcholinesterase (Cartwright blood group) Homo sapiens 152-172 8421706-2 1993 We previously reported that traditional acetylcholinesterase inhibitors such as BW284C51, tacrine, and physostigmine were more potent inhibitors of the acetylcholinesterase in normal axons and cell bodies than of the acetylcholinesterase in plaques and tangles. Physostigmine 103-116 acetylcholinesterase (Cartwright blood group) Homo sapiens 152-172 7907455-1 1993 Cholinesterase inhibitors, such as physostigmine and tacrine, have lately gained interest as potential drugs in the treatment of Alzheimer"s disease. Physostigmine 35-48 butyrylcholinesterase Homo sapiens 0-14 1491739-2 1992 In the present study, we determined whether a subeffective dose of the serotonergic type-2 receptor antagonist, ketanserin, would augment the facilitative effects produced by the acetylcholinesterase inhibitor, physostigmine, on memory in aged rats using the same task. Physostigmine 211-224 acetylcholinesterase Rattus norvegicus 179-199 8513134-1 1993 The cerebral distribution of [11C]physostigmine, an acetylcholinesterase inhibitor, was studied with autoradiography in rats and positron emission tomography in primates. Physostigmine 34-47 acetylcholinesterase Rattus norvegicus 52-72 8513134-3 1993 In primate brain, the early blood-flow dependent distribution of [11C]physostigmine was followed by a rapid redistribution to acetylcholinesterase-rich regions such as the striatum. Physostigmine 70-83 acetylcholinesterase Rattus norvegicus 126-146 8513134-5 1993 These results suggest that [11C]physostigmine is a promising new ligand for in vivo imaging of acetylcholinesterase activity with PET. Physostigmine 32-45 acetylcholinesterase Rattus norvegicus 95-115 8103186-5 1993 An almost complete reversal of the effect by physostigmine and potentiation by atropine indicate that AVP might act through an inhibition of the release of acetylcholine. Physostigmine 45-58 arginine vasopressin Mus musculus 102-105 8450938-1 1993 Cholinesterase inhibitors, such as physostigmine and tetrahydroaminoacridine, have been found to alleviate some of the memory deficits characteristic of senile dementia of the Alzheimer"s type (SDAT). Physostigmine 35-48 butyrylcholinesterase Rattus norvegicus 0-14 8441737-8 1993 Pretreatment with physostigmine offered marked protection against inhibition of AChE by soman, as shown by enzyme activity determination in different brain regions and in diaphragm muscle. Physostigmine 18-31 acetylcholinesterase Rattus norvegicus 80-84 8248533-3 1993 The main disadvantages of the cholinesterase inhibitors used in clinical trials are the short duration of action in the case of physostigmine and the potential for liver toxicity seen with the aminoacridine derivatives. Physostigmine 128-141 butyrylcholinesterase Homo sapiens 30-44 7871003-6 1993 However, the AChE inhibitors, tetrahydroaminoacridine (THA) and physostigmine (PHY) attenuated both PCA- and SCOP-induced amnesia when administered immediately after the training session. Physostigmine 64-77 acetylcholinesterase Mus musculus 13-17 7871003-6 1993 However, the AChE inhibitors, tetrahydroaminoacridine (THA) and physostigmine (PHY) attenuated both PCA- and SCOP-induced amnesia when administered immediately after the training session. Physostigmine 79-82 acetylcholinesterase Mus musculus 13-17 7871051-1 1993 Phenserine ((-)-N-phenylcarbamoyl eseroline), a carbamate analog of physostigmine (Phy), is a long-acting inhibitor of cholinesterase. Physostigmine 68-81 butyrylcholinesterase Rattus norvegicus 119-133 7871051-1 1993 Phenserine ((-)-N-phenylcarbamoyl eseroline), a carbamate analog of physostigmine (Phy), is a long-acting inhibitor of cholinesterase. Physostigmine 83-86 butyrylcholinesterase Rattus norvegicus 119-133 7871053-8 1993 Administration of the cholinesterase inhibitor physostigmine (0.1-0.4 mg/kg) induced a dose related increase in the total number of purposeless chews, but primarily these were not associated with facial tremor. Physostigmine 47-60 butyrylcholinesterase Rattus norvegicus 22-36 1426013-4 1992 Inhibitors of cholinesterase (physostigmine, diisopropylfluorophosphate) suppressed by 80% this Ca(2+)-independent efflux of [3H]acetylcholine. Physostigmine 30-43 butyrylcholinesterase Rattus norvegicus 14-28 1450287-8 1992 In one of the subjects, the anticholinesterase inhibitor physostigmine similarly normalized P50 gating. Physostigmine 57-70 nuclear factor kappa B subunit 1 Homo sapiens 92-95 1494302-1 1992 Heptylphysostigmine (HPTL), a derivative of the AChE inhibitor physostigmine (PHY), is under investigation as a therapeutic agent in Alzheimer"s disease. Physostigmine 6-19 acetylcholinesterase (Cartwright blood group) Homo sapiens 48-52 1436398-6 1992 The increase in working memory errors, induced by lesions of the basolateral amygdala was significantly reduced by intraperitoneal administration of the inhibitors of cholinesterase, tetrahydroaminoacridine (0.32-1.0 mg/kg) and physostigmine (0.032-0.1 mg/kg), and the muscarinic receptor agonist, oxotremorine (0.1 mg/kg), before the runway test. Physostigmine 228-241 butyrylcholinesterase Rattus norvegicus 167-181 1436399-1 1992 The central cardiovascular effects of a cholinesterase inhibitor, physostigmine, were studied in alpha-chloralose- and urethane-anesthetized cats, to determine the underlying site and mechanism of action. Physostigmine 66-79 butyrylcholinesterase Felis catus 40-54 1498727-4 1992 The AChase inhibitor, physostigmine, augmented ACh-elicited ATmax in 10-week-old (27% increase; p less than 0.01) but not in 2-week-old swine (2% increase; p is NS) and caused a greater increase in sensitivity to muscarinic activation in 2 versus 10 week-old swine (p less than 0.02), thus demonstrating increased contraction of TSM in 2 versus 10-week-old swine, which results at least in part from reduced AChase activity in immature animals. Physostigmine 22-35 acetylcholinesterase (Yt blood group) Sus scrofa 4-10 1511335-8 1992 Intrathecal administration of physostigmine, an acetylcholinesterase inhibitor, significantly reduced the threshold intensity of conditioning CRD necessary to inhibit the TF reflex to cut off (mean 36.0 +/- 4.0 mmHg; n = 5). Physostigmine 30-43 acetylcholinesterase Rattus norvegicus 48-68 1506754-0 1992 Vascular effects of acetylcholinesterase inhibitors in the rabbit eye: a study with fasciculin and physostigmine. Physostigmine 99-112 ACE-1 Oryctolagus cuniculus 20-40 1528356-6 1992 Other drugs such as physostigmine, echothiophate, BW284C51, tetrahydroaminoacridine, and metrifonate inhibited both aqueous- and detergent-soluble AChE molecular forms with similar potency. Physostigmine 20-33 acetylcholinesterase Rattus norvegicus 147-151 1579914-2 1992 Physostigmine was originally isolated from the Calabar Bean, which was used for ordeal by poison in West Africa. Physostigmine 0-13 brain expressed associated with NEDD4 1 Homo sapiens 55-59 1594645-1 1992 Whether the pharmacodynamics of physostigmine (Phy) [rate of decarbamylation of cholinesterase (ChE) enzyme] (Kd) is altered due to acute and/or trained exercise in brain and various tissues of rat has been addressed. Physostigmine 32-45 butyrylcholinesterase Rattus norvegicus 80-94 1594645-1 1992 Whether the pharmacodynamics of physostigmine (Phy) [rate of decarbamylation of cholinesterase (ChE) enzyme] (Kd) is altered due to acute and/or trained exercise in brain and various tissues of rat has been addressed. Physostigmine 32-45 butyrylcholinesterase Rattus norvegicus 96-99 1552502-4 1992 The most active AChE inhibitors were N,N"-disubstituted derivatives of 2-nitro-1,1-ethenediamine and 4,6-dinitro-1,3-benzenediamine, with compound 8 demonstrating activity greater than physostigmine. Physostigmine 185-198 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-20 1597127-0 1992 Acetylcholinesterase inhibition and anti-soman efficacy of homologs of physostigmine. Physostigmine 71-84 acetylcholinesterase Cavia porcellus 0-20 1498727-4 1992 The AChase inhibitor, physostigmine, augmented ACh-elicited ATmax in 10-week-old (27% increase; p less than 0.01) but not in 2-week-old swine (2% increase; p is NS) and caused a greater increase in sensitivity to muscarinic activation in 2 versus 10 week-old swine (p less than 0.02), thus demonstrating increased contraction of TSM in 2 versus 10-week-old swine, which results at least in part from reduced AChase activity in immature animals. Physostigmine 22-35 acetylcholinesterase (Yt blood group) Sus scrofa 408-414 1640506-1 1992 This study sought to determine the effect of heptylphysostigmine (H-PHY), a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer duration of action than physostigmine, on resting and basal forebrain (BF)-elicited increases in cortical cerebral blood flow (CBF). Physostigmine 51-64 butyrylcholinesterase Rattus norvegicus 103-106 1507523-7 1992 The increase in working errors in hippocampal-lesioned rats was significantly reduced by treatment with the cholinesterase inhibitor physostigmine at 0.1 mg/kg and the cholinergic activating drug minaprine at 10 mg/kg. Physostigmine 133-146 butyrylcholinesterase Rattus norvegicus 108-122 1601960-1 1992 An analytical method was developed with sensitivity to detect clinically significant concentrations of heptylphysostigmine (HP), a new physostigmine derivative with potent and long-lasting inhibitory activity on cholinesterase. Physostigmine 109-122 butyrylcholinesterase Homo sapiens 212-226 1597127-1 1992 Inhibition of acetylcholinesterase (AChE) activity by physostigmine (PHY) is reversible due to spontaneous decarbamylation. Physostigmine 54-67 acetylcholinesterase Cavia porcellus 14-34 1597127-1 1992 Inhibition of acetylcholinesterase (AChE) activity by physostigmine (PHY) is reversible due to spontaneous decarbamylation. Physostigmine 54-67 acetylcholinesterase Cavia porcellus 36-40 1597127-1 1992 Inhibition of acetylcholinesterase (AChE) activity by physostigmine (PHY) is reversible due to spontaneous decarbamylation. Physostigmine 69-72 acetylcholinesterase Cavia porcellus 14-34 1597127-1 1992 Inhibition of acetylcholinesterase (AChE) activity by physostigmine (PHY) is reversible due to spontaneous decarbamylation. Physostigmine 69-72 acetylcholinesterase Cavia porcellus 36-40 1288668-3 1992 Based on earlier positive findings in Alzheimer patients with the monoamine oxidase B inhibitor, 1-deprenyl, the authors speculate that a combination of physostigmine, the short-acting cholinesterase inhibitor, and 1-deprenyl might be more beneficial than either agent alone. Physostigmine 153-166 monoamine oxidase B Homo sapiens 66-85 1542401-1 1992 The purpose of this study was to determine which inhibitory pathway(s) mediate the alterations in the monosynaptic (MSR) and polysynaptic (PSR) reflexes after two different doses of physostigmine. Physostigmine 182-195 5-methyltetrahydrofolate-homocysteine methyltransferase reductase Homo sapiens 116-119 1542401-1 1992 The purpose of this study was to determine which inhibitory pathway(s) mediate the alterations in the monosynaptic (MSR) and polysynaptic (PSR) reflexes after two different doses of physostigmine. Physostigmine 182-195 jumonji domain containing 6, arginine demethylase and lysine hydroxylase Homo sapiens 139-142 1542401-2 1992 It was found previously that 0.8 mg/kg physostigmine facilitated the MSR and 2.0 mg/kg initially depressed and then facilitated the MSR. Physostigmine 39-52 5-methyltetrahydrofolate-homocysteine methyltransferase reductase Homo sapiens 69-72 1542401-2 1992 It was found previously that 0.8 mg/kg physostigmine facilitated the MSR and 2.0 mg/kg initially depressed and then facilitated the MSR. Physostigmine 39-52 5-methyltetrahydrofolate-homocysteine methyltransferase reductase Homo sapiens 132-135 1542401-5 1992 It was found that both strychnine and bicuculline blocked the facilitation produced by the small dose of physostigmine, while bicuculline alone blocked the depression of the MSR produced by the large dose of physostigmine. Physostigmine 105-118 5-methyltetrahydrofolate-homocysteine methyltransferase reductase Homo sapiens 174-177 1542401-5 1992 It was found that both strychnine and bicuculline blocked the facilitation produced by the small dose of physostigmine, while bicuculline alone blocked the depression of the MSR produced by the large dose of physostigmine. Physostigmine 208-221 5-methyltetrahydrofolate-homocysteine methyltransferase reductase Homo sapiens 174-177 1542401-6 1992 Strychnine partially blocked the effects of both doses of physostigmine on the PSR, while bicuculline only partially blocked the effects of the small dose of physostigmine. Physostigmine 58-71 jumonji domain containing 6, arginine demethylase and lysine hydroxylase Homo sapiens 79-82 1529165-2 1992 The cholinergic agonist nicotine and the acetylcholinesterase inhibitor physostigmine decreased DTH, whereas the alpha-adrenergic agonist clonidine stimulated DTH. Physostigmine 72-85 acetylcholinesterase Mus musculus 41-61 1814763-0 1991 Difference between the cerebrovascular effect of purinergic Co-ATP and that of the cholinesterase inhibitor, physostigmine, in vivo. Physostigmine 109-122 cholinesterase Oryctolagus cuniculus 83-97 1797447-7 1991 Administration of the cholinesterase inhibitor physostigmine (0.3 mg/kg), intravenously, produced a small but significant increase (39%) from basal concentrations of NPY. Physostigmine 47-60 neuropeptide Y Rattus norvegicus 166-169 1928367-7 1991 The concentration of physostigmine (PS), an inhibitor of cholinesterase, that elicited half-maximal inhibition of AChase activity also was similar for 2ws and 10ws. Physostigmine 21-34 acetylcholinesterase (Yt blood group) Sus scrofa 114-120 1684812-8 1991 1) The antagonism of physostigmine antinociception produced by Dyn A(1-17) given i.t. Physostigmine 21-34 prodynorphin Mus musculus 63-66 1787292-2 1991 Although refractory to precordial thump, synchronous cardioversion, and lidocaine, the ventricular tachycardia was reversed by intravenous administration of the tertiary acetylcholinesterase inhibitor physostigmine. Physostigmine 201-214 acetylcholinesterase (Cartwright blood group) Homo sapiens 170-190 1928367-7 1991 The concentration of physostigmine (PS), an inhibitor of cholinesterase, that elicited half-maximal inhibition of AChase activity also was similar for 2ws and 10ws. Physostigmine 36-38 acetylcholinesterase (Yt blood group) Sus scrofa 114-120 1794099-5 1991 An intraperitoneal injection of physostigmine (0.0032-0.32 mg/kg), an acetylcholinesterase (AChE) inhibitor, significantly ameliorated the spatial memory deficit induced by MS lesion, but hardly affected that by FF lesion. Physostigmine 32-45 acetylcholinesterase Rattus norvegicus 92-96 1794099-5 1991 An intraperitoneal injection of physostigmine (0.0032-0.32 mg/kg), an acetylcholinesterase (AChE) inhibitor, significantly ameliorated the spatial memory deficit induced by MS lesion, but hardly affected that by FF lesion. Physostigmine 32-45 acetylcholinesterase Rattus norvegicus 70-90 1955905-6 1991 These data suggest that the doses of physostigmine used were insufficient to produce marked inhibition of AChE within the central nervous system. Physostigmine 37-50 acetylcholinesterase (Cartwright blood group) Homo sapiens 106-110 1954303-0 1991 Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Physostigmine 100-113 acetylcholinesterase (Cartwright blood group) Homo sapiens 14-34 1954303-2 1991 Acetylcholinesterase activity was most effectively inhibited in all tissues by physostigmine, followed by tacrine and galanthamine. Physostigmine 79-92 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 1954303-5 1991 While physostigmine and tacrine acted equally on acetylcholinesterase from different sources, galanthamine was 10-fold less potent in inhibiting the enzyme activity from human brain that from human erythrocytes. Physostigmine 6-19 acetylcholinesterase (Cartwright blood group) Homo sapiens 49-69 1791534-1 1991 Physostigmine, an acetyl cholinesterase inhibitor, and arecoline, a muscarinic agonist, have been shown to improve Alzheimer presenile dementia in some patients when administered parenterally. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 25-39 1907148-7 1991 The rate of recovery of red cell AChE and plasma ChE activities, following incubation of whole blood with physostigmine (1 x 10(-7) M), was in the order human greater than rhesus monkey greater than marmoset greater than guinea-pig. Physostigmine 106-119 acetylcholinesterase (Cartwright blood group) Homo sapiens 33-37 1908687-5 1991 The concentration of physostigmine eliciting half-maximal inhibition (Ki) of AChase activity also was similar for tissues from sensitized (-7.92 +/- 0.032 log M) and control animals (-7.86 +/- 0.012 log M; P = NS). Physostigmine 21-34 acetylcholinesterase Canis lupus familiaris 77-83 2071560-1 1991 BACKGROUND: Previous investigators have reported improvements in verbal learning in outpatients suffering from dementia of the Alzheimer type (DAT) when they were treated daily with oral physostigmine for periods of days to months. Physostigmine 187-200 solute carrier family 6 member 3 Homo sapiens 143-146 2071560-2 1991 Questions remain, however, regarding both the specificity of the induced cognitive changes and the time course of the biological activity of the drug when physostigmine was used to treat DAT patients. Physostigmine 155-168 solute carrier family 6 member 3 Homo sapiens 187-190 2071560-4 1991 METHOD: Eight DAT patients were treated for 3 weeks with oral physostigmine administered four times daily in a double-blind, crossover, placebo-controlled study. Physostigmine 62-75 solute carrier family 6 member 3 Homo sapiens 14-17 2055694-7 1991 Physostigmine, an inhibitor of acetylcholinesterase, did not potentiate or prolong the relaxant action of ACh. Physostigmine 0-13 acetylcholinesterase Bos taurus 31-51 1661000-5 1991 Intrathecal administration of the cholinesterase inhibitor physostigmine produced a rapid, reversible and significant increase in the mechanical withdrawal threshold; TF latency was increased slightly but not significantly. Physostigmine 59-72 butyrylcholinesterase Rattus norvegicus 34-48 1946575-1 1991 This study sought to determine whether the choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) enzymes in the brain were affected in a regionally selective manner by chemical and physical stressors: 1) subacute administration of physostigmine (Phy); 2) exercise; and 3) the combination of these two stressors. Physostigmine 242-255 choline O-acetyltransferase Rattus norvegicus 43-68 1946575-1 1991 This study sought to determine whether the choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) enzymes in the brain were affected in a regionally selective manner by chemical and physical stressors: 1) subacute administration of physostigmine (Phy); 2) exercise; and 3) the combination of these two stressors. Physostigmine 242-255 acetylcholinesterase Rattus norvegicus 80-100 1946590-1 1991 An in vitro comparison demonstrated that the concentration of NIK-247 that inhibited cholinesterase (ChE) activities to half the normal level (ID50) was 1.3 x 10(-6) M. This value was higher than those for both physostigmine (PHY; 1.2 x 10(-7) M) and tetrahydroaminoacridine (THA; 3.6 x 10(-7) M), which are used as cholinesterase inhibitors in the treatment of cholinergic deficits. Physostigmine 211-224 butyrylcholinesterase Rattus norvegicus 101-104 1680183-5 1991 In separate experiments, the time course of acetylcholinesterase (AChE) activity recovery was evaluated in the brain and diaphragm of mice pretreated with meptazinol (30 mg kg-1) or physostigmine (0.1 mg kg-1) 15 min before poisoning with DFP (8 mg kg-1). Physostigmine 182-195 acetylcholinesterase Mus musculus 44-64 1680183-5 1991 In separate experiments, the time course of acetylcholinesterase (AChE) activity recovery was evaluated in the brain and diaphragm of mice pretreated with meptazinol (30 mg kg-1) or physostigmine (0.1 mg kg-1) 15 min before poisoning with DFP (8 mg kg-1). Physostigmine 182-195 acetylcholinesterase Mus musculus 66-70 1680183-7 1991 Twenty four hours after poisoning, brain AChE activity averaged 31 and 47% of that in controls in mice protected by meptazinol and physostigmine, respectively. Physostigmine 131-144 acetylcholinesterase Mus musculus 41-45 1879804-5 1991 Arecoline at 4 mg/kg, s.c., and physostigmine at 0.06-0.5 mg/kg, s.c., extended LAT, but both drugs showed no effects on % CR at the delay time of 4 sec in rats treated with AF64A. Physostigmine 32-45 linker for activation of T cells Rattus norvegicus 80-83 1886293-4 1991 The IC50 values for THA, 9-aminoacridine and physostigmine in the inhibition of HMT determined at fixed concentrations of histamine (20 microM) and S-adenosylmethionine (50 microM) were 0.2, 0.37 and 20 microM, respectively. Physostigmine 45-58 histamine N-methyltransferase Mus musculus 80-83 2054572-2 1991 Central cholinergic stimulation with physostigmine produced a focal increase in rCBF in the posterior parietotemporal region in the patients with AD but not in controls. Physostigmine 37-50 CCAAT/enhancer binding protein zeta Rattus norvegicus 80-84 1904998-3 1991 Studies in marmosets to assess the behavioural toxicology of physostigmine showed that the corresponding ED50 and ChE activity values were 34.3 (21.5-55.8) micrograms/kg and 66% respectively. Physostigmine 61-74 butyrylcholinesterase Homo sapiens 114-117 1851454-0 1991 Chronic treatment with scopolamine and physostigmine changes nerve growth factor (NGF) receptor density and NGF content in rat brain. Physostigmine 39-52 nerve growth factor receptor Rattus norvegicus 61-95 1851454-0 1991 Chronic treatment with scopolamine and physostigmine changes nerve growth factor (NGF) receptor density and NGF content in rat brain. Physostigmine 39-52 nerve growth factor Rattus norvegicus 82-85 1851454-7 1991 NGF content in cortex and hippocampus was reduced by about 50% following 7, but not 3, days of chronic physostigmine infusion. Physostigmine 103-116 nerve growth factor Rattus norvegicus 0-3 2036533-1 1991 The effects of physostigmine on patterns of rCBF in patients with pre-senile Alzheimer"s disease were studied using 99mTc-labelled HMPAO SPECT. Physostigmine 15-28 CCAAT/enhancer binding protein zeta Rattus norvegicus 44-48 1676644-0 1991 Correlation between plasma physostigmine concentrations and percentage of acetylcholinesterase inhibition over time after controlled release of physostigmine in volunteer subjects. Physostigmine 27-40 acetylcholinesterase (Cartwright blood group) Homo sapiens 74-94 1676644-3 1991 Plasma physostigmine concentrations correlated with percentage of AChE inhibition across time by dose and across all doses and subjects tested. Physostigmine 7-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 66-70 1676644-4 1991 These data should be helpful to physicians in adjusting physostigmine dosing, enabling them to use the relatively simple and widely available AChE assay to approximate plasma physostigmine concentrations. Physostigmine 56-69 acetylcholinesterase (Cartwright blood group) Homo sapiens 142-146 1676644-4 1991 These data should be helpful to physicians in adjusting physostigmine dosing, enabling them to use the relatively simple and widely available AChE assay to approximate plasma physostigmine concentrations. Physostigmine 175-188 acetylcholinesterase (Cartwright blood group) Homo sapiens 142-146 1856884-6 1991 Physostigmine intravenous infusion (3.3 micrograms.kg-1.min-1) enhanced rCBF in frontal, parietal, occipital, and temporal cortex. Physostigmine 0-13 CCAAT/enhancer binding protein zeta Rattus norvegicus 72-76 15374451-3 1991 In the aged rats there was a slight increase in acetylcholinesterase activity after physostigmine but no convincing evidence of enhanced (14)C-2-deoxyglucose uptake. Physostigmine 84-97 acetylcholinesterase Rattus norvegicus 48-68 2029342-5 1991 Systemic co-administration of the cholinesterase inhibitor physostigmine (0, 0.1, 0.2 mg/kg; i.p.) Physostigmine 59-72 butyrylcholinesterase Rattus norvegicus 34-48 2094316-3 1990 Furthermore variations of the topographical scalp distribution of P300 in normal volunteers after administration of physostigmine and biperiden was investigated. Physostigmine 116-129 E1A binding protein p300 Homo sapiens 66-70 1953352-6 1991 In separate experiments, the time-course of acetylcholinesterase (AChE; EC 3.1.1.7) activity recovery was evaluated in the whole brain and diaphragm tissues of mice pretreated with THA (5 mg/kg) and physostigmine (0.1 mg/kg) 15 min before poisoning with DFP (8 mg/kg). Physostigmine 199-212 acetylcholinesterase Mus musculus 44-64 1953352-8 1991 At 24 h after poisoning, brain AChE activity averaged 34 and 47% of that in controls in the mice protected by THA and physostigmine, respectively. Physostigmine 118-131 acetylcholinesterase Mus musculus 31-35 1825627-11 1991 If the effects of the nondepolarizing neuromuscular blocking agents must be reversed more rapidly, acetylcholinesterase-inhibiting agents such as physostigmine, neostigmine, pyridostigmine, and edrophonium can be used. Physostigmine 146-159 acetylcholinesterase (Cartwright blood group) Homo sapiens 99-119 20504702-2 1991 The lower dose combination (physostigmine 20 ?g/kg, hyoscine 10 ?g/kg, s.c.) inhibited brain regional acetylcholinesterase (AChE) by between 13.5 and 37.6% in all regions except the striatum, where there was no statistically significant inhibition. Physostigmine 28-41 acetylcholinesterase Cavia porcellus 102-122 20504702-2 1991 The lower dose combination (physostigmine 20 ?g/kg, hyoscine 10 ?g/kg, s.c.) inhibited brain regional acetylcholinesterase (AChE) by between 13.5 and 37.6% in all regions except the striatum, where there was no statistically significant inhibition. Physostigmine 28-41 acetylcholinesterase Cavia porcellus 124-128 1700067-6 1990 A cholinesterase inhibitor, physostigmine, at doses higher than 0.1 mg/kg, s.c., significantly inhibited the HA turnover. Physostigmine 28-41 butyrylcholinesterase Rattus norvegicus 2-16 1967018-1 1990 The centrally active cholinesterase inhibitor physostigmine induces a behavioral syndrome which is thought to represent a model of spontaneous depression. Physostigmine 46-59 butyrylcholinesterase Homo sapiens 21-35 1982308-0 1990 The binding of physostigmine to human serum albumin. Physostigmine 15-28 albumin Homo sapiens 38-51 1982308-1 1990 The binding of [3H]physostigmine to crystallized human serum albumin (HSA) has been investigated using equilibrium dialysis. Physostigmine 19-32 albumin Homo sapiens 55-68 2174982-4 1990 The electrically evoked release of radioactivity was reduced by the muscarinic agonist oxotremorine and the delta selective opiate receptor agonist Metenkephalin, and was enhanced in the presence of the cholinesterase inhibitor physostigmine by the muscarinic antagonist atropine. Physostigmine 228-241 butyrylcholinesterase Rattus norvegicus 203-217 2213555-7 1990 Chronic physostigmine treatment resulted in a 62% inhibition of AChE activity and elicited a significant increase in the amount of L-[3H] nicotine binding in midbrain, hippocampus, striatum and colliculi; alpha-[125I]bungarotoxin and [3H]quinuclidinyl benzilatl binding were not changed. Physostigmine 8-21 acetylcholinesterase Mus musculus 64-68 2239207-6 1990 Results showed that TTS (Transdermal Therapeutic System)-scopolamine administration facilitated habituation to rotation, whereas physostigmine, a centrally acting cholinesterase inhibitor, suppressed it, and neostigmine, a peripherally active cholinesterase inhibitor, had no effect on habituation at all. Physostigmine 129-142 butyrylcholinesterase Rattus norvegicus 163-177 2095716-0 1990 Interactive effects of physostigmine and exercise on cholinesterase activity in red blood cells and tissues of rat. Physostigmine 23-36 butyrylcholinesterase Rattus norvegicus 53-67 2095716-5 1990 In unexercised rats given physostigmine, the cholinesterase activity ranges were 73-79, 66-68, 68-74, 67-81 and 57-61% of controls from 10-30 min in red blood cells, brain, heart, diaphragm and thigh muscle, respectively. Physostigmine 26-39 butyrylcholinesterase Rattus norvegicus 45-59 2095716-6 1990 In exercised rats exposed to physostigmine, the cholinesterase activity ranges were 54-51, 58-50, 77-73, 71-83 and 54-58% of controls from 10-30 min in red blood cells, brain, heart, diaphragm and thigh muscle, respectively. Physostigmine 29-42 butyrylcholinesterase Rattus norvegicus 48-62 2095716-8 1990 Acute exercise modifies the effect of physostigmine significantly (p less than 0.01) by increasing the cholinesterase inhibition in red blood cells and brain without affecting other tissues. Physostigmine 38-51 butyrylcholinesterase Rattus norvegicus 103-117 1979353-5 1990 The AChE inhibitors eserine and hexamethonium were competitive inhibitors of the membrane-bound enzyme, whereas lidocaine was a noncompetitive inhibitor; these results were comparable to the effect of these inhibitors on diaphragm muscle AChE. Physostigmine 20-27 acetylcholinesterase Bos taurus 4-8 2382731-6 1990 The AChase inhibitor, physostigmine, caused 1) greater sensitivity of responses elicited by electrical field stimulation in 2ws (P less than 0.05) but not in 10ws (P = NS), 2) augmentation of maximal responses to exogenous ACh in 10ws (27% increase; P less than 0.01) but not 2ws (2% increase; P = NS), and 3) a greater increase in sensitivity to cholinomimetic activation in 2ws compared with 10ws (P less than 0.02). Physostigmine 22-35 acetylcholinesterase (Yt blood group) Sus scrofa 4-10 2299363-8 1990 Serum butyrylcholinesterase (EC 3.1.1.8) appears to be responsible for this hydrolysis, as evidenced by its inhibition by physostigmine and catalysis by commercially available pseudocholinesterase from horse and human blood. Physostigmine 122-135 butyrylcholinesterase Equus caballus 6-27 2243341-3 1990 The cholinesterase inhibitor physostigmine (0.03-0.175 mg/kg) was without effect on locomotor activity when administered alone, whereas the cholinesterase inhibitor tetrahydroaminoacridine hydrate (0.3-10 mg/kg) decreased locomotor activity. Physostigmine 29-42 butyrylcholinesterase Mus musculus 4-18 2217513-2 1990 The present study examined the facilitative effects of the acetylcholinesterase inhibitor, physostigmine (eserine), on sexual behavior in intact, cycling female rats. Physostigmine 91-104 acetylcholinesterase Rattus norvegicus 59-79 1972432-2 1990 Central cholinergic stimulation with physostigmine produced a focal increase in rCBF in the posterior parietotemporal region in the patients with AD but not in controls. Physostigmine 37-50 CCAAT/enhancer binding protein zeta Rattus norvegicus 80-84 2366261-7 1990 Structures with high cholinesterase activity (caudate-putamen, amygdala, hippocampus) showed greater retention of physostigmine over time. Physostigmine 114-127 butyrylcholinesterase Rattus norvegicus 21-35 2294657-0 1990 Effects of tacrine, aminopyridines, and physostigmine on acetylcholinesterase, acetylcholine release, and potassium currents. Physostigmine 40-53 acetylcholinesterase (Cartwright blood group) Homo sapiens 57-77 2350265-1 1990 The purpose of this study was to see if physostigmine, a reversible cholinesterase inhibitor, affects the secretion and composition of saliva of the major salivary glands of the rat. Physostigmine 40-53 butyrylcholinesterase Rattus norvegicus 68-82 2326327-4 1990 Intraventricular administration of the acetylcholinesterase inhibitor, physostigmine (10 micrograms bilaterally), activated lordosis of short duration in ovariectomized hamsters primed only with estrogen. Physostigmine 71-84 acetylcholinesterase (Cartwright blood group) Homo sapiens 39-59 2276342-0 1990 Acetylcholinesterase inhibition by (+)physostigmine and efficacy against lethality induced by soman. Physostigmine 35-51 acetylcholinesterase Cavia porcellus 0-20 2293258-9 1990 On the other hand, intracerebral injections of physostigmine (100 micrograms/microliter), an acetylcholinesterase inhibitor which elevates the level of endogenous acetylcholine, induced the fully developed emotional-aversive response comparable with natural behaviour and with responses induced by carbachol (10 micrograms/microliter). Physostigmine 47-60 acetylcholinesterase Felis catus 93-113 2288243-9 1990 The time-dependent reversal of the aged-like retention deficits by the cholinesterase inhibitor, physostigmine, suggests that cholinergic modulation of memory storage processes may be impaired in NZB/BINJ mice. Physostigmine 97-110 butyrylcholinesterase Mus musculus 71-85 2875917-5 1986 Addition of the acetylcholinesterase inhibitor, physostigmine, caused a leftward shift in the GABA dose-response curve and increased by 10-fold the sensitivity of the antral preparation to GABA stimulation. Physostigmine 48-61 acetylcholinesterase Rattus norvegicus 16-36 33819530-6 2021 Moreover, we observed the effect of the acetylcholinesterase inhibitor physostigmine on ZnSO4-induced learning and memory deficits. Physostigmine 71-84 acetylcholinesterase Mus musculus 40-60 33818816-8 2021 M502 formation by HLM was inhibited by BNPP and eserine (10 muM). Physostigmine 48-55 oxysterol binding protein 2 Homo sapiens 18-21 33818816-10 2021 M460 formation in HLM was inhibited by eserine, and M460 was N-acetylated in HLC. Physostigmine 39-46 oxysterol binding protein 2 Homo sapiens 18-21 33766648-8 2021 Studies also showed that these pesticides and eserine decreased three to five times the acetylcholinesterase activity in the serum compared to controls whereas terminal end buds increased in number, being inhibited by atropine. Physostigmine 46-53 acetylcholinesterase Rattus norvegicus 88-108 25865152-4 2015 Here, male Sprague-Dawley rats received systemic or VTA-specific administration of the acetylcholinesterase inhibitor, physostigmine (systemic; 0.06 or 0.125mg/kg, intra-cranial; 1 or 2mug/side), the muscarinic acetylcholine receptor (AChR) antagonist scopolamine (2.4 or 24mug/side), or the nicotinic AChR antagonist mecamylamine (3 or 30mug/side), prior to the FST test session. Physostigmine 119-132 acetylcholinesterase Rattus norvegicus 87-107 20407407-4 2010 By inhibition of the cholinesterase, physostigmine increases acetylcholine and induces the cholinergic anti-inflammatory pathway. Physostigmine 37-50 butyrylcholinesterase Rattus norvegicus 21-35 34224070-6 2021 However, enzyme linked immunosorbent assays (ELISA) was performed to determine the concentrations of Prostaglandins E2 (PGE2) and tumor necrosis factor-alpha in arthritic rats after treatment with physostigmine. Physostigmine 197-210 tumor necrosis factor Rattus norvegicus 130-157 7696893-1 1994 Experiments on non-inbred albino mice have demonstrated that aminostigmine is an active reversible centrally active cholinesterase inhibitor close to the properties of physostigmine, but greatly superior to it in its action duration. Physostigmine 168-181 butyrylcholinesterase Mus musculus 116-130 34964643-2 2022 The effect of FIB on the therapeutic potency of four FDA-approved Alzheimer"s disease drugs, namely, tacrine (TAC), donepezil (DON), eserine (ESE), and huperzine (HUP), was investigated through a combination of different in vitro and in silico experiments. Physostigmine 133-140 fibrinogen beta chain Homo sapiens 14-17 34964643-2 2022 The effect of FIB on the therapeutic potency of four FDA-approved Alzheimer"s disease drugs, namely, tacrine (TAC), donepezil (DON), eserine (ESE), and huperzine (HUP), was investigated through a combination of different in vitro and in silico experiments. Physostigmine 142-145 fibrinogen beta chain Homo sapiens 14-17 33478277-2 2021 In the present study, we used three docking-based virtual screening approaches to screen both ZINC15 and MolPort databases for synthetic analogs of physostigmine and donepezil, two highly potent AChE inhibitors. Physostigmine 148-161 acetylcholinesterase (Cartwright blood group) Homo sapiens 195-199 34224070-10 2021 Moreover, significant (p < 0.001) reduction in the levels of inflammatory markers (PGE2 and TNF-alpha) at doses of 10 and 20 mg/kg of physostigmine has been observed in ELISA test. Physostigmine 134-147 tumor necrosis factor Homo sapiens 92-101 34224070-11 2021 Likewise, there was a prominent rise in levels of SOD and CAT in animals treated with physostigmine. Physostigmine 86-99 superoxide dismutase 1 Homo sapiens 50-53 34224070-11 2021 Likewise, there was a prominent rise in levels of SOD and CAT in animals treated with physostigmine. Physostigmine 86-99 catalase Homo sapiens 58-61 2810114-1 1989 Acute peripheral administration of physostigmine inhibits cortical acetylcholinesterase (AChE) for about 1 hr in the rat and improves performance on learning and memory paradigms after excitotoxic lesions of the nucleus basalis magnocellularis (NBM) in rats. Physostigmine 35-48 acetylcholinesterase Rattus norvegicus 67-87 2574738-0 1989 Intracerebroventricular physostigmine-induced analgesia: enhancement by naloxone, beta-funaltrexamine and nor-binaltorphimine and antagonism by dynorphin A (1-17). Physostigmine 24-37 prodynorphin Mus musculus 144-161 2694528-8 1989 Clinically, the centrally active cholinesterase inhibitor physostigmine has been shown to give postoperative pain relief although of short duration. Physostigmine 58-71 butyrylcholinesterase Rattus norvegicus 33-47 2810114-1 1989 Acute peripheral administration of physostigmine inhibits cortical acetylcholinesterase (AChE) for about 1 hr in the rat and improves performance on learning and memory paradigms after excitotoxic lesions of the nucleus basalis magnocellularis (NBM) in rats. Physostigmine 35-48 acetylcholinesterase Rattus norvegicus 89-93 2810114-3 1989 One week of continuous physostigmine infusion in normal animals inhibited cortical AChE activity in a dose-dependent manner. Physostigmine 23-36 acetylcholinesterase Rattus norvegicus 83-87 2608162-1 1989 Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound. Physostigmine 7-20 butyrylcholinesterase Rattus norvegicus 154-168 2608162-1 1989 Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound. Physostigmine 7-20 butyrylcholinesterase Rattus norvegicus 170-173 2608162-1 1989 Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound. Physostigmine 29-32 butyrylcholinesterase Rattus norvegicus 154-168 2608162-1 1989 Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound. Physostigmine 29-32 butyrylcholinesterase Rattus norvegicus 170-173 2571301-7 1989 In untreated strips, physostigmine (10(-10)-10(-8) M) enhanced the off contraction in response to electrical stimulation, whereas atropine caused a dose-dependent reduction with complete abolition at 10(-4) M. These data suggest that in the esophagus inhibition and excitation are mediated by distinct mechanisms: VIP mediates inhibition and acetylcholine is responsible for the off contraction in response to electrical stimulation. Physostigmine 21-34 vasoactive intestinal peptide Homo sapiens 314-317 2759942-8 1989 However, cholinesterase inhibition with 10(-7) M physostigmine augmented the response to ACh in 10ws (P less than 0.02) but not 2ws. Physostigmine 49-62 cholinesterase Sus scrofa 9-23 2760844-2 1989 Release was monitored by measuring endogenous ACh when acetylcholinesterase (AChE) was inhibited with physostigmine (30 microM) or by measuring endogenous choline when AChE activity was left intact. Physostigmine 102-115 acetylcholinesterase Rattus norvegicus 55-75 2760844-2 1989 Release was monitored by measuring endogenous ACh when acetylcholinesterase (AChE) was inhibited with physostigmine (30 microM) or by measuring endogenous choline when AChE activity was left intact. Physostigmine 102-115 acetylcholinesterase Rattus norvegicus 77-81 2525015-2 1989 Physostigmine promptly increased plasma arginine vasopressin (tenfold), beta-endorphin (twofold to threefold) and epinephrine (threefold) levels in elderly control subjects. Physostigmine 0-13 arginine vasopressin Homo sapiens 49-60 2525015-2 1989 Physostigmine promptly increased plasma arginine vasopressin (tenfold), beta-endorphin (twofold to threefold) and epinephrine (threefold) levels in elderly control subjects. Physostigmine 0-13 proopiomelanocortin Homo sapiens 72-86 2498396-3 1989 For evaluating skin penetration of physostigmine the decrease of whole blood cholinesterase was measured. Physostigmine 35-48 butyrylcholinesterase Rattus norvegicus 77-91 2498396-6 1989 Ultrasound treatment also significantly increased (P less than 0.05) the inhibition of cholinesterase during the first hour after application in both physostigmine treated rats and guinea pigs: while in control guinea pigs no significant inhibition of cholinesterase could be detected during the first 2 h after application of physostigmine, the ultrasound treated group showed a 15 +/- 5% (mean +/- SEM) decrease in blood cholinesterase 1 h after ultrasound application. Physostigmine 150-163 butyrylcholinesterase Rattus norvegicus 87-101 2498396-7 1989 For physostigmine-treated rats the level of cholinesterase inhibition 1 h after ultrasound application was 53 +/- 5% in the ultrasound-treated group and 35 +/- 5% in the controls. Physostigmine 4-17 butyrylcholinesterase Rattus norvegicus 44-58 2786563-5 1989 Contractions to field stimulation were increased greatly by the cholinesterase inhibitor physostigmine (1.1 x 10(-6) M). Physostigmine 89-102 butyrylcholinesterase Bos taurus 64-78 2526916-0 1989 Physostigmine induced beta-endorphin release as a mechanism for physostigmine management of early alcohol withdrawal. Physostigmine 0-13 proopiomelanocortin Homo sapiens 22-36 2526916-0 1989 Physostigmine induced beta-endorphin release as a mechanism for physostigmine management of early alcohol withdrawal. Physostigmine 64-77 proopiomelanocortin Homo sapiens 22-36 2526916-1 1989 It is suggested that the mechanism involved in physostigmine management of early alcohol withdrawal may lie in physostigmine induced beta-endorphin release. Physostigmine 47-60 proopiomelanocortin Homo sapiens 133-147 2526916-1 1989 It is suggested that the mechanism involved in physostigmine management of early alcohol withdrawal may lie in physostigmine induced beta-endorphin release. Physostigmine 111-124 proopiomelanocortin Homo sapiens 133-147 2525672-7 1989 Addition of 1 mumol/l physostigmine to isolated left atria from guinea pigs for blockade of acetylcholinesterase decreased contractility at all stimulation rates, but did not change the ascending character of the staircase. Physostigmine 22-35 acetylcholinesterase Cavia porcellus 92-112 2922758-0 1989 Effects of subacute administration of physostigmine on blood acetylcholinesterase activity, motor performance, and soman intoxication. Physostigmine 38-51 acetylcholinesterase Rattus norvegicus 61-81 2714216-1 1989 In vitro inhibition of goat cerebellar acetylcholinesterase by pure and commercial anticholinesterase pesticides clearly indicates a remarkably high inhibitory effect of commercial carbamate and organophosphate pesticides containing a lower percentage of the respective active ingredients comparable to that of the known anticholinesterase agents such as DFP and physostigmine. Physostigmine 363-376 acetylcholinesterase Capra hircus 39-59 2683549-11 1989 This is achieved with physostigmine, a cholinesterase inhibitor able to easily cross the blood-brain barrier. Physostigmine 22-35 butyrylcholinesterase Homo sapiens 39-53 2688700-3 1989 Therefore, prior to the commitment of major resources in efficacy studies, feasibility pilot studies are necessary to ensure that physostigmine and clonidine, combined, can be safely administered to DAT patients. Physostigmine 130-143 solute carrier family 6 member 3 Homo sapiens 199-202 2688700-4 1989 Physostigmine, 2 mg every 2 h, and clonidine, up to 0.3 mg/day, were tolerated by the nine DAT patients without clinically meaningful adverse effects. Physostigmine 0-13 solute carrier family 6 member 3 Homo sapiens 91-94 2557047-2 1989 The atropine + clonidine-induced locomotor stimulation was counteracted by both the alpha 2-adrenoceptor antagonist idazoxan and the acetylcholinesterase inhibitor physostigmine. Physostigmine 164-177 acetylcholinesterase Mus musculus 133-153 2490104-1 1989 Antibodies were produced in rabbits immunized with physostigmine conjugated to bovine serum albumin (BSA) by two different methods: a diazo immunogen coupled to BSA with carbodiimide and a Mannich coupled immunogen. Physostigmine 51-64 albumin Oryctolagus cuniculus 86-99 2499742-4 1989 The effect of cyproheptadine on extinction of conflict behaviour was decreased by co-administration of physostigmine, an acetylcholinesterase inhibitor, but not affected by the concomitant administration of the muscarine receptor agonist oxotremorine. Physostigmine 103-116 acetylcholinesterase Rattus norvegicus 121-141 20504464-6 1989 Gallamine increased the rate of carbamylation of acetylcholinesterase by physostigmine and neostigmine at low ionic strength; however the data were not consistent with a simple model of complexing inhibition by these carbamates. Physostigmine 73-86 ACE-1 Oryctolagus cuniculus 49-69 2646552-2 1989 Experiment 1 replicated the previously reported deficit in conditional learning produced by ibotenate-induced lesions of the ventral pallidum/substantia innominata, but failed to demonstrate any restoration of learning by a subchronic regimen of the acetylcholinesterase inhibitor physostigmine sufficient to produce significant (30%), but equivalent, degrees of inhibition in the frontal cortex of ventral pallidum/substantia innominata-lesioned or sham-operated rats. Physostigmine 281-294 acetylcholinesterase Rattus norvegicus 250-270 2489433-6 1989 injection of a carbamate cholinesterase inhibitor, physostigmine, in a dose of 1.0 mg/kg resulted in a dramatic increase of the theta content in the hippocampal EEG, and in the total disappearance of the spontaneous seizures. Physostigmine 51-64 butyrylcholinesterase Rattus norvegicus 25-39 2489433-7 1989 Determination of cholinesterase activity in blood and in the brain in a separate group of subjects showed that after injection of physostigmine (1.0 mg/kg), the inhibition of this enzyme does not exceed the inhibition after injecting CVP in the doses used. Physostigmine 130-143 butyrylcholinesterase Rattus norvegicus 17-31 2570433-2 1989 These impairments can be reversed by appropriate agents such as the cholinesterase inhibitor physostigmine in the case of scopolamine or the benzodiazepine antagonist Ro 15-1788 in the case of lorazepam. Physostigmine 93-106 butyrylcholinesterase Homo sapiens 68-82 2497488-1 1989 The involvement of central and peripheral muscarinic cholinergic receptors in the behavioral effects of the cholinesterase inhibitor physostigmine was evaluated by comparing the ability of atropine and methylatropine to reverse the effects of physostigmine, the muscarinic agonist oxotremorine, or their quaternary analogs neostigmine and oxotremorine-M. Avoidance behavior was maintained under a schedule in which every lever press postponed delivery of electric shock for 20 s; shock occurred every 5 s in the absence of responding. Physostigmine 133-146 butyrylcholinesterase Homo sapiens 108-122 2852536-6 1988 Atropine (1 microM) blocked the inhibitory effect of physostigmine on the depressant action of D-Pen2,L-Pen5-enkephalin. Physostigmine 53-66 proenkephalin Rattus norvegicus 109-119 3150807-1 1988 Inhibition of central nervous system cholinesterase with a single pulse of physostigmine induces a pronounced increase of blood flow in the neocortex, cingulate gyrus, claustrum, and amygdala. Physostigmine 75-88 butyrylcholinesterase Homo sapiens 37-51 3215282-6 1988 Perfusion of physostigmine (10(-5) M) or bicuculline (10(-6) M) elicited second spikes following the population spikes in CA1 pyramidal cells. Physostigmine 13-26 carbonic anhydrase 1 Rattus norvegicus 122-125 2854073-1 1988 The reversible acetylcholinesterase inhibitor, physostigmine, stimulated in a dose-dependent manner the accumulation of [3H]inositol monophosphate ([3H]IP1) in lithium-treated neostriatal slices. Physostigmine 47-60 acetylcholinesterase Rattus norvegicus 15-35 2854073-7 1988 The physostigmine dose-response curve for the stimulation of [3H]IP1 accumulation was similar to its dose-response curve to inhibit acetylcholinesterase activity in the neostriatum. Physostigmine 4-17 acetylcholinesterase Rattus norvegicus 132-152 3069749-4 1988 Physostigmine also significantly decreased plasma cholinesterase (ChE). Physostigmine 0-13 butyrylcholinesterase Homo sapiens 50-64 3069749-4 1988 Physostigmine also significantly decreased plasma cholinesterase (ChE). Physostigmine 0-13 butyrylcholinesterase Homo sapiens 66-69 3069749-5 1988 There was a significant positive correlation between the effects of physostigmine on increasing cortisol and decreasing ChE; there was no correlation between the increase in cortisol of cholinesterase inhibitor following neostigmine administration, but neither of these chemical parameters is related to the drug"s effects on cognitive functioning. Physostigmine 68-81 butyrylcholinesterase Homo sapiens 120-123 3185960-3 1988 IC50 values (the concentration required to reduce enzyme activity by 50%) for the inhibition of total tissue AChE were 7.9 x 10(-7) M and 4.5 x 10(-8) M for THA and physostigmine, respectively, and similar values were also obtained for individual molecular forms of AChE (monomer G1, dimer G2 and tetramer G4) separated by sucrose density gradient centrifugation. Physostigmine 165-178 acetylcholinesterase (Cartwright blood group) Homo sapiens 109-113 3346683-5 1988 The possibility of ejaculation after physostigmine mainly depended on the integrity of the T12-L2 metamers. Physostigmine 37-50 CD6 molecule Homo sapiens 91-94 3058269-3 1988 When the same animals were treated with the acetylcholinesterase inhibitor physostigmine (0.05 mg/kg), however, performance on the behavioral task was not further promoted, and therefore, under these conditions, the cholinergic cortical transplants appear not to be subject to modulation by anticholinesterase drugs. Physostigmine 75-88 acetylcholinesterase Rattus norvegicus 44-64 2460268-0 1988 [Descending bulbospinal substance-P-containing pathway involved in the pressor response evoked by physostigmine]. Physostigmine 98-111 tachykinin precursor 1 Homo sapiens 24-35 3074841-8 1988 Electrophysiological data showed that (-)physostigmine, among several reversible ChE inhibitors, showed greater potency in depressing both endplate current (EPC) peak amplitude and tau EPC. Physostigmine 41-54 butyrylcholinesterase Homo sapiens 81-84 2900756-16 1988 After physostigmine, seven patients had an increase in heart rate to 140 beats min-1 and blood pressure decreased in three patients. Physostigmine 6-19 CD59 molecule (CD59 blood group) Homo sapiens 79-84 3339943-7 1988 B10 mice were more sensitive than NZB or NZBWF mice to both the disruptive effects of scopolamine and the facilitory effects of physostigmine on swim maze learning. Physostigmine 128-141 granzyme C Mus musculus 0-3 3188065-0 1988 Comparison of effects of anatoxin-a(s) and paraoxon, physostigmine and pyridostigmine on mouse brain cholinesterase activity. Physostigmine 53-66 butyrylcholinesterase Mus musculus 101-115 3435078-1 1987 The histochemical distribution of cholinesterases in the cerebral cortex and their response to cholinesterase inhibitors such as physostigmine and tetrahydroaminoacridine (THA) were investigated in brains from patients with Alzheimer"s disease and control subjects. Physostigmine 129-142 butyrylcholinesterase Homo sapiens 34-48 3435078-3 1987 In keeping with their well-known cholinomimetic effects, physostigmine and THA effectively inhibited this cholinesterase activity. Physostigmine 57-70 butyrylcholinesterase Homo sapiens 106-120 3694255-3 1987 The effects of acetylcholine (ACh), the muscarinic antagonist scopolamine (Sco), the nicotinic antagonist dihydro-beta-erythroidine (DBE), and the acetylcholinesterase inhibitor physostigmine (Phy) on maintained and light-evoked ganglion cell discharge was examined using iontophoresis techniques. Physostigmine 178-191 acetylcholinesterase (Cartwright blood group) Homo sapiens 147-167 22155841-4 1988 Physostigmine also elevated subjects" plasma ACTH levels, a marker of central cholinergic activity. Physostigmine 0-13 proopiomelanocortin Homo sapiens 45-49 22155841-9 1988 Physostigmine administered with a peripherally active cholinergic antagonist (glycopyrrolate 0.2 mg intramuscularly) produced a rise in ACTH level which reached a peak 30 min after drug administration. Physostigmine 0-13 proopiomelanocortin Homo sapiens 136-140 3685073-3 1987 A rate-decreasing dose of physostigmine, an acetylcholinesterase inhibitor, was studied in combination with the range of atropine doses. Physostigmine 26-39 acetylcholinesterase (Cartwright blood group) Homo sapiens 44-64 3691642-3 1987 administration of the cholinomimetics oxotremorine and arecoline and the cholinesterase blocker physostigmine evoked theta wave activity in the hippocampus, which was blocked by scopolamine. Physostigmine 96-109 butyrylcholinesterase Rattus norvegicus 73-87 3691642-8 1987 injections of oxotremorine, arecoline and physostigmine in doses that induce theta activity diminished the excitability of CA1 pyramidal cells in a dose-dependent manner, as judged by the reduction in the amplitude of the population spike and the dendritic epsp. Physostigmine 42-55 carbonic anhydrase 1 Rattus norvegicus 123-126 2822903-8 1987 The cholinesterase inhibitor physostigmine (50 microM) enhanced the response produced by elevated K+ at 14, 21 and 40 days but had no effect at 2 or 7 days. Physostigmine 29-42 butyrylcholinesterase Rattus norvegicus 4-18 2890115-2 1987 In the presence of the cholinesterase inhibitor physostigmine, acetylcholine significantly (p less than 0.05-p less than 0.01) stimulated inositol phosphate formation in a concentration-related fashion: carbachol, but not oxotremorine, produced similar effects. Physostigmine 48-61 butyrylcholinesterase Rattus norvegicus 23-37 3666046-3 1987 Treatment of animals with the cholinesterase inhibitor, physostigmine, markedly inhibited the renal vasodilation produced by ibopamine, but had no effect on the renal vasodilator response of epinine. Physostigmine 56-69 butyrylcholinesterase Canis lupus familiaris 30-44 3509961-4 1987 Pilocarpine and physostigmine at concentrations of 10(-5) M reduced the CCK output to 24 and 40% of basal, respectively, and also abolished the GRP-stimulated CCK response. Physostigmine 16-29 cholecystokinin Homo sapiens 72-75 3509961-4 1987 Pilocarpine and physostigmine at concentrations of 10(-5) M reduced the CCK output to 24 and 40% of basal, respectively, and also abolished the GRP-stimulated CCK response. Physostigmine 16-29 gastrin releasing peptide Homo sapiens 144-147 3509961-4 1987 Pilocarpine and physostigmine at concentrations of 10(-5) M reduced the CCK output to 24 and 40% of basal, respectively, and also abolished the GRP-stimulated CCK response. Physostigmine 16-29 cholecystokinin Homo sapiens 159-162 3682413-3 1987 Physostigmine, a cholinesterase inhibitor, antagonized these changes at the doses of 0.03 to 0.1 mg/kg. Physostigmine 0-13 butyrylcholinesterase Rattus norvegicus 17-31 3617097-1 1987 Physostigmine (1.5 mg/kg, s.c.) and neostigmine (1.0 mg/kg, s.c.) injection into male mice produced signs of toxicosis characteristic of cholinesterase inhibition and evoked death in 95 and 94% of the animals respectively. Physostigmine 0-13 butyrylcholinesterase Mus musculus 137-151 2821940-6 1987 Compounds containing C = O in the spacing moiety were active inhibitors of cholinesterase with some derivatives being nearly as active as physostigmine. Physostigmine 138-151 butyrylcholinesterase Homo sapiens 75-89 3658115-2 1987 The maximal inhibition of ChE (78%) in plasma at 2 min correlated with the largest concentration of physostigmine (124 ng/ml). Physostigmine 100-113 butyrylcholinesterase Canis lupus familiaris 26-29 3658115-3 1987 The concentration of physostigmine decreased by 88% to 16 ng/ml at 45 min when the activity of ChE was still 59% inhibited. Physostigmine 21-34 butyrylcholinesterase Canis lupus familiaris 95-98 3607358-11 1987 It is suggested that prevention of physostigmine-induced lethality by meptazinol is a consequence of its protective action on AChE in the central nervous system. Physostigmine 35-48 acetylcholinesterase Mus musculus 126-130 3037420-5 1987 However, in the presence of the cholinesterase inhibitor physostigmine, the responses to these stimuli were greatly enhanced and this could be blocked by atropine. Physostigmine 57-70 butyrylcholinesterase Rattus norvegicus 32-46 3601008-3 1987 of physostigmine are compared and the effect of two drugs producing inhibition of cholinesterase, physostigmine and metrifonate, on the activity of cholinesterase in the brain of the rat and on levels of acetylcholine (ACh) and choline (Ch). Physostigmine 98-111 butyrylcholinesterase Rattus norvegicus 82-96 3601008-3 1987 of physostigmine are compared and the effect of two drugs producing inhibition of cholinesterase, physostigmine and metrifonate, on the activity of cholinesterase in the brain of the rat and on levels of acetylcholine (ACh) and choline (Ch). Physostigmine 98-111 butyrylcholinesterase Rattus norvegicus 148-162 3601008-4 1987 After intramuscular administration of physostigmine (500 micrograms/kg), the activity of cholinesterase in brain was maximally inhibited (76%) at 5 min and recovered to 50% at 40 min. Physostigmine 38-51 butyrylcholinesterase Homo sapiens 89-103 3601008-7 1987 With the exception of the cerebellum, there was a direct correlation between the concentration of physostigmine and inhibition of cholinesterase in a given area. Physostigmine 98-111 butyrylcholinesterase Homo sapiens 130-144 3028835-4 1986 Results in this communication identify several quaternary amines which are equipotent with physostigmine for inhibition of cholinesterase. Physostigmine 91-104 butyrylcholinesterase Rattus norvegicus 123-137 3575379-1 1987 A series of analogues of physostigmine were prepared with the aim of investigating their inhibitory effects on acetylcholinesterase in the treatment of Alzheimer"s disease. Physostigmine 25-38 acetylcholinesterase (Cartwright blood group) Homo sapiens 111-131 3575359-4 1987 Mecamylamine pretreatment also reduced lordotic behavior induced by bilateral intracerebroventricular (ICV) injection of the cholinesterase inhibitor, eserine (5 micrograms/cannula). Physostigmine 151-158 butyrylcholinesterase Rattus norvegicus 125-139 3588658-4 1987 All three cholinesterase inhibitors caused an initial rise in corticosterone; DFP decreased growth hormone; physostigmine reduced prolactin. Physostigmine 108-121 butyrylcholinesterase Rattus norvegicus 10-24 3588658-4 1987 All three cholinesterase inhibitors caused an initial rise in corticosterone; DFP decreased growth hormone; physostigmine reduced prolactin. Physostigmine 108-121 prolactin Rattus norvegicus 130-139 3809224-2 1986 However, these behaviors have also been induced or enhanced by physostigmine, a cholinesterase inhibitor. Physostigmine 63-76 butyrylcholinesterase Homo sapiens 80-94 3039125-3 1986 In the presence of the acetylcholinesterase (AChE) inhibitor, physostigmine, these potentials were followed by a slow e.p.s.p. Physostigmine 62-75 acetylcholinesterase Rattus norvegicus 23-43 3559884-6 1986 This acetylcholinesterase activity was inhibited by ranitidine and this inhibition was weaker than that caused by physostigmine. Physostigmine 114-127 acetylcholinesterase Cavia porcellus 5-25 3785584-0 1986 The effects of physostigmine on acetylcholinesterase activity of CSF plasma and brain. Physostigmine 15-28 acetylcholinesterase Canis lupus familiaris 32-52 3785584-2 1986 The effects of various doses of physostigmine (Phy) on the activity of acetylcholinesterase (AChE) in plasma, cerebrospinal fluid (CSF) and brain were studied in beagle dogs. Physostigmine 32-45 acetylcholinesterase Canis lupus familiaris 71-91 3785584-2 1986 The effects of various doses of physostigmine (Phy) on the activity of acetylcholinesterase (AChE) in plasma, cerebrospinal fluid (CSF) and brain were studied in beagle dogs. Physostigmine 32-45 acetylcholinesterase Canis lupus familiaris 93-97 3785584-2 1986 The effects of various doses of physostigmine (Phy) on the activity of acetylcholinesterase (AChE) in plasma, cerebrospinal fluid (CSF) and brain were studied in beagle dogs. Physostigmine 47-50 acetylcholinesterase Canis lupus familiaris 71-91 3785584-2 1986 The effects of various doses of physostigmine (Phy) on the activity of acetylcholinesterase (AChE) in plasma, cerebrospinal fluid (CSF) and brain were studied in beagle dogs. Physostigmine 47-50 acetylcholinesterase Canis lupus familiaris 93-97 3785584-7 1986 The activity of AChE in plasma was only minimally inhibited by intraventricular administration of physostigmine. Physostigmine 98-111 acetylcholinesterase Canis lupus familiaris 16-20 3785584-13 1986 At 5 min, with intravenous administration, physostigmine (1000 micrograms) reached greater concentrations and caused greater inhibition of AChE in the cortex. Physostigmine 43-56 acetylcholinesterase Canis lupus familiaris 139-143 3785584-17 1986 This study suggests that intraventricular administration of physostigmine, a reversible inhibitor of cholinesterase (ChE), may offer distinct advantages over intravenous administration. Physostigmine 60-73 butyrylcholinesterase Canis lupus familiaris 101-115 3785584-17 1986 This study suggests that intraventricular administration of physostigmine, a reversible inhibitor of cholinesterase (ChE), may offer distinct advantages over intravenous administration. Physostigmine 60-73 butyrylcholinesterase Canis lupus familiaris 117-120 3785584-18 1986 Inhibition of acetylcholinesterase in CSF was more pronounced and persisted longer when physostigmine was administered directly into the CSF than when given intravenously. Physostigmine 88-101 acetylcholinesterase Canis lupus familiaris 14-34 2877020-9 1986 The effect of vagus nerve stimulation on insulin and PP secretion was augmented by physostigmine, and inhibited (but not abolished) by atropine at 10(-7)-10(-6) M. The effect on glucagon secretion was inhibited by physostigmine and unaffected by atropine. Physostigmine 83-96 insulin Sus scrofa 41-48 2877020-9 1986 The effect of vagus nerve stimulation on insulin and PP secretion was augmented by physostigmine, and inhibited (but not abolished) by atropine at 10(-7)-10(-6) M. The effect on glucagon secretion was inhibited by physostigmine and unaffected by atropine. Physostigmine 83-96 pancreatic polypeptide Sus scrofa 53-55 2877020-9 1986 The effect of vagus nerve stimulation on insulin and PP secretion was augmented by physostigmine, and inhibited (but not abolished) by atropine at 10(-7)-10(-6) M. The effect on glucagon secretion was inhibited by physostigmine and unaffected by atropine. Physostigmine 214-227 insulin Sus scrofa 41-48 2877064-4 1986 The in-vivo results indicated that the physostigmine emulsion was able to inhibit the cholinesterase activity for only 1 to 2 h. The preliminary pharmacokinetic analysis showed that the physostigmine emulsion apparently increased the bioavailability compared with the conventional injectable solution. Physostigmine 39-52 cholinesterase Oryctolagus cuniculus 86-100 2877064-4 1986 The in-vivo results indicated that the physostigmine emulsion was able to inhibit the cholinesterase activity for only 1 to 2 h. The preliminary pharmacokinetic analysis showed that the physostigmine emulsion apparently increased the bioavailability compared with the conventional injectable solution. Physostigmine 186-199 cholinesterase Oryctolagus cuniculus 86-100 3039125-3 1986 In the presence of the acetylcholinesterase (AChE) inhibitor, physostigmine, these potentials were followed by a slow e.p.s.p. Physostigmine 62-75 acetylcholinesterase Rattus norvegicus 45-49 3039125-29 1986 amplitude resulted also from inhibition of AChE by application of physostigmine (1-100 microM). Physostigmine 66-79 acetylcholinesterase Rattus norvegicus 43-47 3748273-0 1986 Relation of brain regional physostigmine concentration to cholinesterase activity and acetylcholine and choline levels in rat. Physostigmine 27-40 butyrylcholinesterase Rattus norvegicus 58-72 2939779-5 1986 Alone, B-CCT increased CBF and CMRO2, and these changes were potentiated by physostigmine. Physostigmine 76-89 FLVCR heme transporter 2 Rattus norvegicus 9-12 2939779-7 1986 The ability of physostigmine to antagonize the metabolic effects of midazolam and to potentiate the stimulation produced by B-CCT suggests an additive effect of the two neurotransmitter systems rather than a direct interaction at the central receptor sites. Physostigmine 15-28 FLVCR heme transporter 2 Rattus norvegicus 126-129 3524957-12 1986 Pharmacokinetic studies of the tertiary reversible cholinesterase inhibitor physostigmine, an important tool in experimental cholinergic neuropharmacology, are still in their initial stages. Physostigmine 76-89 butyrylcholinesterase Homo sapiens 51-65 3699340-4 1986 Physostigmine caused only slight inhibition of cholinesterase in blood and skeletal muscle. Physostigmine 0-13 butyrylcholinesterase Rattus norvegicus 47-61 3958964-5 1986 In the presence of physostigmine, an acetylcholinesterase inhibitor, the PAF-induced contractions of lung strips were modestly enhanced, consistent with release of endogenous acetylcholine. Physostigmine 19-32 acetylcholinesterase Cavia porcellus 37-57 3945161-0 1986 Protection from quinidine or physostigmine against in vitro inhibition by sarin of acetylcholinesterase activity. Physostigmine 29-42 acetylcholinesterase Canis lupus familiaris 83-103 3945161-1 1986 We have studied the relative effectiveness of quinidine and physostigmine in protecting against the inhibition of acetylcholinesterase (AChE) by sarin, an organophosphate (OP) compound. Physostigmine 60-73 acetylcholinesterase Canis lupus familiaris 114-134 3945161-1 1986 We have studied the relative effectiveness of quinidine and physostigmine in protecting against the inhibition of acetylcholinesterase (AChE) by sarin, an organophosphate (OP) compound. Physostigmine 60-73 acetylcholinesterase Canis lupus familiaris 136-140 3945161-6 1986 Addition of sarin to physostigmine-treated control brain samples allowed partial recovery of the AChE activity. Physostigmine 21-34 acetylcholinesterase Canis lupus familiaris 97-101 3735142-4 1986 Physostigmine also enhanced the growth hormone rise and prolactin decline, and limited the increase in heart rate following methylphenidate administration. Physostigmine 0-13 growth hormone 1 Homo sapiens 32-46 3018822-4 1986 Administration of physostigmine, unlike that of neostigmine, was associated with statistically significant increases in plasma concentrations of cortisol, prolactin, ACTH, beta-endorphin/beta-lipotropin-like immunoreactivity, and epinephrine, presumably via central mechanisms. Physostigmine 18-31 proopiomelanocortin Homo sapiens 166-170 3018822-4 1986 Administration of physostigmine, unlike that of neostigmine, was associated with statistically significant increases in plasma concentrations of cortisol, prolactin, ACTH, beta-endorphin/beta-lipotropin-like immunoreactivity, and epinephrine, presumably via central mechanisms. Physostigmine 18-31 proopiomelanocortin Homo sapiens 172-186 3018822-6 1986 Scopolamine significantly attenuated the physostigmine-associated increase in plasma concentrations of cortisol, growth hormone, prolactin, ACTH, and dopamine compared to methscopolamine, and a close-to-significant attenuation of epinephrine as well. Physostigmine 41-54 growth hormone 1 Homo sapiens 113-127 3018822-6 1986 Scopolamine significantly attenuated the physostigmine-associated increase in plasma concentrations of cortisol, growth hormone, prolactin, ACTH, and dopamine compared to methscopolamine, and a close-to-significant attenuation of epinephrine as well. Physostigmine 41-54 proopiomelanocortin Homo sapiens 140-144 3797688-9 1986 The degree of memory improvement correlated with increasing cerebrospinal fluid cholinesterase inhibition suggesting that memory improvement is associated with entry of physostigmine into the brain. Physostigmine 169-182 butyrylcholinesterase Homo sapiens 80-94 3699340-5 1986 Cholinesterase activity in blood and muscle of rats pretreated with physostigmine before sarin administration was significantly higher than in tissues from rats injected with sarin alone. Physostigmine 68-81 butyrylcholinesterase Rattus norvegicus 0-14 3699340-8 1986 Effective protection against lethality by physostigmine could be related to protection of cerebral cholinesterase since inhibition of this enzyme by sarin was lowered significantly after pretreatment with physostigmine. Physostigmine 42-55 butyrylcholinesterase Rattus norvegicus 99-113 3699340-8 1986 Effective protection against lethality by physostigmine could be related to protection of cerebral cholinesterase since inhibition of this enzyme by sarin was lowered significantly after pretreatment with physostigmine. Physostigmine 205-218 butyrylcholinesterase Rattus norvegicus 99-113 4092872-7 1985 After treatment with the reversible inhibitor, physostigmine at 0.5 mg/ml, recovery of AChE activity was complete within 24 hr after treatment. Physostigmine 47-60 acetylcholinesterase Mus musculus 87-91 2869170-8 1985 Apomorphine, thyrotropin-releasing hormone (TRH), methamphetamine, physostigmine and amantadine dose-relatedly increased the cortical beta 2 band in PIR, and these increasing effects, except in the case of physostigmine, were antagonized by the pretreatment of haloperidol. Physostigmine 206-219 thyrotropin releasing hormone Rattus norvegicus 44-47 3896015-1 1985 A translation of Pal"s original paper, "Physostigmine, an antidote to curare", 1900. Physostigmine 40-53 leucine rich repeat, Ig-like and transmembrane domains 1 Homo sapiens 17-20 2868959-13 1985 The acetylcholinesterase inhibitor physostigmine and the muscarinic receptor antagonist atropine decreased the survival of mice given sodium cyanide. Physostigmine 35-48 acetylcholinesterase Mus musculus 4-24 2868960-10 1985 Single-channel recordings showed that physostigmine decreases conductance and open times of the channels activated in the presence of ACh and in addition has an agonistic property on the nicotinic AChR. Physostigmine 38-51 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 197-201 4040999-5 1985 These retention deficits could be reversed by the postacquisition administration of the acetylcholinesterase inhibitor, physostigmine. Physostigmine 120-133 acetylcholinesterase Rattus norvegicus 88-108 4033355-3 1985 At 30 min pre-soman, guinea pigs and rats received (im) either pyridostigmine (Py) or physostigmine (Ph) to inhibit whole blood AChE from 10 to 70%; at 1 min post-soman (sc), they received (im) atropine (16 mg/kg)/2-PAMCl (50 mg/kg) and mecamylamine (0.8 mg/kg)/atropine (16 mg/kg), respectively. Physostigmine 86-99 acetylcholinesterase Rattus norvegicus 128-132 4077467-2 1985 The inhibition of eel acetylcholinesterase by physostigmine at 20 degrees and 25 degrees C have been investigated. Physostigmine 46-59 acetylcholinesterase (Cartwright blood group) Homo sapiens 22-42 3896015-3 1985 Pal of Vienna in 1900, which showed that physostigmine reverses the neuromuscular blocking properties of curare. Physostigmine 41-54 leucine rich repeat, Ig-like and transmembrane domains 1 Homo sapiens 0-3 2991804-1 1985 Inhibition of acetylcholinesterase (AChE) by more than 80% by neostigmine or physostigmine resulted in a failure of tetanic contraction (100 Hz) in the isolated mouse nerve-diaphragm preparation. Physostigmine 77-90 acetylcholinesterase Mus musculus 14-34 2991804-1 1985 Inhibition of acetylcholinesterase (AChE) by more than 80% by neostigmine or physostigmine resulted in a failure of tetanic contraction (100 Hz) in the isolated mouse nerve-diaphragm preparation. Physostigmine 77-90 acetylcholinesterase Mus musculus 36-40 2580948-5 1985 Physostigmine completely inhibits the hydrolysis of butyrylthiocholine by such purified cholinesterase preparations, but not their substance P-degrading activity. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 88-102 4000406-8 1985 Physostigmine, an anti-cholinesterase lacking agonistic action, decreased the uptake of Ch to 73% of control at 1 mM. Physostigmine 0-13 butyrylcholinesterase Rattus norvegicus 23-37 3999598-7 1985 Local application of cholinesterase inhibitors in the form of Eserine, Prostigmin etc. Physostigmine 62-69 butyrylcholinesterase Homo sapiens 21-35 3980055-2 1985 In the current study we contrasted the cardiovascular effects of the centrally acting cholinesterase inhibitor physostigmine, which increases central and peripheral acetylcholine levels, with those of saline placebo and with those of the non-centrally acting cholinesterase inhibitor neostigmine, which only increases peripheral acetylcholine levels. Physostigmine 111-124 butyrylcholinesterase Homo sapiens 86-100 2858526-2 1985 Eseroline afforded 50% protection (ED 50) of erythrocyte AChE against inactivation by 1 microM DFP, physostigmine or neostigmine, at concentrations of 4.3, 22 and 23.5 microM, respectively, while for eel AChE protection against 10 and 30 microM DFP, 0.3 and 1 microM physostigmine and 1 microM neostigmine the eseroline ED 50 values were 0.3, 0.4, 0.7, 1.9 and 5.6 microM, respectively. Physostigmine 100-113 acetylcholinesterase Mus musculus 57-61 2858526-2 1985 Eseroline afforded 50% protection (ED 50) of erythrocyte AChE against inactivation by 1 microM DFP, physostigmine or neostigmine, at concentrations of 4.3, 22 and 23.5 microM, respectively, while for eel AChE protection against 10 and 30 microM DFP, 0.3 and 1 microM physostigmine and 1 microM neostigmine the eseroline ED 50 values were 0.3, 0.4, 0.7, 1.9 and 5.6 microM, respectively. Physostigmine 267-280 acetylcholinesterase Mus musculus 57-61 6326923-3 1984 Compared to physostigmine, the analogues were weak inhibitors of cholinesterase enzymes. Physostigmine 12-25 butyrylcholinesterase Rattus norvegicus 65-79 6516793-2 1984 It has been shown that systemically administered physostigmine, a cholinesterase inhibitor that penetrates the blood-brain barrier, causes barrier opening. Physostigmine 49-62 butyrylcholinesterase Homo sapiens 66-80 6149777-4 1984 TRH appeared to bean antagonist of atropine and physostigmine by locomotor activity and hypnotic effect of hexenal and to be an agonist of phenylephrine, isadrin, amphetamine and an antagonist of phentolamine and propranolol as shown by behavioral tests. Physostigmine 48-61 thyrotropin releasing hormone Mus musculus 0-3 6440800-2 1984 The present study was to elucidate the influence of dopaminergic (pimozide, apomorphine) and cholinergic (atropine, physostigmine) drugs on the antiataxic effect of TRH. Physostigmine 116-129 thyrotropin releasing hormone Mus musculus 165-168 6440800-4 1984 The increase of spontaneous motor activities after TRH injection was antagonized by pretreatment with pimozide and physostigmine, but accentuated by pretreatment with atropine. Physostigmine 115-128 thyrotropin releasing hormone Mus musculus 51-54 6504953-1 1984 This paper reports the use of an RF capacitance field transducer and spectral analysis to examine the effects of the cholinesterase inhibitor physostigmine on the behavior of unrestrained rats. Physostigmine 142-155 butyrylcholinesterase Rattus norvegicus 117-131 6511307-1 1984 The authors, with a spectrophotometric procedure, have evaluated the kinetic constants of physostigmine, a cholinesterase inhibitor which assumes an important function when the degeneration of cholinergic projections is observed. Physostigmine 90-103 butyrylcholinesterase Homo sapiens 107-121 6470148-3 1984 We stimulated central cholinergic activity in man by administering the cholinesterase inhibitor physostigmine to subjects pretreated with peripheral cholinergic blocking agents. Physostigmine 96-109 butyrylcholinesterase Homo sapiens 71-85 6487203-3 1984 Physostigmine, a centrally active cholinesterase inhibitor which increases brain acetylcholine, was found to cause a motion sickness-like syndrome--in psychiatric patients and normals--including nausea, emesis, malaise, dysphoria, increases in serum ACTH, beta-endorphin, cortisol, and prolactin, Neostigmine, a non-centrally acting cholinesterase inhibitor, and saline placebo caused no such effects. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 34-48 6487203-3 1984 Physostigmine, a centrally active cholinesterase inhibitor which increases brain acetylcholine, was found to cause a motion sickness-like syndrome--in psychiatric patients and normals--including nausea, emesis, malaise, dysphoria, increases in serum ACTH, beta-endorphin, cortisol, and prolactin, Neostigmine, a non-centrally acting cholinesterase inhibitor, and saline placebo caused no such effects. Physostigmine 0-13 proopiomelanocortin Homo sapiens 250-254 6487203-3 1984 Physostigmine, a centrally active cholinesterase inhibitor which increases brain acetylcholine, was found to cause a motion sickness-like syndrome--in psychiatric patients and normals--including nausea, emesis, malaise, dysphoria, increases in serum ACTH, beta-endorphin, cortisol, and prolactin, Neostigmine, a non-centrally acting cholinesterase inhibitor, and saline placebo caused no such effects. Physostigmine 0-13 proopiomelanocortin Homo sapiens 256-270 6487203-3 1984 Physostigmine, a centrally active cholinesterase inhibitor which increases brain acetylcholine, was found to cause a motion sickness-like syndrome--in psychiatric patients and normals--including nausea, emesis, malaise, dysphoria, increases in serum ACTH, beta-endorphin, cortisol, and prolactin, Neostigmine, a non-centrally acting cholinesterase inhibitor, and saline placebo caused no such effects. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 333-347 6747844-4 1984 Met-enkephalin had no effect on the release of ACh evoked by a 2-Hz stimulation when cholinesterase was inhibited by physostigmine. Physostigmine 117-130 butyrylcholinesterase Homo sapiens 85-99 6148931-10 1984 The simultaneous administration of beta-endorphin (0.10 microgram/kg) with the central muscarinic agonist oxotremorine (12.5 or 50.0 micrograms/kg) completely prevented the impairment of retention induced by beta-endorphin, while the simultaneous administration of the central-acting anticholinesterase physostigmine (17 or 68 micrograms/kg) only partially but significantly attenuated the effect of beta-endorphin on retention. Physostigmine 303-316 pro-opiomelanocortin-alpha Mus musculus 35-49 6707949-7 1984 Physostigmine, an acetylcholinesterase inhibitor, decreased ACh release with an inverse relationship to stimulation frequency. Physostigmine 0-13 ACE-1 Oryctolagus cuniculus 18-38 6202869-5 1984 Whereas the muscarinic agonists pilocarpine and McN-A-343, the nonclassical antagonist pirenzepine, and the acetylcholinesterase inhibitor physostigmine reduced (+)-[3H]CD binding in both tissues, their inhibitory effects were more potent (4- to 77-fold) in cerebral cortical membranes. Physostigmine 139-152 acetylcholinesterase Rattus norvegicus 108-128 6327444-1 1984 The actions of pyridostigmine (Pyr), a quaternary carbamate compound, and physostigmine ( Phy ), a tertiary carbamate, both known for their reversible inhibition of acetylcholinesterase (AChE), were studied on the electrically excitable membrane and acetylcholine (ACh) receptor of the frog cutaneous pectoris, sartorius, and interosseal muscles, as well as the chronically denervated soleus muscle of the rat and myoballs from neonatal rats. Physostigmine 74-87 acetylcholinesterase Rattus norvegicus 165-185 6327444-1 1984 The actions of pyridostigmine (Pyr), a quaternary carbamate compound, and physostigmine ( Phy ), a tertiary carbamate, both known for their reversible inhibition of acetylcholinesterase (AChE), were studied on the electrically excitable membrane and acetylcholine (ACh) receptor of the frog cutaneous pectoris, sartorius, and interosseal muscles, as well as the chronically denervated soleus muscle of the rat and myoballs from neonatal rats. Physostigmine 74-87 acetylcholinesterase Rattus norvegicus 187-191 6327444-1 1984 The actions of pyridostigmine (Pyr), a quaternary carbamate compound, and physostigmine ( Phy ), a tertiary carbamate, both known for their reversible inhibition of acetylcholinesterase (AChE), were studied on the electrically excitable membrane and acetylcholine (ACh) receptor of the frog cutaneous pectoris, sartorius, and interosseal muscles, as well as the chronically denervated soleus muscle of the rat and myoballs from neonatal rats. Physostigmine 90-93 acetylcholinesterase Rattus norvegicus 165-185 6327444-1 1984 The actions of pyridostigmine (Pyr), a quaternary carbamate compound, and physostigmine ( Phy ), a tertiary carbamate, both known for their reversible inhibition of acetylcholinesterase (AChE), were studied on the electrically excitable membrane and acetylcholine (ACh) receptor of the frog cutaneous pectoris, sartorius, and interosseal muscles, as well as the chronically denervated soleus muscle of the rat and myoballs from neonatal rats. Physostigmine 90-93 acetylcholinesterase Rattus norvegicus 187-191 6319456-3 1984 However, each subject had a marked increase in ACTH and cortisol levels after the largest dose of physostigmine. Physostigmine 98-111 proopiomelanocortin Homo sapiens 47-51 6319456-5 1984 Four subjects who received physostigmine (12 micrograms/kg) without glycopyrrolate pretreatment also experienced noxious side effects; these symptoms were followed by elevations in ACTH, cortisol, and PRL levels. Physostigmine 27-40 proopiomelanocortin Homo sapiens 181-185 6319456-6 1984 These findings suggest that physostigmine stimulates ACTH and cortisol secretion through a stress-mediated effect rather than through a specific cholinergic mechanism. Physostigmine 28-41 proopiomelanocortin Homo sapiens 53-57 6143326-3 1984 The study reported here examined the effects of the cholinesterase inhibitor physostigmine, and several other cholinergic and anticholinergic drugs, on stimulant-induced behavior. Physostigmine 77-90 butyrylcholinesterase Homo sapiens 52-66 6427818-5 1984 In addition, a single low dose of TRH elicited tremor and salivation which were potentiated by physostigmine (0.1 mg/kg IP). Physostigmine 95-108 thyrotropin releasing hormone Mus musculus 34-37 6661467-4 1983 Greater than 90% of AChE activity in CSF could be inhibited by 10(-3) M eserine. Physostigmine 72-79 acetylcholinesterase (Cartwright blood group) Homo sapiens 20-24 6661467-4 1983 Greater than 90% of AChE activity in CSF could be inhibited by 10(-3) M eserine. Physostigmine 72-79 colony stimulating factor 2 Homo sapiens 37-40 6138014-2 1983 60 min before sacrifice) did not modify cholinesterase (ChE) activity, but considerably enhanced the inhibition of total ChE induced by physostigmine (PhS, 0.5 mg/kg i.p. Physostigmine 136-149 butyrylcholinesterase Rattus norvegicus 121-124 6887013-2 1983 In the heart, the phospholipase A2 inhibitor mepacrine (10(-4) M) reduced the choline efflux (1.1 nmol g-1 min-1) by 51 +/- 5% (N = 3), whereas several cholinesterase inhibitors (physostigmine, neostigmine and diisopropylfluorophosphate) and muscarinic agonists (acetylcholine, oxotremorine and bethanechol) caused an increase. Physostigmine 179-192 phospholipase A2 group IB Rattus norvegicus 18-34 6318208-1 1983 Subjects with major depressive illness had greater increases in plasma concentrations of ACTH and B-endorphin immunoreactivity in response to central muscarinic stimulation by physostigmine, than did normal control subjects, or psychiatric control subjects without major depressive illness. Physostigmine 176-189 proopiomelanocortin Homo sapiens 89-93 6194444-6 1983 Addition of physostigmine to the atropine + 2-PAM treatment regimen resulted in appreciable AChE reactivation but reduced RNA levels. Physostigmine 12-25 peptidylglycine alpha-amidating monooxygenase Rattus norvegicus 46-49 6194444-6 1983 Addition of physostigmine to the atropine + 2-PAM treatment regimen resulted in appreciable AChE reactivation but reduced RNA levels. Physostigmine 12-25 acetylcholinesterase Rattus norvegicus 92-96 6347034-6 1983 The decrease in intrusions was strongly correlated with increasing inhibition of cholinesterase activity in cerebrospinal fluid, suggesting that the degree of improvement in the patient"s memory was related to the amount of physostigmine that reached the brain. Physostigmine 224-237 butyrylcholinesterase Homo sapiens 81-95 6149635-1 1983 Atropine, in combination with 1 of 6 other drugs, was tested in mice for the ability to prevent death by an otherwise lethal dose of the cholinesterase inhibitor, physostigmine. Physostigmine 163-176 butyrylcholinesterase Mus musculus 137-151 6138014-2 1983 60 min before sacrifice) did not modify cholinesterase (ChE) activity, but considerably enhanced the inhibition of total ChE induced by physostigmine (PhS, 0.5 mg/kg i.p. Physostigmine 151-154 butyrylcholinesterase Rattus norvegicus 121-124 6840979-2 1983 The individual physostigmine dose was assessed by means of serum cholinesterase activity monitoring. Physostigmine 15-28 butyrylcholinesterase Homo sapiens 65-79 6293594-2 1982 Furthermore, physostigmine-stimulated release of beta-endorphin immunoreactivity was also significantly greater in the depressed patients. Physostigmine 13-26 proopiomelanocortin Homo sapiens 49-63 7119894-5 1982 The acetylcholinesterase inhibitor physostigmine was as effective as thiamin in decreasing staring in pyrithiamin-treated rats, but its peripherally acting analogue neostigmine had no effect. Physostigmine 35-48 acetylcholinesterase Rattus norvegicus 4-24 6289994-3 1982 Exposure to the acetylcholinesterase (AChe) inhibitor physostigmine (1 microM) resulted in a 50% increase in electrically evoked [3H]dopamine release. Physostigmine 54-67 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-36 6289994-3 1982 Exposure to the acetylcholinesterase (AChe) inhibitor physostigmine (1 microM) resulted in a 50% increase in electrically evoked [3H]dopamine release. Physostigmine 54-67 acetylcholinesterase (Cartwright blood group) Homo sapiens 38-42 6286926-3 1982 Physostigmine, a central and peripheral cholinesterase inhibitor produced tremors, and at high doses death, by respiratory paralysis. Physostigmine 0-13 butyrylcholinesterase Mus musculus 40-54 7180539-5 1982 Adding eserine (10(-5) M) or soman (10(-6) M) to the superfusion medium increased ACh content to 133 +/- 8 pmol and 101 +/- 8 pmol, respectively, and markedly reduced AChE-activity; ChAT activity was not effected. Physostigmine 7-14 acetylcholinesterase Rattus norvegicus 167-171 7121614-10 1982 Physostigmine decreased atrial cholinesterase activity by 80% and increased the fraction of stimulation-evoked unhydrolyzed 14C-acetylcholine in the persufates from 58 to 86%. Physostigmine 0-13 cholinesterase Oryctolagus cuniculus 31-45 7116155-3 1982 These data contrast with our previous findings that physostigmine-induced theta (I theta) is specifically associated with a decrease in 2-DG uptake in the stratum lacunosum moleculare of hippocampal CA1-CA2 areas. Physostigmine 52-65 carbonic anhydrase 1 Rattus norvegicus 199-202 7116155-3 1982 These data contrast with our previous findings that physostigmine-induced theta (I theta) is specifically associated with a decrease in 2-DG uptake in the stratum lacunosum moleculare of hippocampal CA1-CA2 areas. Physostigmine 52-65 carbonic anhydrase 2 Rattus norvegicus 203-206 6752738-1 1982 Ten patients with clinically diagnosed Alzheimer"s disease were given tests of recognition memory while receiving placebo or physostigmine, a cholinesterase inhibitor, given intravenously over 30 min. Physostigmine 125-138 butyrylcholinesterase Homo sapiens 142-156 7096782-0 1982 [Effect of intraperitoneal physostigmine administration on the multiple forms of acetylcholinesterase in different brain structures]. Physostigmine 27-40 acetylcholinesterase (Cartwright blood group) Homo sapiens 81-101 6289276-2 1982 Notably, in humans, intravenous infusion of centrally active cholinomimetic drugs, such as physostigmine or arecoline, may produce significant increases in plasma concentrations of prolactin and beta-endorphin immunoreactivity. Physostigmine 91-104 proopiomelanocortin Homo sapiens 195-209 6289276-3 1982 In three separate studies, conducted collaboratively between the National Institute of Mental Health and the University of California at San Diego, physostigmine and arecoline associated increases in plasma concentrations of beta-endorphin immunoreactivity were highly correlated with increases in plasma prolactin concentrations. Physostigmine 148-161 proopiomelanocortin Homo sapiens 225-239 7092918-0 1982 Reversible inhibition of acetylcholinesterase by eseroline, an opioid agonist structurally related to physostigmine (eserine) and morphine. Physostigmine 102-115 acetylcholinesterase (Cartwright blood group) Homo sapiens 25-45 7097593-3 1982 Physostigmine, an acetylcholinesterase inhibitor, and nicotine increased the spontaneous activity of nearly all retinal ganglion cell types. Physostigmine 0-13 ACE-1 Oryctolagus cuniculus 18-38 6273940-6 1981 This THC effect was slightly increased by physostigmine, a cholinesterase inhibitor, relatively unaffected by scopolamine, a muscarinic antagonist, and almost completely blocked by ethopropazine, an anticholinergic antiparkinson drug. Physostigmine 42-55 butyrylcholinesterase Rattus norvegicus 59-73 7070215-3 1982 Neostigmine (1 microgram) and physostigmine (15 microgram) caused nearly maximal and approximately equal degrees of cholinesterase inhibition in several brain regions. Physostigmine 30-43 butyrylcholinesterase Rattus norvegicus 116-130 7070215-4 1982 The recovery of the cardiovascular parameters and of brain cholinesterase activity was significantly faster following physostigmine compared to neostigmine. Physostigmine 118-131 butyrylcholinesterase Rattus norvegicus 59-73 6804471-2 1982 Intravenously administered physostigmine, a cholinesterase inhibitor, increased CBF under normocapnia and enhanced the cerebral vasodilatation of hypercapnia, but did not alter the cerebral metabolic rate of oxygen (CMRO2). Physostigmine 27-40 cholinesterase Oryctolagus cuniculus 44-58 6281836-4 1982 The jumping elicited by TRH (20 mg/kg IP) in combination with apomorphine (0.25 mg/kg IP) was decreased by pretreatment with haloperidol (1 mg/kg IP), physostigmine (0.2 mg/kg IP) or phentolamine (10 mg/kg IP), unaffected by propranolol (10 mg/kg IP), and markedly increased by atropine (5 mg/kg IP) or clonidine (0.5 mg/kg IP). Physostigmine 151-164 thyrotropin releasing hormone Mus musculus 24-27 7135153-2 1982 If these neuronal effects are associated with CNS depression, then administration of a cholinesterase inhibitor (physostigmine) with ethanol should result in antagonism of this CNS depression. Physostigmine 113-126 butyrylcholinesterase Homo sapiens 87-101 7298772-0 1981 Quantitative determination of the cholinesterase inhibitor physostigmine in brain tissue samples using reversed-phase high-performance liquid chromatography. Physostigmine 59-72 butyrylcholinesterase Homo sapiens 34-48 7336979-1 1981 The early and late effect of three anticholinesterase agents (physostigmine, paraoxon and soman) on core temperature and brain acetylcholinesterase (AcChE) inhibition are compared. Physostigmine 62-75 acetylcholinesterase Rattus norvegicus 127-147 6459593-3 1981 If cholinesterase activity was inhibited with physostigmine, the differences between the various age groups were obliterated. Physostigmine 46-59 butyrylcholinesterase Rattus norvegicus 3-17 7229989-4 1981 The acetylcholinesterase inhibitor physostigmine improved the low string test scores in 69.2% of trials with the pyrithiamine-treated rats, whereas neostigmine, which acts peripherally, had no effect. Physostigmine 35-48 acetylcholinesterase Rattus norvegicus 4-24 7184786-0 1981 The inhibition and protection of cholinesterase by physostigmine and pyridostigmine against Soman poisoning in vivo. Physostigmine 51-64 butyrylcholinesterase Mus musculus 33-47 7184786-1 1981 It has been shown that some reversible cholinesterase (ChE) inhibitors as physostigmine and pyridostigmine are prophylactically effective in organophosphate poisoning. Physostigmine 74-87 butyrylcholinesterase Mus musculus 39-53 7184786-1 1981 It has been shown that some reversible cholinesterase (ChE) inhibitors as physostigmine and pyridostigmine are prophylactically effective in organophosphate poisoning. Physostigmine 74-87 butyrylcholinesterase Mus musculus 55-58 7184786-3 1981 (1) Physostigmine and pyridostigmine significantly inhibited the ChE in whole blood in vivo and their inhibitory potencies with equitoxic doses were approximately equal (1/5LD50 about 30%; 1/2 LD50 about 45% respectively). Physostigmine 4-17 butyrylcholinesterase Mus musculus 65-68 7184786-4 1981 Physostigmine also significantly inhibited brain ChE and its potency was slightly weaker than that in blood; but pyridostigmine only slightly inhibited brain ChE (17%) with large dose (1/2 LD50). Physostigmine 0-13 butyrylcholinesterase Mus musculus 49-52 7184786-6 1981 (2) Physostigmine had definite protection in the blood and brain ChE against Soman poisoning. Physostigmine 4-17 butyrylcholinesterase Mus musculus 65-68 7184786-10 1981 (3) The inhibitory potency of equitoxic doses of physostigmine and pyridostigmine in the ChE of diaphragm muscle was equal too (1/2 LD50 about 45%), and the protective effect of physostigmine was still greater than that of pyridostigmine in Soman poisoning. Physostigmine 49-62 butyrylcholinesterase Mus musculus 89-92 7184786-11 1981 (4) The time course of blood ChE inhibition by physostigmine in vivo was of short duration. Physostigmine 47-60 butyrylcholinesterase Mus musculus 29-32 7184786-12 1981 While 30 minutes after administration of physostigmine, the ChE activity gradually recovered and it returned to normal level after 4 hours. Physostigmine 41-54 butyrylcholinesterase Mus musculus 60-63 7184786-14 1981 Physostigmine and pyridostigmine, the reversible ChE inhibitors with carbamate structure, have definite ChE protection against Soman poisoning. Physostigmine 0-13 butyrylcholinesterase Mus musculus 49-52 7184786-14 1981 Physostigmine and pyridostigmine, the reversible ChE inhibitors with carbamate structure, have definite ChE protection against Soman poisoning. Physostigmine 0-13 butyrylcholinesterase Mus musculus 104-107 7217205-10 1981 As in the normal SCG, physostigmine-resistant staining, caused by noncholinesterase enzymes plus the possible presence of very low concentrations of AChE or BuChE, was noted at external mitochondrial membranes, elements of the endoplasmic reticulum of neurites and Schwann cells, and also in lysosomes. Physostigmine 22-35 acetylcholinesterase (Cartwright blood group) Homo sapiens 149-153 7217205-10 1981 As in the normal SCG, physostigmine-resistant staining, caused by noncholinesterase enzymes plus the possible presence of very low concentrations of AChE or BuChE, was noted at external mitochondrial membranes, elements of the endoplasmic reticulum of neurites and Schwann cells, and also in lysosomes. Physostigmine 22-35 butyrylcholinesterase Homo sapiens 157-162 7188667-1 1980 Patients undergoing dental extraction under intravenous diazepam sedation were studied to determine whether physostigmine, a cholinesterase inhibitor, reverses diazepam-induced sedation. Physostigmine 108-121 butyrylcholinesterase Homo sapiens 125-139 7433977-0 1980 Mood and behavioral effects of physostigmine on humans are accompanied by elevations in plasma beta-endorphin and cortisol. Physostigmine 31-44 proopiomelanocortin Homo sapiens 95-109 7433977-1 1980 Administration of physostigmine to normal volunteers produced significant elevations in plasma cortisol and beta-endorphin immunoreactivity as well as alterations in mood, cognition, and behavior. Physostigmine 18-31 proopiomelanocortin Homo sapiens 108-122 7433977-3 1980 However, peak elevations in plasma beta-endorphin immunoreactivity (but not in plasma cortisol) were significantly correlated with physostigmine-induced increases in depression ratings. Physostigmine 131-144 proopiomelanocortin Homo sapiens 35-49 6255749-8 1980 In the same observation period the activity of AChE in the tibialis muscle of rats was found to be highest after physostigmine injection before administration of DDVP or phospholine. Physostigmine 113-126 acetylcholinesterase Rattus norvegicus 47-51 6247214-6 1980 Cholinergic agonists, physostigmine and pilocarpine, antagonized the growth hormone and prolactin release induced by morphine sulfate. Physostigmine 22-35 gonadotropin releasing hormone receptor Rattus norvegicus 69-83 7398832-3 1980 If the slices were exposed to an acetylcholinesterase (AChE)-inhibitor (paraoxon 1--20 muM, physostigmine 0.1--0.5 muM), the synaptic potentials were potentiated. Physostigmine 92-105 acetylcholinesterase Rattus norvegicus 33-53 7398832-3 1980 If the slices were exposed to an acetylcholinesterase (AChE)-inhibitor (paraoxon 1--20 muM, physostigmine 0.1--0.5 muM), the synaptic potentials were potentiated. Physostigmine 92-105 acetylcholinesterase Rattus norvegicus 55-59 6771826-2 1980 A cholinesterase inhibitor, physostigmine, was administered in conjunction with imipramine to determine if these effects of imipramine were cholinergically medicated. Physostigmine 28-41 butyrylcholinesterase Rattus norvegicus 2-16 503252-1 1979 The cholinergic agonists, pilocarpine, physostigmine and nicotine, inhibited the prolactin release induced by morphine in male rats in vivo. Physostigmine 39-52 prolactin Rattus norvegicus 81-90 443426-7 1979 In contrast, physostigmine, the cholinesterase inhibitor, caused displacement of the curve to the left. Physostigmine 13-26 butyrylcholinesterase Rattus norvegicus 32-46 112633-1 1979 Physostigmine, a centrally acting cholinesterase inhibitor, antagonizes methylphenidate-induced stereotyped gnawing behavior in mice and rats. Physostigmine 0-13 butyrylcholinesterase Mus musculus 34-48 219652-2 1978 Physostigmine was less effective in augmenting twitch height in preparations from alloxan diabetic rats and such preparations had a significantly lowered total cholinesterase activity compared with control preparations. Physostigmine 0-13 butyrylcholinesterase Rattus norvegicus 160-174 119254-2 1979 Similar results (i.e., tolerance to pilocarpine and cross-tolerance to chlorpromazine) were noted in mice chronically treated with the cholinesterase inhibitor physostigmine but not in mice chronically treated with neostigmine, a cholinesterase inhibitor which does not penetrate the central nervous system. Physostigmine 160-173 butyrylcholinesterase Mus musculus 135-149 445230-3 1979 It was found that stimulation induced vasoconstrictor responses which were enhanced by physostigmine, a cholinesterase inhibitor, and blocked by atropine. Physostigmine 87-100 butyrylcholinesterase Homo sapiens 104-118 155828-1 1979 In vivo inhibition of blood acetylcholinesterase activity by 9-amino-1, 2, 3, 4-tetrahydroacridine, its 7-methoxy derivative and physostigmine was studied in rats. Physostigmine 129-142 acetylcholinesterase Rattus norvegicus 28-48 30564-2 1978 Physostigmine is known to reverse the central muscarinic anticholinergic manifestations by inhibition of the enzyme cholinesterase. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 116-130 27608-1 1978 The effect of physostigmine has been studied on cholinesterase in homogenates of chick biventer cervicis muscles and on the contractile responses of the intact muscles to acetylcholine and carbachol. Physostigmine 14-27 butyrylcholinesterase Gallus gallus 48-62 27608-2 1978 The concentration of physostigmine required to produce the maximum increase in sensitivity to acetylcholine almost completely inhibited the cholinesterase in muscle homogenates. Physostigmine 21-34 butyrylcholinesterase Gallus gallus 140-154 247534-3 1978 Physostigmine caused similar potentiation of responses to acetylcholine and MCh which implies that acetylcholinesterase is located close to the site(s) at which the drugs act to stimulate chemoreceptor activity. Physostigmine 0-13 acetylcholinesterase Felis catus 99-119 618734-2 1978 These contractions were selectively and reversibly inhibited by carbamate-type cholinesterase inhibitors, such as neostigmine and eserine, and quaternary ammonium compounds, such as tetraethylammonium and decamethonium. Physostigmine 130-137 butyrylcholinesterase Rattus norvegicus 79-93 203742-7 1977 Of great significance in ocular myasthenia is the local application of cholinesterase inhibitors like Eserine, Prostigmin or Phospholine Iodide. Physostigmine 102-109 butyrylcholinesterase Homo sapiens 71-85 145765-6 1977 The blockator of cholinesterase physostigmine had opposite effects. Physostigmine 32-45 butyrylcholinesterase Rattus norvegicus 17-31 1192181-10 1975 Experiments using physostigmine, an AChE inhibitor, demonstrated that inhibition of AChE can potentiate the effects of ACh in unlesioned preparations, but not in lesioned preparations. Physostigmine 18-31 acetylcholinesterase Rattus norvegicus 36-40 921895-1 1977 Local injection of physostigmine revealed that dermatomally distributed vitiligo was associated with a dysfunction of the sympathetic nerves in the affected skin and that non-dermatomally distributed vitiligo was not. Physostigmine 19-32 VAMAS6 Homo sapiens 72-80 15097-6 1977 Physostigmine (1.0 mg/kg), pilocarpine (25-50 mg/kg) and nicotine (10 mg/kg) increased TH activity in LC and adrenal. Physostigmine 0-13 tyrosine hydroxylase Rattus norvegicus 87-89 589954-1 1977 Subtoxic doses of physostigmine have been found to potentiate the convulsive toxicity and lethality of amitriptyline and imipramine in CD1 and B6A mice. Physostigmine 18-31 CD1 antigen complex Mus musculus 135-138 335493-3 1977 The serine-specific inhibitors phenylmethylsulfonyl fluoride (PMSF) and physostigmine (eserine) markedly reduced LIF activity, whereas the histidine-specific inhibitors N-tosyl-L-lysine chloromethyl ketone (TLCK) and L-tosylamide-2-phenylethyl chloromethyl ketone (TPCK) were inactive. Physostigmine 72-85 LIF interleukin 6 family cytokine Homo sapiens 113-116 335493-3 1977 The serine-specific inhibitors phenylmethylsulfonyl fluoride (PMSF) and physostigmine (eserine) markedly reduced LIF activity, whereas the histidine-specific inhibitors N-tosyl-L-lysine chloromethyl ketone (TLCK) and L-tosylamide-2-phenylethyl chloromethyl ketone (TPCK) were inactive. Physostigmine 87-94 LIF interleukin 6 family cytokine Homo sapiens 113-116 975633-4 1976 A combination of reserpine plus a cholinesterase inhibitor significantly increased lethality in adult male Swiss-Webster mice above that caused by either neostigmine, physostigmine, or reserpine alone. Physostigmine 167-180 butyrylcholinesterase Mus musculus 34-48 1192181-10 1975 Experiments using physostigmine, an AChE inhibitor, demonstrated that inhibition of AChE can potentiate the effects of ACh in unlesioned preparations, but not in lesioned preparations. Physostigmine 18-31 acetylcholinesterase Rattus norvegicus 84-88 1151640-1 1975 NMR was used to study the binding of acetylcholine, atropine, and physostigmine to acetylcholinesterase. Physostigmine 66-79 acetylcholinesterase (Cartwright blood group) Homo sapiens 83-103 1151640-4 1975 The dissociation constant, KD and the linewidth of the acetylcholinesterase-inhibitor complex, increment v bound, for atropine and physostigmine can be estimated from the linewidth changes of the N-methyl and phenyl group resonances of atropine and from the N-methyl and C-methyl group resonances of physostigmine resulting from association with the enzyme. Physostigmine 131-144 acetylcholinesterase (Cartwright blood group) Homo sapiens 55-75 1151640-4 1975 The dissociation constant, KD and the linewidth of the acetylcholinesterase-inhibitor complex, increment v bound, for atropine and physostigmine can be estimated from the linewidth changes of the N-methyl and phenyl group resonances of atropine and from the N-methyl and C-methyl group resonances of physostigmine resulting from association with the enzyme. Physostigmine 300-313 acetylcholinesterase (Cartwright blood group) Homo sapiens 55-75 241944-2 1975 The cholinesterase inhibitors paraoxon and physostigmine caused an elevation only in "cerebrum", whereas the cGMP content of the cerebellum even decreased. Physostigmine 43-56 butyrylcholinesterase Mus musculus 4-18 19873399-0 1944 THE MECHANISM OF ENZYME-INHIBITOR-SUBSTRATE REACTIONS : ILLUSTRATED BY THE CHOLINESTERASE-PHYSOSTIGMINE-ACETYLCHOLINE SYSTEM. Physostigmine 90-103 butyrylcholinesterase Homo sapiens 75-89 4460070-0 1974 The effects of lithium and physostigmine on rat brain acetylcholinesterase activity. Physostigmine 27-40 acetylcholinesterase Rattus norvegicus 54-74 4656608-5 1972 Only slices from physostigmine-treated rats had a significantly lower cholinesterase activity.4. Physostigmine 17-30 butyrylcholinesterase Rattus norvegicus 70-84 4651776-3 1972 Of the compounds tested, chlorpromazine HC1 (15 mg/kg) and reserpine (10 mg/kg) had the greatest potentiating effect on the tremor-producing action of physostigmine. Physostigmine 151-164 Hypercalciuria QTL 1 Rattus norvegicus 40-43 4343315-2 1972 Studies involving the electrophoretic administration of antagonists of ACh (atropine, DHbetaE) and cholinesterase inhibitors (neostigmine, physostigmine) to MGN neurones indicate that ACh is an excitatory transmitter in the feline MGN, most probably released from fibres which originate in or traverse the mesencephalon.2. Physostigmine 139-152 butyrylcholinesterase Homo sapiens 99-113 5315359-8 1971 A unique cholinesterase was found in motor end-plates of cricket muscle, which hydrolyses acetylthiocholine and which was inhibited by physostigmine. Physostigmine 135-148 butyrylcholinesterase Homo sapiens 9-23 5472872-0 1970 The glycogenolytic and hypertensive effect of physostigmine in the anti-nerve-growth-factor-serum-treated rats. Physostigmine 46-59 nerve growth factor Rattus norvegicus 72-91 4394344-0 1970 Increased plasma renin activity induced in rats by physostigmine and effects of alpha- and beta-receptors blocking drugs thereon. Physostigmine 51-64 renin Rattus norvegicus 17-22 5873635-0 1965 [Acetylcholinesterase and the bioelectrical activity of the brain under the action of eserine and galanthamine in animals with premesencephalic section of the brain]. Physostigmine 86-93 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-21 14099400-0 1963 [ON THE INHIBITION OF THE HISTOCHEMICAL ACETYLCHOLINESTERASE REACTION ON MOTOR END-PLATES BY INJECTIONS OF NEOSTIGMINE AND PHYSOSTIGMINE]. Physostigmine 123-136 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-60 13536279-4 1958 The greater sensitivity of the leech muscle to eserine is fully accounted for by the fact that its cholinesterase is more sensitive to eserine than to neostigmine. Physostigmine 47-54 butyrylcholinesterase Equus caballus 99-113 13525672-7 1958 The inhibition of sodium extrusion by physostigmine was correlated with the inhibition of the intracellular cholinesterase. Physostigmine 38-51 butyrylcholinesterase Homo sapiens 108-122 19873399-10 1944 The inhibition of cholinesterase by physostigmine is competitive. Physostigmine 36-49 butyrylcholinesterase Homo sapiens 18-32 19873399-11 1944 A single molecule of physostigmine or acetylcholine combines with one center of cholinesterase-n = 1; and the mechanism n = 2 has been. Physostigmine 21-34 butyrylcholinesterase Homo sapiens 80-94 19873399-23 1944 The destruction of physostigmine or acetylcholine by cholinesterase follows the predicted curve; k(D) for the destruction of physostigmine is found to be > 0.00182; k(D) for acetylcholine destruction is > 3500. Physostigmine 19-32 butyrylcholinesterase Homo sapiens 53-67 19873399-23 1944 The destruction of physostigmine or acetylcholine by cholinesterase follows the predicted curve; k(D) for the destruction of physostigmine is found to be > 0.00182; k(D) for acetylcholine destruction is > 3500. Physostigmine 125-138 butyrylcholinesterase Homo sapiens 53-67 19873367-0 1943 ZONE BEHAVIOR OF ENZYMES : ILLUSTRATED BY THE EFFECT OF DISSOCIATION CONSTANT AND DILUTION ON THE SYSTEM CHOLINESTERASE-PHYSOSTIGMINE. Physostigmine 120-133 butyrylcholinesterase Homo sapiens 105-119 33317802-2 2021 In addition, the anti-cholinesterase drug physostigmine that increases synaptic acetylcholine concentrations has anti-inflammatory effects. Physostigmine 42-55 butyrylcholinesterase Homo sapiens 22-36 31709829-7 2020 The cholinesterase inhibitor, physostigmine, increased the probability of a full intestine MC, but had no significant effect on frequency, speed, or direction. Physostigmine 30-43 butyrylcholinesterase Mus musculus 4-18 33357230-7 2020 Inhibition of this cancer-cell-intrinsic AChE via pyridostigmine and physostigmine, or administration of acetylcholine (ACh), diminished PCa cell viability and invasion in vitro and in vivo via suppression of pERK signaling, and reduced tumor-associated macrophage (TAM) infiltration and serum pro-inflammatory cytokine levels. Physostigmine 69-82 acetylcholinesterase (Cartwright blood group) Homo sapiens 41-45 32729530-2 2020 Among several drugs, we designed the device for evaluating the efficacy of compounds (e.g. physostigmine, rivastigmine, donepezil) which are able to inhibit in a reversible way the cholinesterase enzyme. Physostigmine 91-104 butyrylcholinesterase Homo sapiens 181-195 31825510-3 2020 We trained separate groups of adult mice on the rotarod walking task and the single pellet reaching task, and after training, administered physostigmine, an acetylcholinesterase inhibitor, to increase cholinergic tone in subsequent sleep. Physostigmine 139-152 acetylcholinesterase Mus musculus 157-177 32230733-4 2020 Comparing the protective efficacy of five such cholinesterase inhibitors (physostigmine, pyridostigmine, ranitidine, tacrine, or K-27), we observed best protection for the experimental oxime K-27. Physostigmine 74-87 butyrylcholinesterase Rattus norvegicus 47-61 32230733-4 2020 Comparing the protective efficacy of five such cholinesterase inhibitors (physostigmine, pyridostigmine, ranitidine, tacrine, or K-27), we observed best protection for the experimental oxime K-27. Physostigmine 74-87 keratin 27 Rattus norvegicus 191-195 31398669-12 2019 Physostigmine inhibited AChE activity with a sigmoidal concentration-response effect. Physostigmine 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 24-28 31517779-6 2019 Nicotine and the acetylcholinesterase inhibitor physostigmine reduced the chronotropism of right atria from either NWR or SHR. Physostigmine 48-61 acetylcholinesterase Rattus norvegicus 17-37 31185278-4 2019 The current experiment examined if systemic administration of the acetylcholinesterase inhibitor physostigmine (PHY) prior to context learning would rescue prefrontal IEG expression and freezing in the CPFE. Physostigmine 97-110 acetylcholinesterase Rattus norvegicus 66-86 31517530-2 2019 The structural properties and binding interactions of the AD drug physostigmine (-)-phy, and its analogues (-)-hex and (-)-phe and (+)-phe, were examined, as well as their impact on the conformational changes of two different AD target enzymes AChE and BChE. Physostigmine 66-79 hematopoietically expressed homeobox Homo sapiens 111-114 31517530-2 2019 The structural properties and binding interactions of the AD drug physostigmine (-)-phy, and its analogues (-)-hex and (-)-phe and (+)-phe, were examined, as well as their impact on the conformational changes of two different AD target enzymes AChE and BChE. Physostigmine 66-79 acetylcholinesterase (Cartwright blood group) Homo sapiens 244-248 31517530-2 2019 The structural properties and binding interactions of the AD drug physostigmine (-)-phy, and its analogues (-)-hex and (-)-phe and (+)-phe, were examined, as well as their impact on the conformational changes of two different AD target enzymes AChE and BChE. Physostigmine 66-79 butyrylcholinesterase Homo sapiens 253-257 31185278-4 2019 The current experiment examined if systemic administration of the acetylcholinesterase inhibitor physostigmine (PHY) prior to context learning would rescue prefrontal IEG expression and freezing in the CPFE. Physostigmine 112-115 acetylcholinesterase Rattus norvegicus 66-86 31185278-10 2019 EtOH-PHY treatment rescued mPFC expression of c-Fos in ethanol-exposed rats and increased Arc and Npas4 regardless of dosing condition. Physostigmine 5-8 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 46-51 31185278-10 2019 EtOH-PHY treatment rescued mPFC expression of c-Fos in ethanol-exposed rats and increased Arc and Npas4 regardless of dosing condition. Physostigmine 5-8 nucleolar protein 3 Rattus norvegicus 90-93 31185278-10 2019 EtOH-PHY treatment rescued mPFC expression of c-Fos in ethanol-exposed rats and increased Arc and Npas4 regardless of dosing condition. Physostigmine 5-8 neuronal PAS domain protein 4 Rattus norvegicus 98-103 31003155-5 2019 Then, PBOCCA rats received ip injections with, either vehicle (control group), the muscarinic receptor agonist oxotremorine (0.1 mg/kg), or the acetylcholinesterase inhibitor physostigmine (0.1 mg/kg). Physostigmine 175-188 acetylcholinesterase Rattus norvegicus 144-164 30389473-1 2018 Pre-administration of physostigmine can prevent poisoning against nerve agent exposure by reversibly binding to cholinesterase. Physostigmine 22-35 butyrylcholinesterase Rattus norvegicus 112-126 30682440-1 2019 BACKGROUND: Carbamates physostigmine and pyridostigmine have been used as a pretreatment against poisoning with nerve agents in order to reversibly inhibit and thus protect from irreversible inhibition a portion of acetylcholinesterase (AChE) in brain and respiratory muscles that is crucial for survival. Physostigmine 23-36 acetylcholinesterase Rattus norvegicus 215-235 30682440-1 2019 BACKGROUND: Carbamates physostigmine and pyridostigmine have been used as a pretreatment against poisoning with nerve agents in order to reversibly inhibit and thus protect from irreversible inhibition a portion of acetylcholinesterase (AChE) in brain and respiratory muscles that is crucial for survival. Physostigmine 23-36 acetylcholinesterase Rattus norvegicus 237-241 30804708-7 2019 Treatment with physostigmine or neostigmine significantly reduced ROS production and CD11b upregulation by PMNs 20 h after CLP induction. Physostigmine 15-28 integrin subunit alpha M Rattus norvegicus 85-90 30389473-15 2018 These results suggest that PEG liposomes have potential to enhance the duration of cholinesterase-protecting effect of physostigmine. Physostigmine 119-132 butyrylcholinesterase Rattus norvegicus 83-97 30245349-5 2018 Acarbose was used as a reference standard for alpha-glucosidase inhibition while eserine for AChE and BChE inhibition. Physostigmine 81-88 butyrylcholinesterase Homo sapiens 102-106 29790105-6 2018 Furthermore, it led to a decreased expression of ATG-3 after 24 h and an increased expression of p62/ SQSTM1 after 1 h and 24 h. Administration of physostigmine significantly increased autophagy related markers and restored the autophagic flux after surgery stress, detected by increased degradation of p62/ SQSTM1 in the hippocampus after 1 h and 24 h. Furthermore, physostigmine reduced activated microglia and apoptosis relevant proteins and elevated the increased expression of TGF-beta1 and MFG-E8 after surgery stress. Physostigmine 147-160 autophagy related 3 Rattus norvegicus 49-54 29589284-13 2018 Acetylcholinesterase inhibitor physostigmine partially reversed the impaired learning and memory of hypoxic zebrafish. Physostigmine 31-44 acetylcholinesterase Danio rerio 0-20 29790105-6 2018 Furthermore, it led to a decreased expression of ATG-3 after 24 h and an increased expression of p62/ SQSTM1 after 1 h and 24 h. Administration of physostigmine significantly increased autophagy related markers and restored the autophagic flux after surgery stress, detected by increased degradation of p62/ SQSTM1 in the hippocampus after 1 h and 24 h. Furthermore, physostigmine reduced activated microglia and apoptosis relevant proteins and elevated the increased expression of TGF-beta1 and MFG-E8 after surgery stress. Physostigmine 147-160 KH RNA binding domain containing, signal transduction associated 1 Rattus norvegicus 97-100 29790105-6 2018 Furthermore, it led to a decreased expression of ATG-3 after 24 h and an increased expression of p62/ SQSTM1 after 1 h and 24 h. Administration of physostigmine significantly increased autophagy related markers and restored the autophagic flux after surgery stress, detected by increased degradation of p62/ SQSTM1 in the hippocampus after 1 h and 24 h. Furthermore, physostigmine reduced activated microglia and apoptosis relevant proteins and elevated the increased expression of TGF-beta1 and MFG-E8 after surgery stress. Physostigmine 147-160 sequestosome 1 Rattus norvegicus 102-108 29790105-6 2018 Furthermore, it led to a decreased expression of ATG-3 after 24 h and an increased expression of p62/ SQSTM1 after 1 h and 24 h. Administration of physostigmine significantly increased autophagy related markers and restored the autophagic flux after surgery stress, detected by increased degradation of p62/ SQSTM1 in the hippocampus after 1 h and 24 h. Furthermore, physostigmine reduced activated microglia and apoptosis relevant proteins and elevated the increased expression of TGF-beta1 and MFG-E8 after surgery stress. Physostigmine 147-160 KH RNA binding domain containing, signal transduction associated 1 Rattus norvegicus 303-306 29790105-6 2018 Furthermore, it led to a decreased expression of ATG-3 after 24 h and an increased expression of p62/ SQSTM1 after 1 h and 24 h. Administration of physostigmine significantly increased autophagy related markers and restored the autophagic flux after surgery stress, detected by increased degradation of p62/ SQSTM1 in the hippocampus after 1 h and 24 h. Furthermore, physostigmine reduced activated microglia and apoptosis relevant proteins and elevated the increased expression of TGF-beta1 and MFG-E8 after surgery stress. Physostigmine 147-160 sequestosome 1 Rattus norvegicus 308-314 29790105-6 2018 Furthermore, it led to a decreased expression of ATG-3 after 24 h and an increased expression of p62/ SQSTM1 after 1 h and 24 h. Administration of physostigmine significantly increased autophagy related markers and restored the autophagic flux after surgery stress, detected by increased degradation of p62/ SQSTM1 in the hippocampus after 1 h and 24 h. Furthermore, physostigmine reduced activated microglia and apoptosis relevant proteins and elevated the increased expression of TGF-beta1 and MFG-E8 after surgery stress. Physostigmine 147-160 transforming growth factor, beta 1 Rattus norvegicus 482-491 29790105-6 2018 Furthermore, it led to a decreased expression of ATG-3 after 24 h and an increased expression of p62/ SQSTM1 after 1 h and 24 h. Administration of physostigmine significantly increased autophagy related markers and restored the autophagic flux after surgery stress, detected by increased degradation of p62/ SQSTM1 in the hippocampus after 1 h and 24 h. Furthermore, physostigmine reduced activated microglia and apoptosis relevant proteins and elevated the increased expression of TGF-beta1 and MFG-E8 after surgery stress. Physostigmine 147-160 milk fat globule EGF and factor V/VIII domain containing Rattus norvegicus 496-502 29790105-6 2018 Furthermore, it led to a decreased expression of ATG-3 after 24 h and an increased expression of p62/ SQSTM1 after 1 h and 24 h. Administration of physostigmine significantly increased autophagy related markers and restored the autophagic flux after surgery stress, detected by increased degradation of p62/ SQSTM1 in the hippocampus after 1 h and 24 h. Furthermore, physostigmine reduced activated microglia and apoptosis relevant proteins and elevated the increased expression of TGF-beta1 and MFG-E8 after surgery stress. Physostigmine 367-380 KH RNA binding domain containing, signal transduction associated 1 Rattus norvegicus 97-100 30176331-11 2018 Oxime HI-6 50 mg/kg reactivated acetylcholinesterase (AChE) in brain inhibited by physostigmine and in diaphragm inhibited by pyridostigmine. Physostigmine 82-95 acetylcholinesterase Rattus norvegicus 54-58 30176331-12 2018 CONCLUSIONS: Mechanism of physostigmine-induced lethal effect is predominantly central and it involves inhibition of brain AChE, while pyridostigmine produces the same effect exclusively outside the central nervous system, by inhibiting AChE in the respiratory muscles. Physostigmine 26-39 acetylcholinesterase Rattus norvegicus 123-127 30176331-12 2018 CONCLUSIONS: Mechanism of physostigmine-induced lethal effect is predominantly central and it involves inhibition of brain AChE, while pyridostigmine produces the same effect exclusively outside the central nervous system, by inhibiting AChE in the respiratory muscles. Physostigmine 26-39 acetylcholinesterase Rattus norvegicus 237-241 30176331-14 2018 The oxime acts as antidote against physostigmine and pyridostigmine poisoning by reactivating AChE in the brain and diaphragm, respectively. Physostigmine 35-48 acetylcholinesterase Rattus norvegicus 94-98 28264149-6 2018 MLA also decreased physostigmine-induced c-fos immunoreactivity (a marker of neuronal activity) in hippocampus. Physostigmine 19-32 FBJ osteosarcoma oncogene Mus musculus 41-46 29796810-1 2018 Parameters of cardiac activity after administration of the cholinesterase inhibitor physostigmine were analyzed in newborn rats and on day 16 of postnatal development. Physostigmine 84-97 butyrylcholinesterase Rattus norvegicus 59-73 28630263-4 2017 Chimeric constructs of the alpha2 and alpha4 subunits located two regions in the extracellular amino-terminal domain of the subunit: the E loop (a loop of the transmitter-binding domain) and a region closer to the amino-terminus that collectively could completely determine the different effects of physostigmine. Physostigmine 299-312 immunoglobulin binding protein 1 Homo sapiens 38-44 29122691-2 2018 We previously investigated the role of muscarinic receptors in this regulation by administering physostigmine (PHYSO), an acetylcholinesterase inhibitor, to male and female rats pretreated with scopolamine (SCOP), a nonselective muscarinic antagonist. Physostigmine 96-109 acetylcholinesterase Rattus norvegicus 122-142 28571775-11 2017 Moreover, intra-CA1 injection of sub-threshold dose of physostigmine (0.0001mug/rat) and scopolamine (0.01mug/rat) could restore the memory acquisition deficit induced by RSD, while scopolamine could restore TSD-induced amnesia. Physostigmine 55-68 carbonic anhydrase 1 Rattus norvegicus 16-19 28373858-3 2017 To determine if enhancing central cholinergic activity with the centrally acting acetylcholinesterase inhibitor, physostigmine would increase CBF when upright compared to the peripherally acting acetylcholinesterase inhibitor, neostigmine, or saline. Physostigmine 113-126 acetylcholinesterase (Cartwright blood group) Homo sapiens 81-101 27895161-1 2017 Physostigmine is a well known inhibitor of acetylcholinesterase, which can also activate, potentiate, and inhibit acetylcholine receptors, including neuronal nicotinic receptors comprising alpha4 and beta2 subunits. Physostigmine 0-13 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 200-205 27895161-3 2017 The form containing three copies of alpha4 and two of beta2 was potentiated at low concentrations of acetylcholine chloride (ACh) and physostigmine, whereas the form containing two copies of alpha4 and three of beta2 was inhibited. Physostigmine 134-147 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 54-59 26991753-4 2016 The objective of this study was to test the hypothesis that physostigmine, a centrally acting cholinesterase inhibitor, induces reanimation from isoflurane anesthesia in adult rats. Physostigmine 60-73 butyrylcholinesterase Rattus norvegicus 94-108 27378362-1 2016 Physostigmine, an acetylcholinesterase inhibitor, is known to affect the brain function in various aspects. Physostigmine 0-13 acetylcholinesterase Danio rerio 18-38 26772968-6 2016 In vitro, the enzyme activity of human AChE and BChE was inhibited in a concentration-dependent manner until a residual activity of 4-6% for AChE and 20-30% for BChE (IC 50 human AChE: 0.117 +- 0.007 muM physostigmine, 0.062 +- 0.003 muM neostigmine; IC 50 human BChE: 0.373 +- 0.089 muM neostigmine; 0.059 +- 0.012 muM physostigmine). Physostigmine 204-217 butyrylcholinesterase Homo sapiens 48-52 26772968-6 2016 In vitro, the enzyme activity of human AChE and BChE was inhibited in a concentration-dependent manner until a residual activity of 4-6% for AChE and 20-30% for BChE (IC 50 human AChE: 0.117 +- 0.007 muM physostigmine, 0.062 +- 0.003 muM neostigmine; IC 50 human BChE: 0.373 +- 0.089 muM neostigmine; 0.059 +- 0.012 muM physostigmine). Physostigmine 320-333 butyrylcholinesterase Homo sapiens 48-52 27095151-15 2016 Furthermore, physostigmine reduced IL1beta (p < 0.05). Physostigmine 13-26 interleukin 1 beta Rattus norvegicus 35-42 27089282-5 2016 A pretest intra-CA1 injection of physostigmine (1 mug/mouse) reversed the memory impairment induced by post-training administration of tramadol (1 mug/mouse, intra-CA1). Physostigmine 33-46 carbonic anhydrase 1 Mus musculus 16-19 27089282-5 2016 A pretest intra-CA1 injection of physostigmine (1 mug/mouse) reversed the memory impairment induced by post-training administration of tramadol (1 mug/mouse, intra-CA1). Physostigmine 33-46 carbonic anhydrase 1 Mus musculus 164-167 27089282-6 2016 Moreover, pretest administration of physostigmine (0.5 and 1 mug/mouse, intra-CA1) with an ineffective dose of tramadol (0.25 mug/mouse, intra-CA1) also significantly restored retrieval. Physostigmine 36-49 carbonic anhydrase 1 Mus musculus 78-81 27089282-6 2016 Moreover, pretest administration of physostigmine (0.5 and 1 mug/mouse, intra-CA1) with an ineffective dose of tramadol (0.25 mug/mouse, intra-CA1) also significantly restored retrieval. Physostigmine 36-49 carbonic anhydrase 1 Mus musculus 143-146 27234531-2 2016 The results of ChE characterization by using different substrates and the selective inhibitors ethopropazine and physostigmine showed that the main enzyme existing in porcine saliva was butyrylcholinesterase (BChE). Physostigmine 113-126 cholinesterase Sus scrofa 15-18 27234531-2 2016 The results of ChE characterization by using different substrates and the selective inhibitors ethopropazine and physostigmine showed that the main enzyme existing in porcine saliva was butyrylcholinesterase (BChE). Physostigmine 113-126 cholinesterase Sus scrofa 186-207 27234531-2 2016 The results of ChE characterization by using different substrates and the selective inhibitors ethopropazine and physostigmine showed that the main enzyme existing in porcine saliva was butyrylcholinesterase (BChE). Physostigmine 113-126 cholinesterase Sus scrofa 209-213 26902639-1 2016 Human serum albumin (HSA) induced modulation of acetylcholinesterase (AChE) inhibition activity of four well-known cholinergic inhibitors like tacrine hydrochloride (TAC), donepezil hydrochloride monohydrate (DON), (-) Huperzine A (HuPA), eserine (ESE) was monitored quantitatively by Ellman"s method. Physostigmine 239-246 albumin Homo sapiens 6-19 26902639-1 2016 Human serum albumin (HSA) induced modulation of acetylcholinesterase (AChE) inhibition activity of four well-known cholinergic inhibitors like tacrine hydrochloride (TAC), donepezil hydrochloride monohydrate (DON), (-) Huperzine A (HuPA), eserine (ESE) was monitored quantitatively by Ellman"s method. Physostigmine 239-246 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-74 26902639-1 2016 Human serum albumin (HSA) induced modulation of acetylcholinesterase (AChE) inhibition activity of four well-known cholinergic inhibitors like tacrine hydrochloride (TAC), donepezil hydrochloride monohydrate (DON), (-) Huperzine A (HuPA), eserine (ESE) was monitored quantitatively by Ellman"s method. Physostigmine 248-251 albumin Homo sapiens 6-19 26902639-1 2016 Human serum albumin (HSA) induced modulation of acetylcholinesterase (AChE) inhibition activity of four well-known cholinergic inhibitors like tacrine hydrochloride (TAC), donepezil hydrochloride monohydrate (DON), (-) Huperzine A (HuPA), eserine (ESE) was monitored quantitatively by Ellman"s method. Physostigmine 248-251 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-74 26828299-4 2016 Adult Sprague Dawley male rats received VTA infusion of the acetylcholinesterase inhibitor, physostigmine (0, 1, 2mug/side), immediately prior to the FST, EPM, or SPT. Physostigmine 92-105 acetylcholinesterase Rattus norvegicus 60-80 26589572-3 2016 Cholinesterase inhibitors, such as physostigmine, are effective but widespread use has been limited by concerns about safety, optimal dosing and variable supply. Physostigmine 35-48 butyrylcholinesterase Homo sapiens 0-14 27132443-1 2015 OBJECTIVE: To observe the effect of acetylcholine (ACh) on lipopolysaccharide (LPS) induced inflammatory model of rat alveolar macrophages, and to observe the effect of the acetylcholinesterase inhibitor physostigmine (Phy) on the anti-inflammatory effect of ACh. Physostigmine 204-217 acetylcholinesterase Rattus norvegicus 173-193 26578914-9 2015 By contrast, the muscarinic agonist oxotremorine, the cholinesterase inhibitor physostigmine, the KCNQ channel blocker XE-991, and ghrelin all increased the durations of licking bouts when infused into the mPFC. Physostigmine 79-92 butyrylcholinesterase Rattus norvegicus 54-68 26318401-2 2015 All analogs exhibited varied butyrylcholinesterase inhibitory activity with IC50 value ranging between 1.59+-0.01 and 389.25+-1.75muM when compared with the standard eserine (IC50, 0.85+-0.0001muM). Physostigmine 166-173 butyrylcholinesterase Homo sapiens 29-50 26200465-1 2015 BACKGROUND: Physostigmine, a centrally acting acetylcholinesterase inhibitor, is most commonly used by anesthesiologists in the postanesthetic setting to reverse confusion caused by central anticholinergic medication effects. Physostigmine 12-25 acetylcholinesterase (Cartwright blood group) Homo sapiens 46-66 24890001-10 2014 Physostigmine administration significantly reduced IL-1beta and AChE levels. Physostigmine 0-13 interleukin 1 beta Rattus norvegicus 51-59 25870334-6 2015 In the presence of agonist, [(3)H]dFBr also photolabeled amino acids in the nAChR extracellular domain within binding pockets identified previously for the nonselective nAChR PAMs galantamine and physostigmine at the canonical alpha-gamma interface containing the transmitter binding sites and at the noncanonical delta-beta subunit interface. Physostigmine 196-209 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 76-81 25968237-4 2015 We used zebrafish as a model for acute and chronic developmental exposure to PB and two related carbamate acetylcholinesterase (AChE) inhibitors, neostigmine bromide (NB) and physostigmine (PS). Physostigmine 175-188 acetylcholinesterase Danio rerio 128-132 25446352-3 2015 Using the pyrithiamine-induced thiamine deficiency (PTD) rat model of human Wernicke-Korsakoff syndrome, we tested the hypothesis that co-infusion of the acetylcholinesterase inhibitor physostigmine across the PFC and HPC would recover spatial alternation performance in PTD rats. Physostigmine 185-198 acetylcholinesterase (Cartwright blood group) Homo sapiens 154-174 25383314-3 2014 To assess the influence of AChE inhibition on lipid metabolism, the effect of physostigmine, an AChE inhibitor, on fasting-induced increase in liver TG was investigated in mice. Physostigmine 78-91 acetylcholinesterase Mus musculus 96-100 25383314-6 2014 Furthermore, physostigmine significantly attenuated the fasting-induced decrease of both mRNA and protein levels of SREBP-1 and L-FABP, and increased IRS-2 protein levels in the liver. Physostigmine 13-26 sterol regulatory element binding transcription factor 1 Mus musculus 116-123 25383314-6 2014 Furthermore, physostigmine significantly attenuated the fasting-induced decrease of both mRNA and protein levels of SREBP-1 and L-FABP, and increased IRS-2 protein levels in the liver. Physostigmine 13-26 fatty acid binding protein 1, liver Mus musculus 128-134 25383314-6 2014 Furthermore, physostigmine significantly attenuated the fasting-induced decrease of both mRNA and protein levels of SREBP-1 and L-FABP, and increased IRS-2 protein levels in the liver. Physostigmine 13-26 insulin receptor substrate 2 Mus musculus 150-155 25383314-7 2014 The muscarinic receptor antagonist atropine blocked these effects of physostigmine on liver TG, serum insulin, and hepatic protein levels of SREBP-1 and L-FABP. Physostigmine 69-82 sterol regulatory element binding transcription factor 1 Mus musculus 141-148 25383314-7 2014 The muscarinic receptor antagonist atropine blocked these effects of physostigmine on liver TG, serum insulin, and hepatic protein levels of SREBP-1 and L-FABP. Physostigmine 69-82 fatty acid binding protein 1, liver Mus musculus 153-159 24136594-7 2014 Best in vivo protection from terbufos sulfone-induced mortality was achieved, when K-27 was given before terbufos sulfone exposure (RR = 0.06), which was significantly (P <= 0.05) superior to the pre-treatment with all other tested compounds, for example tacrine (RR = 0.21), pyridostigmine (RR = 0.28), physostigmine (RR = 0.29) and ranitidine (RR = 0.33). Physostigmine 307-320 keratin 27 Rattus norvegicus 83-87 24890001-10 2014 Physostigmine administration significantly reduced IL-1beta and AChE levels. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 64-68 24914105-7 2014 Plasma levels of IL-1beta and TNF-alpha increased significantly following radiation (P < 0.01 and P < 0.001, respectively) as compared with non-irradiated controls, and physostigmine treatment prevented the increase in the pro-inflammatory cytokines (P < 0.01 and P < 0.001, respectively). Physostigmine 175-188 interleukin 1 beta Rattus norvegicus 17-25 24914105-8 2014 Plasma IL-10 levels were not found to be significantly changed following radiation, whereas physostigmine augmented IL-10 levels during the late phase (P < 0.01). Physostigmine 92-105 interleukin 10 Rattus norvegicus 116-121 24914105-9 2014 In the liver and ileum homogenates, IL-1beta and TNF-alpha levels were also elevated following radiation, and this effect was inhibited by physostigmine treatment but not by atropine. Physostigmine 139-152 interleukin 1 beta Rattus norvegicus 36-44 24914105-9 2014 In the liver and ileum homogenates, IL-1beta and TNF-alpha levels were also elevated following radiation, and this effect was inhibited by physostigmine treatment but not by atropine. Physostigmine 139-152 tumor necrosis factor Rattus norvegicus 49-58 24914105-10 2014 Similarly, physostigmine also reversed the changes in MPO activity and in the caspase-3 levels in the liver and ileum. Physostigmine 11-24 myeloperoxidase Rattus norvegicus 54-57 24914105-10 2014 Similarly, physostigmine also reversed the changes in MPO activity and in the caspase-3 levels in the liver and ileum. Physostigmine 11-24 caspase 3 Rattus norvegicus 78-87 24678619-4 2014 RESULTS: Decreased E-cadherin expression and increased vimentin and alpha-SMA expression induced by TGF-beta1 in alveolar epithelial cell (A549) were significantly abrogated by the non-selective mAChR antagonist atropine and enhanced by the acetylcholinesterase inhibitor physostigmine. Physostigmine 272-285 vimentin Homo sapiens 55-63 24678619-4 2014 RESULTS: Decreased E-cadherin expression and increased vimentin and alpha-SMA expression induced by TGF-beta1 in alveolar epithelial cell (A549) were significantly abrogated by the non-selective mAChR antagonist atropine and enhanced by the acetylcholinesterase inhibitor physostigmine. Physostigmine 272-285 transforming growth factor beta 1 Homo sapiens 100-109 24323194-8 2014 However, with 10 min of physostigmine (10 muM) inhibition, the remaining activity of the wild type AChE was significantly lower than that of the mutant AChE. Physostigmine 24-37 acetylcholinesterase type 2 Bombyx mori 99-103 24595240-5 2014 The AChE inhibitor physostigmine ameliorated the MK801-induced reduction of BDNF mRNA and protein levels, reduced MK801-triggered MMP-2 activity and prevented decreased TIMP-2 mRNA expression. Physostigmine 19-32 acetylcholinesterase Rattus norvegicus 4-8 24595240-5 2014 The AChE inhibitor physostigmine ameliorated the MK801-induced reduction of BDNF mRNA and protein levels, reduced MK801-triggered MMP-2 activity and prevented decreased TIMP-2 mRNA expression. Physostigmine 19-32 brain-derived neurotrophic factor Rattus norvegicus 76-80 24595240-5 2014 The AChE inhibitor physostigmine ameliorated the MK801-induced reduction of BDNF mRNA and protein levels, reduced MK801-triggered MMP-2 activity and prevented decreased TIMP-2 mRNA expression. Physostigmine 19-32 matrix metallopeptidase 2 Rattus norvegicus 130-135 24595240-5 2014 The AChE inhibitor physostigmine ameliorated the MK801-induced reduction of BDNF mRNA and protein levels, reduced MK801-triggered MMP-2 activity and prevented decreased TIMP-2 mRNA expression. Physostigmine 19-32 TIMP metallopeptidase inhibitor 2 Rattus norvegicus 169-175 24227628-5 2014 The 8.5 kb gene cluster encodes eight proteins (PsmA-H), seven of which are required for the synthesis of physostigmine from 5-hydroxytryptophan, as shown by in vitro total reconstitution. Physostigmine 106-119 folate hydrolase 1 Homo sapiens 48-52 23736080-3 2014 The aim of this study is to investigate the effects of physostigmine, a cholinesterase inhibitor, on the intestinal microcirculation and vascular contractility in experimental endotoxemia. Physostigmine 55-68 butyrylcholinesterase Rattus norvegicus 72-86 24323194-8 2014 However, with 10 min of physostigmine (10 muM) inhibition, the remaining activity of the wild type AChE was significantly lower than that of the mutant AChE. Physostigmine 24-37 acetylcholinesterase type 2 Bombyx mori 152-156 24323194-10 2014 These results indicated that mutations for the three amino acids reduced the sensitivity of AChE to physostigmine and phoxim, which laid the foundation for future in vivo studies on AChE"s roles in pesticide resistance. Physostigmine 100-113 acetylcholinesterase type 2 Bombyx mori 92-96 24323194-10 2014 These results indicated that mutations for the three amino acids reduced the sensitivity of AChE to physostigmine and phoxim, which laid the foundation for future in vivo studies on AChE"s roles in pesticide resistance. Physostigmine 100-113 acetylcholinesterase type 2 Bombyx mori 182-186 23913347-2 2013 The goal of this work was to use PET imaging to evaluate alterations of in vivo alpha4beta2 nicotinic acetylcholine receptor (nAChR) binding induced by the AChEIs physostigmine (PHY) and galanthamine (GAL). Physostigmine 163-176 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 126-131 24236981-2 2013 In this sense, many alkaloids isolated from natural sources, such as physostigmine, have been long recognized as acetyl- and butyrylcholinesterase (BChE) inhibitors. Physostigmine 69-82 butyrylcholinesterase Homo sapiens 148-152 23913347-2 2013 The goal of this work was to use PET imaging to evaluate alterations of in vivo alpha4beta2 nicotinic acetylcholine receptor (nAChR) binding induced by the AChEIs physostigmine (PHY) and galanthamine (GAL). Physostigmine 178-181 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 126-131 23747570-4 2013 Furthermore, elevating extracellular ACh with the acetylcholinesterase inhibitor physostigmine had a larger effect on depolarizing versus hyperpolarizing responses. Physostigmine 81-94 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-70 23913708-8 2013 Acetylcholinesterase inhibition with physostigmine increased ANP secretion concomitantly with a decrease in atrial dynamics in a concentration-dependent manner. Physostigmine 37-50 acetylcholinesterase Rattus norvegicus 0-20 23913708-8 2013 Acetylcholinesterase inhibition with physostigmine increased ANP secretion concomitantly with a decrease in atrial dynamics in a concentration-dependent manner. Physostigmine 37-50 natriuretic peptide A Rattus norvegicus 61-64 23343118-3 2013 Physostigmine (AChE inhibitor) or saline were administered subcutaneously continuously via implanted minipumps (1.6 micromoles/kg/day) for 3 weeks, followed by cerebral perfusion mapping during treadmill walking using [(14)C]-iodoantipyrine. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 15-19 23975732-6 2013 infusion of saline and the other during an infusion of the acetylcholinesterase inhibitor physostigmine. Physostigmine 90-103 acetylcholinesterase (Cartwright blood group) Homo sapiens 59-79 23434434-9 2013 Physostigmine, in the concentration range tested, suppressed the expression of CD11b following stimulation with PMA not significantly (human PMN: control: 63.1+-10.7 vs. 97 muM physostigmine: 49.9+-12.8 MESF, p=n.s.). Physostigmine 0-13 integrin subunit alpha M Homo sapiens 79-84 23529129-5 2013 Consistent with data from in vitro studies, cholinergic activation by systemic application of the acetylcholinesterase inhibitor, physostigmine, resulted in decreased sag amplitude, increased sag time constant and a decrease of the peak resonance frequency. Physostigmine 130-143 acetylcholinesterase Rattus norvegicus 98-118 23671623-5 2013 Physostigmine, which can overcome the blood-brain barrier or neostigmine acting only peripheral, served as acetylcholinesterase inhibitors. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 107-127 23671623-9 2013 Surgery accompanied by LPS-treatment led to increased IL-1beta gene and protein upregulation in the cortex and hippocampus but was significantly reduced by physostigmine and neostigmine. Physostigmine 156-169 interleukin 1 alpha Rattus norvegicus 54-62 23671623-11 2013 Physostigmine and neostigmine significantly decreased the protein expression of IL-1 and TNF-alpha. Physostigmine 0-13 tumor necrosis factor Rattus norvegicus 89-98 23671623-12 2013 Neuronal degeneration and the activity of acetylcholinesterase were elevated after surgery with LPS-treatment and reduced by physostigmine and neostigmine. Physostigmine 125-138 acetylcholinesterase Rattus norvegicus 42-62 23229229-3 2013 AChE inhibitors such as rivastigmine, galantamine, physostigmine and huperzine are obtained from plants, indicating that plants can serve as a potential source for novel AChE inhibitors. Physostigmine 51-64 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-4 23229229-3 2013 AChE inhibitors such as rivastigmine, galantamine, physostigmine and huperzine are obtained from plants, indicating that plants can serve as a potential source for novel AChE inhibitors. Physostigmine 51-64 acetylcholinesterase (Cartwright blood group) Homo sapiens 170-174 23445753-3 2013 The aim of this study was to investigate the level of neurodegeneration, expression of proinflammatory cytokines, glutathione and lipid peroxidation after hyperoxia and treatment with the acetylcholinesterase (AChE) inhibitors, physostigmine and donepezil in the brain of neonatal rats. Physostigmine 228-241 acetylcholinesterase Rattus norvegicus 188-208 23401542-3 2013 To test this hypothesis, we administered the AChE inhibitor physostigmine to mice and demonstrated an increase in anxiety- and depression-like behaviors that was reversed by administration of nicotinic or muscarinic antagonists. Physostigmine 60-73 acetylcholinesterase Mus musculus 45-49 23142559-6 2013 Furthermore, TNF-alpha-induced CXCL8 secretion was (i) inhibited by the MR antagonist tiotropium and the M3R antagonist 4-DAMP and (ii) enhanced by the M1/M3R agonist pilocarpine and the cholinesterase inhibitor physostigmine. Physostigmine 212-225 tumor necrosis factor Homo sapiens 13-22 23142559-6 2013 Furthermore, TNF-alpha-induced CXCL8 secretion was (i) inhibited by the MR antagonist tiotropium and the M3R antagonist 4-DAMP and (ii) enhanced by the M1/M3R agonist pilocarpine and the cholinesterase inhibitor physostigmine. Physostigmine 212-225 C-X-C motif chemokine ligand 8 Homo sapiens 31-36 23142559-6 2013 Furthermore, TNF-alpha-induced CXCL8 secretion was (i) inhibited by the MR antagonist tiotropium and the M3R antagonist 4-DAMP and (ii) enhanced by the M1/M3R agonist pilocarpine and the cholinesterase inhibitor physostigmine. Physostigmine 212-225 cholinergic receptor muscarinic 1 Homo sapiens 152-158 23142559-8 2013 Western blot analysis revealed that pilocarpine and physostigmine enhanced the TNF-alpha-induced phosphorylation of ERK1/2 and p38 MAPK and the degradation of IkappaBalpha. Physostigmine 52-65 tumor necrosis factor Homo sapiens 79-88 23142559-8 2013 Western blot analysis revealed that pilocarpine and physostigmine enhanced the TNF-alpha-induced phosphorylation of ERK1/2 and p38 MAPK and the degradation of IkappaBalpha. Physostigmine 52-65 mitogen-activated protein kinase 3 Homo sapiens 116-122 23142559-8 2013 Western blot analysis revealed that pilocarpine and physostigmine enhanced the TNF-alpha-induced phosphorylation of ERK1/2 and p38 MAPK and the degradation of IkappaBalpha. Physostigmine 52-65 mitogen-activated protein kinase 1 Homo sapiens 127-130 23142559-8 2013 Western blot analysis revealed that pilocarpine and physostigmine enhanced the TNF-alpha-induced phosphorylation of ERK1/2 and p38 MAPK and the degradation of IkappaBalpha. Physostigmine 52-65 NFKB inhibitor alpha Homo sapiens 159-171 23445753-3 2013 The aim of this study was to investigate the level of neurodegeneration, expression of proinflammatory cytokines, glutathione and lipid peroxidation after hyperoxia and treatment with the acetylcholinesterase (AChE) inhibitors, physostigmine and donepezil in the brain of neonatal rats. Physostigmine 228-241 acetylcholinesterase Rattus norvegicus 210-214 22864020-9 2013 Treatment with acetylcholinesterase (AChE) inhibitors physostigmine (0.05 or 0.1 mg/kg) and donepezil (0.1 and 0.3 mg/kg) reversed the impaired object recognition of the CHT(HET)-6OHDA mice. Physostigmine 54-67 acetylcholinesterase Mus musculus 15-35 22864020-9 2013 Treatment with acetylcholinesterase (AChE) inhibitors physostigmine (0.05 or 0.1 mg/kg) and donepezil (0.1 and 0.3 mg/kg) reversed the impaired object recognition of the CHT(HET)-6OHDA mice. Physostigmine 54-67 acetylcholinesterase Mus musculus 37-41 22796599-12 2012 Stress-related behavioral modulation via central cholinergic pathways was enhanced by the central AChE inhibitor, physostigmine, thus further supporting the notion that stress is associated with long lasting hypersensitivity to acetylcholine. Physostigmine 114-127 acetylcholinesterase Mus musculus 98-102 22909986-5 2012 Also, the result revealed that, intra-CA1/MS administration subthreshold dose of muscimol reduced improvement of memory induced by physostigmine in the MS/CA1, respectively (cross injection). Physostigmine 131-144 carbonic anhydrase 1 Rattus norvegicus 38-41 22909986-5 2012 Also, the result revealed that, intra-CA1/MS administration subthreshold dose of muscimol reduced improvement of memory induced by physostigmine in the MS/CA1, respectively (cross injection). Physostigmine 131-144 carbonic anhydrase 1 Rattus norvegicus 155-158 22369073-6 2012 Blood flow recovery examined by laser Doppler perfusion imaging and capillary density by immunohistochemical staining of CD31-positive cells in the ischaemic hindlimb were significantly decreased in donepezil- and physostigmine-treated mice compared with control mice after 2 weeks. Physostigmine 214-227 platelet/endothelial cell adhesion molecule 1 Mus musculus 121-125 22738336-2 2012 The present investigation was designed to test the ability of continuous administration, starting at the time of injury, of physostigmine (PHY), an acetylcholinesterase (AChE) inhibitor that crosses the blood-brain barrier (BBB), to ameliorate the alterations of learning and memory induced by cerebral cortex impact injury in rats under isoflurane anesthesia. Physostigmine 124-137 acetylcholinesterase Rattus norvegicus 148-168 22738336-2 2012 The present investigation was designed to test the ability of continuous administration, starting at the time of injury, of physostigmine (PHY), an acetylcholinesterase (AChE) inhibitor that crosses the blood-brain barrier (BBB), to ameliorate the alterations of learning and memory induced by cerebral cortex impact injury in rats under isoflurane anesthesia. Physostigmine 124-137 acetylcholinesterase Rattus norvegicus 170-174 22738336-2 2012 The present investigation was designed to test the ability of continuous administration, starting at the time of injury, of physostigmine (PHY), an acetylcholinesterase (AChE) inhibitor that crosses the blood-brain barrier (BBB), to ameliorate the alterations of learning and memory induced by cerebral cortex impact injury in rats under isoflurane anesthesia. Physostigmine 139-142 acetylcholinesterase Rattus norvegicus 148-168 22305751-5 2012 Here we used MEG to record cortical oscillations in the context of administration of a cholinergic agonist (physostigmine) during a spatial visual attention task in humans. Physostigmine 108-121 protein tyrosine phosphatase non-receptor type 4 Homo sapiens 13-16 22461927-5 2012 DISCUSSION: Atropine causes anticholinergic toxicity; physostigmine reverses this by inhibiting acetylcholinesterase. Physostigmine 54-67 acetylcholinesterase (Cartwright blood group) Homo sapiens 96-116 22200647-4 2012 MATERIALS AND METHODS: AChE activity was evaluated utilizing reaction with Ellman"s reagent with physostigmine as a control. Physostigmine 97-110 acetylcholinesterase (Cartwright blood group) Homo sapiens 23-27 22033501-8 2012 In contrast, the higher dose (100 mM solution) of atropine, the cholinergic agonist carbachol (32 mM solution), and the cholinesterase inhibitor physostigmine (13 mM solution) all decreased the number of UP states, delta power (0-3 Hz) and MUA. Physostigmine 145-158 butyrylcholinesterase Rattus norvegicus 120-134 23193393-12 2012 Palmatine and physostigmine also significantly reduced brain acetylcholinesterase activity of mice. Physostigmine 14-27 acetylcholinesterase Mus musculus 61-81 21914840-7 2011 RESULTS: Physostigmine significantly decreased hippocampal rCBF in control subjects (P < .0005) and veterans with syndrome 1 (P < .05) but significantly increased hippocampal rCBF in veterans with syndrome 2 (P < .005) and veterans with syndrome 3 (P < .002). Physostigmine 9-22 CCAAT/enhancer binding protein zeta Rattus norvegicus 59-63 22051905-1 2012 A transdermal patch system containing procyclidine, an N-methyl-d-aspartate receptor antagonist possessing anticholinergic action, and physostigmine, a reversible cholinesterase inhibitor, was developed, and its prophylactic efficacy against soman intoxication was investigated. Physostigmine 135-148 butyrylcholinesterase Macaca mulatta 163-177 21924263-10 2011 However, administration of acetylcholinesterase inhibitors, such as physostigmine and galantamine, resulted in amelioration of the hypobaric hypoxia induced deleterious effects. Physostigmine 68-81 acetylcholinesterase Rattus norvegicus 27-47 20079556-6 2011 We also treated mice with 10-day regimens of olfactory environmental enrichment and/or repeated systemic injections of the acetylcholinesterase inhibitor physostigmine. Physostigmine 154-167 acetylcholinesterase Mus musculus 123-143 21865364-2 2011 The aim of this study was to assess the effects of an anticholinergic agent, atropine, and a cholinergic agent, physostigmine, on insulin sensitivity in lean and abdominally obese subjects. Physostigmine 112-125 insulin Homo sapiens 130-137 21914840-7 2011 RESULTS: Physostigmine significantly decreased hippocampal rCBF in control subjects (P < .0005) and veterans with syndrome 1 (P < .05) but significantly increased hippocampal rCBF in veterans with syndrome 2 (P < .005) and veterans with syndrome 3 (P < .002). Physostigmine 9-22 CCAAT/enhancer binding protein zeta Rattus norvegicus 181-185 21414391-0 2011 In vitro kinetic interactions of pyridostigmine, physostigmine and soman with erythrocyte and muscle acetylcholinesterase from different species. Physostigmine 49-62 acetylcholinesterase (Cartwright blood group) Homo sapiens 101-121 21414391-3 2011 With this kinetic in vitro study the interactions between pyridostigmine, physostigmine and soman with human, Rhesus monkey, swine and guinea pig erythrocyte AChE were investigated. Physostigmine 74-87 acetylcholinesterase Cavia porcellus 158-162 21557951-5 2011 Pre-test intra-CA1 injection of an acetylcholinesterase inhibitor, physostigmine (0.5 and 1 mug/mouse, intra-CA1) reversed the memory impairment induced by pre-training administration of muscimol (0.1 mug/mouse, intra-CA1). Physostigmine 67-80 carbonic anhydrase 1 Mus musculus 15-18 20981864-6 2011 Physostigmine was the strongest in vitro AChE-inhibitor (IC50 = 0.012 micro m), followed by 7-methoxytacrine, tacrine, pyridostigmine and methylene blue. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 41-45 20981864-9 2011 Best in vivo protection from DFP-induced mortality was achieved when physostigmine (RR = 0.02) or tacrine (RR = 0.05) was given before DFP exposure, which was significantly superior to the pretreatment with all other tested compounds, except K-27 (RR = 0.18). Physostigmine 69-82 keratin 27 Rattus norvegicus 242-246 20981864-12 2011 K-27 may be a more efficacious alternative to pyridostigmine, when passage into the brain precludes administration of physostigmine or tacrine. Physostigmine 118-131 keratin 27 Rattus norvegicus 0-4 21557951-5 2011 Pre-test intra-CA1 injection of an acetylcholinesterase inhibitor, physostigmine (0.5 and 1 mug/mouse, intra-CA1) reversed the memory impairment induced by pre-training administration of muscimol (0.1 mug/mouse, intra-CA1). Physostigmine 67-80 carbonic anhydrase 1 Mus musculus 109-112 21557951-5 2011 Pre-test intra-CA1 injection of an acetylcholinesterase inhibitor, physostigmine (0.5 and 1 mug/mouse, intra-CA1) reversed the memory impairment induced by pre-training administration of muscimol (0.1 mug/mouse, intra-CA1). Physostigmine 67-80 carbonic anhydrase 1 Mus musculus 109-112 21557951-6 2011 Moreover, pre-test administration of physostigmine (0.5 and 1 mug/mouse, intra-CA1) with an ineffective dose of muscimol (0.025 mug/mouse, intra-CA1) significantly restored the retrieval and induced muscimol state-dependent memory. Physostigmine 37-50 carbonic anhydrase 1 Mus musculus 79-82 21557951-6 2011 Moreover, pre-test administration of physostigmine (0.5 and 1 mug/mouse, intra-CA1) with an ineffective dose of muscimol (0.025 mug/mouse, intra-CA1) significantly restored the retrieval and induced muscimol state-dependent memory. Physostigmine 37-50 carbonic anhydrase 1 Mus musculus 145-148 21402092-0 2011 Pre- and post-treatment effect of physostigmine on soman-inhibited human erythrocyte and muscle acetylcholinesterase in vitro. Physostigmine 34-47 acetylcholinesterase (Cartwright blood group) Homo sapiens 96-116 21402092-5 2011 The present study was performed to investigate a possible pre- and post-treatment effect of physostigmine on soman-inhibited human AChE given at different time intervals before or after perfusion with soman by using a well-established dynamically working in vitro model for real-time analysis of erythrocyte and muscle AChE. Physostigmine 92-105 acetylcholinesterase (Cartwright blood group) Homo sapiens 131-135 21402092-6 2011 The major findings were that prophylactic physostigmine prevented complete inhibition of AChE by soman and resulted in partial spontaneous recovery of the enzyme by de-carbamylation. Physostigmine 42-55 acetylcholinesterase (Cartwright blood group) Homo sapiens 89-93 21402092-7 2011 Physostigmine given as post-treatment resulted in a time-dependent reduction of the protection from soman inhibition and recovery of AChE. Physostigmine 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 133-137 21533254-6 2011 of the cholinesterase inhibitor physostigmine increased the number of arrests but did not alter arrest lifetimes. Physostigmine 32-45 butyrylcholinesterase Mus musculus 7-21 21285081-10 2011 Restoration of consciousness by physostigmine was associated with rCBF increases in these same structures, with the strongest effect in the thalamus. Physostigmine 32-45 CCAAT/enhancer binding protein zeta Rattus norvegicus 66-70 21116174-1 2011 Acetylcholinesterase inhibitors (AChE-Is), galantamine, physostigmine and tacrine, enhance central levels of synaptic acetylcholine. Physostigmine 56-69 acetylcholinesterase Rattus norvegicus 0-20 20023599-3 2010 We hypothesized that similar responses could be elicited by systemic administration of physostigmine, an acetylcholinesterase inhibitor that penetrates the blood brain barrier. Physostigmine 87-100 acetylcholinesterase Rattus norvegicus 105-125 20600173-4 2010 In this study we have investigated the ability of two AChE inhibitors, donepezil (Aricept) and physostigmine, to induce gamma oscillatory activity in rat hippocampal slices; network activity believed to play a role in higher cognitive function. Physostigmine 95-108 acetylcholinesterase Rattus norvegicus 54-58 20661756-12 2010 Repeated physostigmine injections improved rats" spatial memory and increased cerebral ACh and AChE content (p < 0.05). Physostigmine 9-22 acetylcholinesterase Rattus norvegicus 95-99 20420900-7 2010 Physostigmine (500 microM), an acetylcholinesterase inhibitor, also reduced the number of BrdU-labeled cells in the telencephalic area, diencephalic area, medial tectal proliferation zone, and medial cerebellar proliferation zone to 52.8%, 35.9%, 30.5%, and 39.8% of the controls, respectively. Physostigmine 0-13 acetylcholinesterase Danio rerio 31-51 20071074-5 2010 Experiments were conducted in the presence of muscarinic agonists and antagonist or in the presence of the cholinesterase inhibitor physostigmine. Physostigmine 132-145 butyrylcholinesterase Mus musculus 107-121 20072119-6 2010 Treatment by the acetylcholinesterase inhibitor, physostigmine, was significantly effective for reduction of VCMs in wild-type mice but not in Hspg2 hetero-knockout mice. Physostigmine 49-62 acetylcholinesterase Mus musculus 17-37 20737911-2 2010 Alkaloids, such as physostigmine, galanthamine, and huperzine A, play an important role as AChE inhibitors. Physostigmine 19-32 acetylcholinesterase (Cartwright blood group) Homo sapiens 91-95 20047897-2 2010 The aim of this study was to examine the analgesic and antihyperalgesic properties of the cholinesterase inhibitor physostigmine and the opioid alfentanil, alone and in combination, in an experimental pain model in humans. Physostigmine 115-128 butyrylcholinesterase Homo sapiens 90-104 20144867-1 2010 A series of physostigmine analogues were prepared and evaluated for cholinesterase inhibition activities, including acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Physostigmine 12-25 butyrylcholinesterase Homo sapiens 68-82 19744502-4 2010 Hypothesizing an involvement of alpha(2)-adrenoceptors we studied their role in nefopam- and physostigmine-mediated thermoregulation in a mouse model of nonshivering thermogenesis. Physostigmine 93-106 adrenergic receptor, alpha 2b Mus musculus 32-54 19968973-8 2010 Brain and plasma malondialdehyde, high-mobility group box 1 (HMGB1) protein, and intercellular adhesion molecule 1 (ICAM1) were significantly attenuated in the physostigmine group compared with the control group, except for brain HMGB1. Physostigmine 160-173 high mobility group box 1 Rattus norvegicus 34-59 19968973-8 2010 Brain and plasma malondialdehyde, high-mobility group box 1 (HMGB1) protein, and intercellular adhesion molecule 1 (ICAM1) were significantly attenuated in the physostigmine group compared with the control group, except for brain HMGB1. Physostigmine 160-173 high mobility group box 1 Rattus norvegicus 61-66 19968973-8 2010 Brain and plasma malondialdehyde, high-mobility group box 1 (HMGB1) protein, and intercellular adhesion molecule 1 (ICAM1) were significantly attenuated in the physostigmine group compared with the control group, except for brain HMGB1. Physostigmine 160-173 intercellular adhesion molecule 1 Rattus norvegicus 81-114 19968973-8 2010 Brain and plasma malondialdehyde, high-mobility group box 1 (HMGB1) protein, and intercellular adhesion molecule 1 (ICAM1) were significantly attenuated in the physostigmine group compared with the control group, except for brain HMGB1. Physostigmine 160-173 intercellular adhesion molecule 1 Rattus norvegicus 116-121 19843075-0 2009 Ligand-based 3D-QSAR studies of physostigmine analogues as acetylcholinesterase inhibitors. Physostigmine 32-45 acetylcholinesterase (Cartwright blood group) Homo sapiens 59-79 19778593-5 2009 We found that CNP decreased the power of stimulus- and ACh/physostigmine-induced gamma-oscillations. Physostigmine 59-72 natriuretic peptide C Rattus norvegicus 14-17 19843075-1 2009 Natural alkaloid Physostigmine is one of the most potent pseudo-irreversible inhibitor of Acetylcholinesterase. Physostigmine 17-30 acetylcholinesterase (Cartwright blood group) Homo sapiens 90-110 19843075-7 2009 Furthermore, the analysis of comparative molecular field analysis and comparative molecular similarity indices analysis contour maps within the active site of AChE were conducted in order to understand the interactions between the receptor and the Physostigmine derivatives. Physostigmine 248-261 acetylcholinesterase (Cartwright blood group) Homo sapiens 159-163 19723529-0 2009 Physostigmine-induced hypothermic response in rats and its relationship with endogenous arginine vasopressin. Physostigmine 0-13 arginine vasopressin Rattus norvegicus 97-108 19723529-1 2009 AIMS: It is well known that physostigmine (PHY) and other anticholinesterase (anti-ChE) agents induce hypothermia in rodents but little is known about the mechanism of action. Physostigmine 28-41 butyrylcholinesterase Rattus norvegicus 83-86 19170187-6 2009 In this model, the acetylcholinesterase inhibitor physostigmine is administered at 0.125 mg/kg i.p. Physostigmine 50-63 acetylcholinesterase Rattus norvegicus 19-39 19283689-0 2009 Differential mRNA expression of acetylcholinesterase in the central nervous system of rats with acute and chronic exposure of sarin & physostigmine. Physostigmine 138-151 acetylcholinesterase Rattus norvegicus 32-52 19283689-1 2009 A time-course study was carried out to measure the acetylcholinesterase (AChE) gene expression in the brain of female rats exposed to different doses of sarin and physostigmine. Physostigmine 163-176 acetylcholinesterase Rattus norvegicus 51-71 19283689-1 2009 A time-course study was carried out to measure the acetylcholinesterase (AChE) gene expression in the brain of female rats exposed to different doses of sarin and physostigmine. Physostigmine 163-176 acetylcholinesterase Rattus norvegicus 73-77 19583746-0 2009 The cholinesterase inhibitor physostigmine for the local treatment of dry mouth: a randomized study. Physostigmine 29-42 butyrylcholinesterase Homo sapiens 4-18 19170187-9 2009 Accordingly, physostigmine impairs caspase 3 protease activity. Physostigmine 13-26 caspase 3 Rattus norvegicus 35-44 19170187-10 2009 In fact, the target of the activated caspase 3, the 89-kDa PARP fragment, is significantly less expressed in the ligated nerve of physostigmine-treated rats, reaching levels that are comparable to those in the contralateral unligated nerve. Physostigmine 130-143 caspase 3 Rattus norvegicus 37-46 18687163-6 2009 We recently showed that LI was disrupted by scopolamine at low doses, and this was reversed by typical and atypical antipsychotic drugs (APDs) and the acetylcholinesterase inhibitor physostigmine. Physostigmine 182-195 acetylcholinesterase Rattus norvegicus 151-171 19416629-3 2009 M(1)-muscarinic agonist McN-A-343 and the cholinesterase inhibitor physostigmine also elicited relaxation responses in the coaxial bioassay besides acetylcholine. Physostigmine 67-80 butyrylcholinesterase Homo sapiens 42-56 19416629-6 2009 In addition, McN-A-343, by activating the facilitatory M(1) receptors and physostigmine by inhibiting the acetylcholinesterase may induce the release of this factor through endogenous acetylcholine in the coaxial bioassay system. Physostigmine 74-87 acetylcholinesterase (Cartwright blood group) Homo sapiens 106-126 19367692-11 2009 Treatment with physostigmine resulted in at least 50% inhibition of muscle ChE activity, but produced minimal changes in the MCD values in adults or juveniles. Physostigmine 15-28 butyrylcholinesterase Rattus norvegicus 75-78 21204339-18 2009 Studies with the centrally acting cholinesterase inhibitor physostigmine demonstrated consistent but partial reversal of scopolamine-induced memory deficits [11,12]. Physostigmine 59-72 butyrylcholinesterase Homo sapiens 34-48 18729824-0 2009 Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. Physostigmine 17-30 acetylcholinesterase (Cartwright blood group) Homo sapiens 52-72 18729824-1 2009 The role of the functional architecture of the HuAChE (human acetylcholinesterase) in reactivity toward the carbamates pyridostigmine, rivastigmine and several analogues of physostigmine, that are currently used or considered for use as drugs for Alzheimer"s disease, was analysed using over 20 mutants of residues that constitute the interaction subsites in the active centre. Physostigmine 173-186 acetylcholinesterase (Cartwright blood group) Homo sapiens 61-81 18706897-3 2008 Systemic (Experiment 1) and intrahippocampal (Experiment 2) injections of the acetylcholinesterase inhibitor physostigmine were administered to determine if increasing acetylcholine levels would eliminate the behavioral impairment produced by PTD. Physostigmine 109-122 acetylcholinesterase Rattus norvegicus 78-98 19077124-10 2009 The AChE inhibitors tacrine and physostigmine enhanced control LTP. Physostigmine 32-45 acetylcholinesterase Rattus norvegicus 4-8 18844288-8 2008 Spasm of the gut induced by the acetylcholinesterase inhibitor, physostigmine, was antagonized by ascorbigen with an IC50 of 286 microM. Physostigmine 64-77 acetylcholinesterase (Cartwright blood group) Homo sapiens 32-52 18647636-3 2008 Donepezil significantly potentiated the NGF-induced neurite outgrowth in a concentration-dependent manner whereas the AChE inhibitor physostigmine did not alter NGF-induced neurite outgrowth. Physostigmine 133-146 acetylcholinesterase Rattus norvegicus 118-122 18577377-2 2008 The earliest known ChE inhibitors, namely, physostigmine and tacrine, showed modest improvement in the cognitive function of AD patients. Physostigmine 43-56 butyrylcholinesterase Homo sapiens 19-22 18523135-2 2008 We examined mouse adult-type muscle nAChR activation by physostigmine and found that channel activation by physostigmine exhibits many characteristics common with channel activity elicited by nicotinic agonists. Physostigmine 107-120 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 36-41 18523135-10 2008 These observations indicate that physostigmine is able to activate muscle nAChR by interacting with a site other than the nicotinic ligand binding site. Physostigmine 33-46 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 74-79 18384867-7 2008 Acetylcholinesterase inhibitors and anticholinergics used as prophylactics can offset each other, but exceptions are observed in a previous study when a very potent anticholinergic (scopolamine) or a high dose of procyclidine still results in cognitive deficits in spite of coadministration with physostigmine. Physostigmine 296-309 acetylcholinesterase Rattus norvegicus 0-20 18523135-1 2008 The plant-derived acetylcholinesterase inhibitor physostigmine has previously been shown to act on the nicotinic acetylcholine receptor (nAChR) causing either direct activation or potentiation of currents elicited by low concentrations of nicotinic agonists, or, at higher concentrations, channel block. Physostigmine 49-62 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-135 18523135-1 2008 The plant-derived acetylcholinesterase inhibitor physostigmine has previously been shown to act on the nicotinic acetylcholine receptor (nAChR) causing either direct activation or potentiation of currents elicited by low concentrations of nicotinic agonists, or, at higher concentrations, channel block. Physostigmine 49-62 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 137-142 18523135-2 2008 We examined mouse adult-type muscle nAChR activation by physostigmine and found that channel activation by physostigmine exhibits many characteristics common with channel activity elicited by nicotinic agonists. Physostigmine 56-69 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 36-41 18284346-11 2008 In all of these prefrontal regions, physostigmine administration significantly reduced rCBF during task, particularly at longer task delays, so that no correlation between task delay and rCBF was observed. Physostigmine 36-49 CCAAT/enhancer binding protein zeta Rattus norvegicus 87-91 18284346-12 2008 In the ventral visual cortex, physostigmine increased rCBF at longer task delays in medial regions, and decreased rCBF over delay conditions in lateral cortical areas. Physostigmine 30-43 CCAAT/enhancer binding protein zeta Rattus norvegicus 54-58 18284346-12 2008 In the ventral visual cortex, physostigmine increased rCBF at longer task delays in medial regions, and decreased rCBF over delay conditions in lateral cortical areas. Physostigmine 30-43 CCAAT/enhancer binding protein zeta Rattus norvegicus 114-118 18403125-7 2008 pretreatment with an antisense oligonucleotide (aODN) against type 1 or type 3 RyR prevented cholinergic antinociception in the hotplate test shifting to the right of the physostigmine dose-response curve. Physostigmine 171-184 ryanodine receptor 1, skeletal muscle Mus musculus 79-82 18304715-3 2008 Recently, by using a dynamically working in vitro model with real-time determination of membrane-bound AChE activity, we were able to demonstrate that pre-inhibition of human erythrocyte AChE with pyridostigmine or physostigmine resulted in a markedly higher residual AChE activity after inhibition by soman or paraoxon than in the absence of reversible inhibitors. Physostigmine 215-228 acetylcholinesterase (Cartwright blood group) Homo sapiens 187-191 18065245-8 2008 Pre-test intra-CA1 injection of physostigmine (2.5 and 5 microg/mouse, intra-CA1) or nicotine (0.3 and 0.5 microg/mouse, intra-CA1) improved pre-training ethanol (1g/kg)-induced retrieval impairment. Physostigmine 32-45 carbonic anhydrase 1 Mus musculus 15-18 18065245-8 2008 Pre-test intra-CA1 injection of physostigmine (2.5 and 5 microg/mouse, intra-CA1) or nicotine (0.3 and 0.5 microg/mouse, intra-CA1) improved pre-training ethanol (1g/kg)-induced retrieval impairment. Physostigmine 32-45 carbonic anhydrase 1 Mus musculus 77-80 18065245-8 2008 Pre-test intra-CA1 injection of physostigmine (2.5 and 5 microg/mouse, intra-CA1) or nicotine (0.3 and 0.5 microg/mouse, intra-CA1) improved pre-training ethanol (1g/kg)-induced retrieval impairment. Physostigmine 32-45 carbonic anhydrase 1 Mus musculus 77-80 18065245-9 2008 Moreover, pre-test administration of physostigmine (2.5 and 5 microg/mouse, intra-CA1) or nicotine (0.3 and 0.5 microg/mouse, intra-CA1) with an ineffective dose of ethanol (0.25 g/kg) significantly restored the retrieval and induced ethanol state-dependent memory. Physostigmine 37-50 carbonic anhydrase 1 Mus musculus 82-85 18304715-3 2008 Recently, by using a dynamically working in vitro model with real-time determination of membrane-bound AChE activity, we were able to demonstrate that pre-inhibition of human erythrocyte AChE with pyridostigmine or physostigmine resulted in a markedly higher residual AChE activity after inhibition by soman or paraoxon than in the absence of reversible inhibitors. Physostigmine 215-228 acetylcholinesterase (Cartwright blood group) Homo sapiens 103-107 18304715-3 2008 Recently, by using a dynamically working in vitro model with real-time determination of membrane-bound AChE activity, we were able to demonstrate that pre-inhibition of human erythrocyte AChE with pyridostigmine or physostigmine resulted in a markedly higher residual AChE activity after inhibition by soman or paraoxon than in the absence of reversible inhibitors. Physostigmine 215-228 acetylcholinesterase (Cartwright blood group) Homo sapiens 187-191 18281016-7 2008 Therefore we studied the effects of the oximes obidoxime, HI 6 and MMB-4 on the rate of decarbamylation for physostigmine- and pyridostigmine-inhibited human erythrocyte AChE both in a dynamically working in vitro model and a static cuvette system. Physostigmine 108-121 acetylcholinesterase (Cartwright blood group) Homo sapiens 170-174 18304715-7 2008 Pre-inhibition of AChE with pyridostigmine or physostigmine resulted in a concentration-dependent increase in carbamylation, residual activity after soman inhibition and fraction of decarbamylation AChE after discontinuation of the inhibitors without differences between human erythrocyte and muscle AChE. Physostigmine 46-59 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-22 18304715-7 2008 Pre-inhibition of AChE with pyridostigmine or physostigmine resulted in a concentration-dependent increase in carbamylation, residual activity after soman inhibition and fraction of decarbamylation AChE after discontinuation of the inhibitors without differences between human erythrocyte and muscle AChE. Physostigmine 46-59 acetylcholinesterase (Cartwright blood group) Homo sapiens 198-202 18304715-7 2008 Pre-inhibition of AChE with pyridostigmine or physostigmine resulted in a concentration-dependent increase in carbamylation, residual activity after soman inhibition and fraction of decarbamylation AChE after discontinuation of the inhibitors without differences between human erythrocyte and muscle AChE. Physostigmine 46-59 acetylcholinesterase (Cartwright blood group) Homo sapiens 198-202 17655781-3 2008 The primary aim of this randomized controlled study was to assess the efficiency of the cholinesterase-inhibitor physostigmine in these children and to identify adverse effects. Physostigmine 113-126 butyrylcholinesterase Homo sapiens 88-102 17950687-1 2008 The inhibition of horse serum butyrylcholinesterase (EC 3.1.1.8) by three carbamates (eserine, neostigmine, and rivastigmine) was studied by flow microcalorimetry at 37 degrees C in Tris buffer (pH 7.5). Physostigmine 86-93 butyrylcholinesterase Homo sapiens 30-51 18077465-2 2008 We hypothesised that neural responses in AD during visuo-attentional processing would be impaired relative to controls, yet partially susceptible to improvement with the cholinesterase inhibitor physostigmine. Physostigmine 195-208 butyrylcholinesterase Homo sapiens 170-184 17644430-5 2008 Physostigmine (50 microg/kg) fully reversed memory deficits in the Ts65Dn mice in the 4-month-old group but not in older mice. Physostigmine 0-13 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 67-73 17717233-2 2007 We designed this study to examine whether treatment with physostigmine (PHY), an acetylcholinesterase inhibitor, could improve the impairment of working memory after hypoxic hypoxia. Physostigmine 57-70 acetylcholinesterase Mus musculus 81-101 17950890-13 2008 Inhibition of brain ChE activity occurred at dosages greater than 0.05 mg/kg physostigmine, 1mg/kg carbaryl, and 0.3 mg/kg propoxur. Physostigmine 77-90 butyrylcholinesterase Rattus norvegicus 20-23 17658455-0 2007 Intraoral stimulation of salivary secretion with the cholinesterase inhibitor physostigmine as a mouth spray: a pilot study in healthy volunteers. Physostigmine 78-91 butyrylcholinesterase Homo sapiens 53-67 17658455-3 2007 With a view to enhancing the cholinergic drive on minor salivary glands, whilst at the same time minimising adverse systemic effects, the cholinesterase inhibitor physostigmine was therefore sprayed, in a fixed volume, onto the oral mucosa of seven healthy subjects. Physostigmine 163-176 butyrylcholinesterase Homo sapiens 138-152 17890015-9 2007 A shift to the right of the physostigmine dose-response curve was obtained after anti-type 2 IP3R2 and anti-type 3 IP3R treatments. Physostigmine 28-41 inositol 1,4,5-trisphosphate receptor 1 Mus musculus 93-97 17717233-2 2007 We designed this study to examine whether treatment with physostigmine (PHY), an acetylcholinesterase inhibitor, could improve the impairment of working memory after hypoxic hypoxia. Physostigmine 72-75 acetylcholinesterase Mus musculus 81-101 17303509-1 2007 Previous functional investigations in rats failed to demonstrate that the classical cholinesterase inhibitor, physostigmine, can compensate for cortical cholinergic deficit induced by deafferentation from the nucleus basalis magnocellularis (NBM). Physostigmine 110-123 butyrylcholinesterase Rattus norvegicus 84-98 17350296-6 2007 Physostigmine infusions into dorsal CA3 enhanced both spatial and nonspatial (visual object) novelty detection. Physostigmine 0-13 carbonic anhydrase 3 Rattus norvegicus 36-39 17134713-7 2007 Moreover, noteworthy results were obtained in the application of the AChE-CIM-IMER to the characterization of the carbamoylation and decarbamoylation steps in pseudo-irreversible binding of carbamate derivatives (physostigmine and rivastigmine). Physostigmine 213-226 acetylcholinesterase (Cartwright blood group) Homo sapiens 69-73 16971898-4 2007 Here, we tested whether the muscarinic antagonist scopolamine would disrupt LI and whether such disruption would be reversed by APDs and by the acetylcholinesterase inhibitor physostigmine. Physostigmine 175-188 acetylcholinesterase (Cartwright blood group) Homo sapiens 144-164 17979787-4 2007 [(11)C]physostigmine, [(11)C]CP126,998 and 2-[(18)F]fluoro-CP118,954 were distributed corresponding well to the regional AChE activity in animals, and also former two probes were successfully applied to clinical PET trial. Physostigmine 7-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 121-125 17596712-3 2007 METHODS: We exposed rat hippocampal cultured neurons to BW284C51, the peripheral anionic site inhibitor of AChE, and to the non-selective AChE active site inhibitor, physostigmine for studying the neuronal remodeling of AChE mRNA expression and trafficking. Physostigmine 166-179 acetylcholinesterase Rattus norvegicus 138-142 16904919-7 2007 Similarly, pre-training injections of physostigmine, a cholinesterase inhibitor, enhanced acquisition of trace conditioning in 25-day-old rats but had no effect on long-delay conditioning in rats this age (Experiment 2). Physostigmine 38-51 butyrylcholinesterase Rattus norvegicus 55-69 17596712-3 2007 METHODS: We exposed rat hippocampal cultured neurons to BW284C51, the peripheral anionic site inhibitor of AChE, and to the non-selective AChE active site inhibitor, physostigmine for studying the neuronal remodeling of AChE mRNA expression and trafficking. Physostigmine 166-179 acetylcholinesterase Rattus norvegicus 138-142 16879490-8 2006 A background release of acetylcholine was inferred from the pressure increase induced by the cholinesterase inhibitor physostigmine. Physostigmine 118-131 butyrylcholinesterase Mus musculus 93-107 16443290-6 2006 In another series of experiments, intra-CA1 injection of physostigmine (2, 3 and 4 microg/rat) improved memory retention. Physostigmine 57-70 carbonic anhydrase 1 Rattus norvegicus 40-43 16797163-3 2006 Acetylcholinesterase inhibitors, such as Physostigmine and Rivastigmine, are considered effective treatments for cognitive decline in Alzheimer"s Disease, where the loss of cholinergic neurons is thought to be responsible for various cognitive deficits. Physostigmine 41-54 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 16598702-0 2006 Age and APOE-epsilon4 genotype influence the effect of physostigmine infusion on the in-vivo distribution volume of the muscarinic-2-receptor dependent tracer [18F]FP-TZTP. Physostigmine 55-68 apolipoprotein E Homo sapiens 8-12 16598702-6 2006 The adjusted R2 for the model as a whole was 0.786 (F(2,10) = 23.00, P < 0.0002) with both increasing age and the presence of the APOE-epsilon4 allele modifying the response to physostigmine in the direction of larger decreases in [18F]FP-TZTP distribution volumes in all brain regions examined. Physostigmine 180-193 apolipoprotein E Homo sapiens 133-137 16530961-1 2006 Physostigmine (Phy), a reversible inhibitor of acetylcholine (ACh) esterase (AChE), may also act as a low potency agonist and a modulator of the nicotinic receptor. Physostigmine 0-13 acetylcholinesterase Mus musculus 77-81 16530961-1 2006 Physostigmine (Phy), a reversible inhibitor of acetylcholine (ACh) esterase (AChE), may also act as a low potency agonist and a modulator of the nicotinic receptor. Physostigmine 0-3 acetylcholinesterase Mus musculus 77-81 16464655-5 2006 Co-administration of physostigmine and memantine increased serine-phosphorylated GSK3 levels equally to that achieved by either agent alone, indicating that the actions of these two drugs converge on overlapping pools of GSK3. Physostigmine 21-34 glycogen synthase kinase 3 beta Mus musculus 81-85 16464655-5 2006 Co-administration of physostigmine and memantine increased serine-phosphorylated GSK3 levels equally to that achieved by either agent alone, indicating that the actions of these two drugs converge on overlapping pools of GSK3. Physostigmine 21-34 glycogen synthase kinase 3 beta Mus musculus 221-225 16191443-3 2006 Using a 3-day schedule of conditioning, it was found that intra-CA1 administration of the anticholinesterase, physostigmine (2, 4 and 8 microg/rat) significantly potentiated the morphine (0.5 mg/kg)-induced CPP. Physostigmine 110-123 carbonic anhydrase 1 Rattus norvegicus 64-67 16191443-5 2006 On the other hand, atropine (7 microg/rat, intra-CA1) reversed the physostigmine-induced potentiation of the morphine response. Physostigmine 67-80 carbonic anhydrase 1 Rattus norvegicus 49-52 16381573-0 2006 Co2(CO)8-catalyzed intramolecular hetero-Pauson-Khand reaction of alkynecarbodiimide: synthesis of (+/-)-physostigmine. Physostigmine 99-118 complement C2 Homo sapiens 0-3 16278840-3 2006 Validation of the putative positron emission tomography method included regional distribution, positive correlation with age, and attenuation by the nonselective cholinesterase inhibitor physostigmine, but no attenuation by the AChE-selective inhibitor donepezil. Physostigmine 187-200 butyrylcholinesterase Homo sapiens 162-176 16118037-7 2005 The nitroprusside-induced increase of firing rate of AHA neurons was inhibited by PHN microinjection of the cholinoceptor antagonist scopolamine and potentiated by PHN microinjection of the cholinesterase inhibitor physostigmine. Physostigmine 215-228 butyrylcholinesterase Rattus norvegicus 190-204 16508314-0 2006 Growth hormone responses to low-dose physostigmine in elderly vs. young women and men. Physostigmine 37-50 growth hormone 1 Homo sapiens 0-14 16508314-4 2006 OBJECTIVE: We therefore administered low-dose physostigmine (PHYSO), a cholinesterase inhibitor, to normal, non-hormone-replaced, elderly women and men, to ascertain a potential sex difference in GH response. Physostigmine 46-59 butyrylcholinesterase Homo sapiens 71-85 16958557-39 2006 The converse, giving atropine to treat poisoning with cholinesterase inhibitors, of which physostigmine was the first, has endured more consistently and remains standard practice today. Physostigmine 90-103 butyrylcholinesterase Homo sapiens 54-68 16263845-8 2005 The right prefrontal regions that were selectively recruited in each age group during the placebo condition showed significantly lower rCBF during physostigmine administration. Physostigmine 147-160 CCAAT/enhancer binding protein zeta Rattus norvegicus 135-139 16280029-5 2005 Oxotremorine and physostigmine increased ACTH and corticosterone in all four groups, but to a significantly greater degree in KO males compared to WT males, KO females, and WT females. Physostigmine 17-30 pro-opiomelanocortin-alpha Mus musculus 41-45 15778881-4 2005 OBJECTIVES: The effects of administration of two acetylcholinesterase inhibitors, physostigmine and donepezil, on Abeta plaque formation and memory-related behaviors were investigated in the Tg2576-transgenic mouse model of AD. Physostigmine 82-95 amyloid beta precursor protein Homo sapiens 114-119 16216227-7 2005 Microinjection of the cholinoceptor agonist carbachol, the cholinesterase inhibitor physostigmine and the excitatory amino acid glutamate into the PHN caused increases in firing rate of AHA angiotensin-II-sensitive neurons in anesthetized WKY and SHR. Physostigmine 84-97 butyrylcholinesterase Rattus norvegicus 59-73 16216227-7 2005 Microinjection of the cholinoceptor agonist carbachol, the cholinesterase inhibitor physostigmine and the excitatory amino acid glutamate into the PHN caused increases in firing rate of AHA angiotensin-II-sensitive neurons in anesthetized WKY and SHR. Physostigmine 84-97 angiotensinogen Rattus norvegicus 190-204 16144656-7 2005 Microinjection of carbachol, physostigmine and glutamate into the PHN caused an increase in firing rate of AHA angiotensin II-sensitive neurons in anesthetized rats. Physostigmine 29-42 angiotensinogen Rattus norvegicus 111-125 15974893-2 2005 Novel drug design studies have focused on the classical ChE inhibitor, (-)-physostigmine, producing alterations in chemical composition and three-dimensional structure, which may offer an improved therapeutic index. Physostigmine 75-88 butyrylcholinesterase Homo sapiens 56-59 15683849-2 2005 Here, the current UK and US nerve agent pre-treatment, pyridostigmine bromide (PB) and the related anti-acetylcholinesterase (AChE) compounds physostigmine (PHY) and BW284c51 were tested for their ability to affect mouse splenocyte function in vitro. Physostigmine 142-155 acetylcholinesterase Mus musculus 126-130 15803498-2 2005 Physostigmine, a potent AChE inhibitor, and galantamine, an allosteric modulator of nAChRs, are widely used for the treatment of Alzheimer"s disease. Physostigmine 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 24-28 15803498-12 2005 The effects of physostigmine, a more potent AChE inhibitor than galantamine, could be interpreted as a desensitization of nAChRs, due to a prolonged exposure to high synaptic concentration of acetylcholine or as a competition with acetylcholine. Physostigmine 15-28 acetylcholinesterase (Cartwright blood group) Homo sapiens 44-48 15892689-1 2005 The Electronic-Topological (ETM) and Neural Network methods were applied to the study of the "structure-acetylcholinesterase (AChE) inhibitor activity" relationships for a series of physostigmine and N-benzylpiperidine derivatives. Physostigmine 182-195 acetylcholinesterase (Cartwright blood group) Homo sapiens 93-124 15892689-1 2005 The Electronic-Topological (ETM) and Neural Network methods were applied to the study of the "structure-acetylcholinesterase (AChE) inhibitor activity" relationships for a series of physostigmine and N-benzylpiperidine derivatives. Physostigmine 182-195 acetylcholinesterase (Cartwright blood group) Homo sapiens 126-130 15741579-1 2005 OBJECTIVES: Physostigmine is an acetylcholinesterase inhibitor and can produce fasciculations, seizures, bradycardia, and asystole. Physostigmine 12-25 acetylcholinesterase Rattus norvegicus 32-52 15683849-2 2005 Here, the current UK and US nerve agent pre-treatment, pyridostigmine bromide (PB) and the related anti-acetylcholinesterase (AChE) compounds physostigmine (PHY) and BW284c51 were tested for their ability to affect mouse splenocyte function in vitro. Physostigmine 157-160 acetylcholinesterase Mus musculus 126-130 15611638-0 2005 Novel assay utilizing fluorochrome-tagged physostigmine (Ph-F) to in situ detect active acetylcholinesterase (AChE) induced during apoptosis. Physostigmine 42-55 acetylcholinesterase (Cartwright blood group) Homo sapiens 88-108 15675987-9 2005 Patients in the physostigmine group also exhibited reduced ex-vivo production of the proinflammatory cytokine, IL-1beta. Physostigmine 16-29 interleukin 1 beta Homo sapiens 111-119 15675987-11 2005 CONCLUSIONS: Physostigmine combined with morphine in the postoperative period reduced morphine consumption, enhanced analgesia, and attenuated production of the proinflammatory cytokine, IL-1beta. Physostigmine 13-26 interleukin 1 beta Homo sapiens 187-195 15611638-0 2005 Novel assay utilizing fluorochrome-tagged physostigmine (Ph-F) to in situ detect active acetylcholinesterase (AChE) induced during apoptosis. Physostigmine 42-55 acetylcholinesterase (Cartwright blood group) Homo sapiens 110-114 15611638-2 2005 To obtain a marker of active AChE that could assay this enzyme in live intact cells and be applicable to fluorescence microscopy and cytometry, the fluorescein-tagged physostigmine (Ph-F), high affinity ligand (inhibitor) reactive with the active center of AChE, was constructed and tested for its ability to in situ label AChE and measure its induction during apoptosis. Physostigmine 167-180 acetylcholinesterase (Cartwright blood group) Homo sapiens 29-33 15282260-8 2004 Dentate waves were regularly accompanied by sharp waves in field CA3 and were reduced in size by the acetylcholinesterase inhibitor, physostigmine. Physostigmine 133-146 acetylcholinesterase Rattus norvegicus 101-121 15653001-3 2005 Unilateral microinjection of physostigmine, an acetylcholinesterase inhibitor, into the preBotC increased the frequency of respiratory-related rhythmic activity from XIIn to 116+/-13% (mean+/-S.D.) Physostigmine 29-42 acetylcholinesterase Rattus norvegicus 47-67 15556140-3 2004 The doses of combinational regimen in minipumps were optimized to achieve 30-35% inhibition of blood cholinesterase activity by physostigmine and 50-100 ng/ml of blood concentrations of procyclidine as clinically available doses, respectively. Physostigmine 128-141 butyrylcholinesterase Rattus norvegicus 101-115 15256494-9 2004 In human serum, ghrelin desoctanoylation was partially inhibited by eserine salicylate and sodium fluoride, two butyrylcholinesterase inhibitors, but not by bis-p-nitrophenyl-phosphate and EDTA. Physostigmine 68-75 ghrelin and obestatin prepropeptide Rattus norvegicus 16-23 15351315-10 2004 Physostigmine (PHY), a carbamate compound similar to PB, consistently showed inhibition of T-cell activation, but only at concentrations in excess of those required to inhibit AChE. Physostigmine 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 176-180 15582025-0 2004 Behavioral changes after acetylcholinesterase inhibition with physostigmine in mice. Physostigmine 62-75 acetylcholinesterase Mus musculus 25-45 15582025-1 2004 The effect of the central and peripheral acetylcholinesterase (AChE) inhibitor, physostigmine (PHY), was examined on spatial memory using a water maze, motor activity as well as acoustic startle response (ASR) and prepulse inhibition (PPI) in C57BL/6J mice. Physostigmine 80-93 acetylcholinesterase Mus musculus 41-61 15582025-1 2004 The effect of the central and peripheral acetylcholinesterase (AChE) inhibitor, physostigmine (PHY), was examined on spatial memory using a water maze, motor activity as well as acoustic startle response (ASR) and prepulse inhibition (PPI) in C57BL/6J mice. Physostigmine 80-93 acetylcholinesterase Mus musculus 63-67 15582025-1 2004 The effect of the central and peripheral acetylcholinesterase (AChE) inhibitor, physostigmine (PHY), was examined on spatial memory using a water maze, motor activity as well as acoustic startle response (ASR) and prepulse inhibition (PPI) in C57BL/6J mice. Physostigmine 95-98 acetylcholinesterase Mus musculus 63-67 15351315-10 2004 Physostigmine (PHY), a carbamate compound similar to PB, consistently showed inhibition of T-cell activation, but only at concentrations in excess of those required to inhibit AChE. Physostigmine 15-18 acetylcholinesterase (Cartwright blood group) Homo sapiens 176-180 15496314-2 2004 Other acetylcholinesterase inhibitors also increased the twitches, showing a hierarchy of potencies of galantamine>physostigmine>tacrine>rivastigmine=donepezil. Physostigmine 118-131 acetylcholinesterase Rattus norvegicus 6-26 14704222-6 2004 Acute exposure to eserine (250 microg/ml) also significantly inhibited lung AChE but did not potentiate vagally induced bronchoconstriction. Physostigmine 18-25 acetylcholinesterase Cavia porcellus 76-80 15350815-4 2004 Both the extract (0.3-10 microg/mL) and physostigmine (0.1-3.0 microM) potentiated the effect of a fixed dose of ACh (10 microM) in a dose-dependent fashion, suggesting acetylcholinesterase (AChE) inhibitory effect. Physostigmine 40-53 ACE-1 Oryctolagus cuniculus 169-189 15350815-4 2004 Both the extract (0.3-10 microg/mL) and physostigmine (0.1-3.0 microM) potentiated the effect of a fixed dose of ACh (10 microM) in a dose-dependent fashion, suggesting acetylcholinesterase (AChE) inhibitory effect. Physostigmine 40-53 ACE-1 Oryctolagus cuniculus 191-195 15375642-13 2004 Longer pulse trains, 120 pulses/3 Hz and 600 pulses/5 Hz, were used and the cholinesterase inhibitor physostigmine was added to the superfusion medium to increase synaptic levels of endogenous acetylcholine. Physostigmine 101-114 butyrylcholinesterase Mus musculus 76-90 15265646-2 2004 In this study the model has been utilised to determine the effect of the acetylcholinesterase inhibiting compounds tacrine and physostigmine on spatial working memory deficits associated with the OB rat. Physostigmine 127-140 acetylcholinesterase Rattus norvegicus 73-93 14751462-1 2004 Studies in animals exploring the antagonism of the cholinesterase inhibitors soman and sarin have shown that pretreatment with low doses of the centrally acting cholinesterase inhibitor, physostigmine, alone or in conjunction with the centrally acting anticholinergic agent, scopolamine, is effective against their lethality and toxicity. Physostigmine 187-200 butyrylcholinesterase Rattus norvegicus 51-65 15038335-2 2004 Myoclonus and delirium improved dramatically with the intravenous injection of the acetylcholinesterase inhibitor physostigmine, and this improvement was maintained during the administration of donepezil, an oral medication with similar pharmacodynamic properties. Physostigmine 114-127 acetylcholinesterase (Cartwright blood group) Homo sapiens 83-103 14766981-5 2004 In this study, increasing central nervous cholinergic activation during SWS-rich sleep by posttrial infusion of 0.75 mg of the cholinesterase inhibitor physostigmine completely blocked SWS-related consolidation of declarative memories for word pairs in human subjects. Physostigmine 152-165 butyrylcholinesterase Homo sapiens 127-141 14751462-1 2004 Studies in animals exploring the antagonism of the cholinesterase inhibitors soman and sarin have shown that pretreatment with low doses of the centrally acting cholinesterase inhibitor, physostigmine, alone or in conjunction with the centrally acting anticholinergic agent, scopolamine, is effective against their lethality and toxicity. Physostigmine 187-200 butyrylcholinesterase Rattus norvegicus 161-175 15134572-3 2004 PET studies with [(11)C]physostigmine and [(11)C]CP-126,998 in the brain of healthy subjects have shown a radioactivity distribution corresponding to the regional distribution of AChE activity measured in postmortem human brains. Physostigmine 24-37 acetylcholinesterase (Cartwright blood group) Homo sapiens 179-183 14521875-17 2003 Furthermore, the cholinesterase inhibitor, physostigmine, boosts ACh action during a time when cholinergic levels need to decline for proper consolidation. Physostigmine 43-56 butyrylcholinesterase Rattus norvegicus 17-31 14573394-5 2003 Like nicotine, the contraction induced by 100 nM urotensin II was inhibited by treatment with atropine, hexamethonium, D-tubocurarine, tetrodotoxin or hemicholinium-3, and enhanced by physostigmine. Physostigmine 184-197 urotensin 2 Homo sapiens 49-61 12958052-1 2003 The cholinesterase inhibitor physostigmine (PHYS) was investigated in a double-blind, placebo-controlled, randomized, crossover trial of 10 male patients with moderate to severe obstructive sleep apnea. Physostigmine 29-42 butyrylcholinesterase Homo sapiens 4-18 12958052-1 2003 The cholinesterase inhibitor physostigmine (PHYS) was investigated in a double-blind, placebo-controlled, randomized, crossover trial of 10 male patients with moderate to severe obstructive sleep apnea. Physostigmine 44-48 butyrylcholinesterase Homo sapiens 4-18 12927583-8 2003 In the presence of eserine (physostigmine), the specific inhibitor of AChE, the inhibitory effect of Pb was potentiated and this was more pronounced at low-concentrations of Pb. Physostigmine 28-41 acetylcholinesterase Rattus norvegicus 70-74 12840078-1 2003 Application of the acetylcholinesterase inhibitor physostigmine to conventional hippocampal slices caused a significant reduction of field excitatory postsynaptic potentials (EPSPs) elicited by single pulse stimulation to the medial perforant path. Physostigmine 50-63 acetylcholinesterase (Cartwright blood group) Homo sapiens 19-39 12569072-8 2003 4 Experiments in the urinary bladder with the cholinesterase inhibitor physostigmine and the muscarinic antagonist ipratropium demonstrated that endogenously released acetylcholine predominantly acted through M(2)-receptors to inhibit noradrenaline release. Physostigmine 71-84 butyrylcholinesterase Mus musculus 46-60 12736633-3 2003 pretreatment with antisense oligonucleotides (aODNs) against the alpha subunit of G(q) and G(11) proteins prevented the analgesia induced by physostigmine and oxotremorine. Physostigmine 141-154 serine/threonine kinase 19 Mus musculus 65-96 12736633-5 2003 In mice undergoing treatment with LiCl, which impairs phosphatidylinositol synthesis, or treatment with heparin, an IP(3) receptor antagonist, the antinociception induced by physostigmine and oxotremorine was dose-dependently antagonized. Physostigmine 174-187 inositol 1,4,5-triphosphate receptor 3 Mus musculus 116-130 12785467-0 2003 Growth hormone responses to low-dose physostigmine administration: functional sex differences (sexual diergism) between major depressives and matched controls. Physostigmine 37-50 growth hormone 1 Homo sapiens 0-14 12742187-9 2003 Neostigmine and physostigmine treatment prior to intrarectal dinitrobenzene sulfonic acid significantly attenuated macroscopic damage score, myeloperoxidase activity and smooth muscle thickness on day 5 compared to colitic Sprague-Dawley controls. Physostigmine 16-29 myeloperoxidase Rattus norvegicus 141-156 12742187-10 2003 Significantly greater reductions in myeloperoxidase activity were observed with physostigmine vs. neostigmine pretreatment. Physostigmine 80-93 myeloperoxidase Rattus norvegicus 36-51 12682768-4 2003 Pilocarpine supersensitivity was an indication against a lesion of the sphincter muscle and reduced response to cholinesterase inhibitors (physostigmine) pointed towards a postganglionic lesion. Physostigmine 139-152 butyrylcholinesterase Homo sapiens 112-126 12493626-3 2003 The impairment of learning and memory-related behavior on the 14th day was improved by administration of the cholinesterase inhibitor physostigmine (0.1 mg/kg, i.p. Physostigmine 134-147 butyrylcholinesterase Mus musculus 109-123 12384257-5 2002 These responses were inhibited and enhanced by RVLM application of the muscarinic receptor antagonist scopolamine and the cholinesterase inhibitor physostigmine, respectively. Physostigmine 147-160 butyrylcholinesterase Rattus norvegicus 122-136 12473087-3 2002 The cholinesterase inhibitor physostigmine, or a placebo control, were continuously infused into healthy young volunteers, during differential aversive conditioning whilst brain activity was measured using event-related functional magnetic resonance imaging (fMRI). Physostigmine 29-42 butyrylcholinesterase Homo sapiens 4-18 12431752-2 2002 We previously reported that male rats had significantly greater HPA axis responses to stimulation by physostigmine (PHYSO), an acetylcholinesterase (AChE) inhibitor, compared to females. Physostigmine 101-114 acetylcholinesterase Rattus norvegicus 127-147 12431752-2 2002 We previously reported that male rats had significantly greater HPA axis responses to stimulation by physostigmine (PHYSO), an acetylcholinesterase (AChE) inhibitor, compared to females. Physostigmine 101-114 acetylcholinesterase Rattus norvegicus 149-153 12445575-1 2002 Five inhibitors of acetylcholinesterase, huperzine A, donepezil, tacrine, rivastigmine and physostigmine, were compared with regard to their effects on different molecular forms of acetylcholinesterase in cerebral cortex, hippocampus, and striatum from the rat brain. Physostigmine 91-104 acetylcholinesterase Rattus norvegicus 181-201 12445575-7 2002 In hippocampus, huperzine A and physostigmine were the most potent inhibitors of G4 acetylcholinesterase, while donepezil and tacrine were most potent against G1 acetylcholinesterase. Physostigmine 32-45 acetylcholinesterase Rattus norvegicus 84-104 12438099-11 2002 One possibility is that CGRP(1-6) interacted with nAChRs like an allosteric modulator (e.g., physostigmine). Physostigmine 93-106 calcitonin-related polypeptide alpha Rattus norvegicus 24-28 12438099-12 2002 Coapplication of enhancing concentrations of physostigmine and CGRP(1-6) led to linear summation of the individual effects, while CGRP(1-6) could partly reverse the depression by a large concentration of physostigmine. Physostigmine 204-217 calcitonin-related polypeptide alpha Rattus norvegicus 130-134 12213300-4 2002 We found that microinfusions (10 microg/0.5 microl) of the acetylcholinesterase inhibitor physostigmine in either the dorsal or the ventral hippocampus increased rats" open arm exploration in the plus-maze test, and decreased burying behavior in the shock-probe test. Physostigmine 90-103 acetylcholinesterase Rattus norvegicus 59-79 11814330-4 2002 Addition of the carbamate acetylcholinesterase (AChE) inhibitor physostigmine (20 microM) to the perfusion buffer also decreased ACh release. Physostigmine 64-77 acetylcholinesterase Rattus norvegicus 48-52 12387361-4 2002 Physostigmine and hyoscine inhibited red cell AChE by 18.7 +/- 3.7% and plasma ChE by 44.1 +/- 3.1%. Physostigmine 0-13 acetylcholinesterase Cavia porcellus 46-50 12083745-2 2002 The earliest known ChE inhibitors, namely, physostigmine and tacrine, showed modest improvement in the cognitive function of AD patients. Physostigmine 43-56 butyrylcholinesterase Homo sapiens 19-22 11927192-1 2002 We previously demonstrated that the reversible cholinesterase inhibitor, physostigmine (PHYSO), administered to normal young adult women and men (average age 35 years) at a dose that produced few or no side effects, resulted in a sex difference (sexual diergism) in hypothalamo-pituitary-adrenal cortical (HPA) axis responses: Plasma ACTH(1-39), cortisol, and arginine vasopressin (AVP) concentrations increased to a significantly greater extent in the men than in the women. Physostigmine 73-86 butyrylcholinesterase Homo sapiens 47-61 11927192-1 2002 We previously demonstrated that the reversible cholinesterase inhibitor, physostigmine (PHYSO), administered to normal young adult women and men (average age 35 years) at a dose that produced few or no side effects, resulted in a sex difference (sexual diergism) in hypothalamo-pituitary-adrenal cortical (HPA) axis responses: Plasma ACTH(1-39), cortisol, and arginine vasopressin (AVP) concentrations increased to a significantly greater extent in the men than in the women. Physostigmine 73-86 arginine vasopressin Homo sapiens 369-380 12073883-1 2002 An enzyme inhibition biosensor, developed in our laboratory and previously used for the analysis of compounds with anticholinesterase activity (e.g. physostigmine, neostigmine, pyridostigmine nicotine and organophosphorus compounds) has now been tested for the analysis of another recently synthesized cholinesterase inhibitor, i.e. eptastigmine. Physostigmine 149-162 butyrylcholinesterase Homo sapiens 119-133 11956509-9 2002 In vitro, the activity of acetylcholinesterase was inhibited by 100-micromol/L irinotecan (-24.8%) and markedly reduced by 1-micromol/L physostigmine (-86.7%), whereas neither SN-38 nor camptothecin had an effect. Physostigmine 136-149 acetylcholinesterase (Cartwright blood group) Homo sapiens 26-46 11979423-0 2002 Inhibition of acetylcholinesterase by physostigmine analogs: conformational mobility of cysteine loop due to the steric effect of the alkyl chain. Physostigmine 38-51 acetylcholinesterase (Cartwright blood group) Homo sapiens 14-34 11979423-1 2002 The effect of a series of physostigmine analogs on acetylcholinesterase activity was investigated. Physostigmine 26-39 acetylcholinesterase (Cartwright blood group) Homo sapiens 51-71 11740913-10 2001 The in vitro activity of human erythrocyte acetylcholinesterase was significantly inhibited by irinotecan (-21.5% at 100 microM) or physostigmine (-84.8% at 1 microM), whereas SN-38 or camptothecin had no effect. Physostigmine 132-145 acetylcholinesterase Rattus norvegicus 43-63 11767272-0 2001 Stimulation of minor salivary glands by intraoral treatment with the cholinesterase inhibitor physostigmine in man. Physostigmine 94-107 butyrylcholinesterase Homo sapiens 69-83 11767272-2 2001 The aim of the present investigation was to stimulate the minor salivary glands by the topical application of the cholinesterase inhibitor physostigmine. Physostigmine 139-152 butyrylcholinesterase Homo sapiens 114-128 11711044-3 2001 The cholinesterase inhibitor physostigmine at a dose of 3.2 microg/side and D-cycloserine (1.0 and 10 microg/side), which is a partial agonist acting at the glycine binding site of the NMDA receptor/channel complex, reduced the increase in working memory errors induced by 100 ng/side interleukin-1beta. Physostigmine 29-42 butyrylcholinesterase Rattus norvegicus 4-18 11766895-1 2001 Statistical analysis of EEG spectra averaged over 10-min intervals showed that in rats performing free behavior, peripheral administration of the acetylcholinesterase inhibitor physostigmine induced long-lasting characteristic changes (lasting tens of minutes) in the electrical activity of the dorsal hippocampus (field CAI) and the somatosensory cortex. Physostigmine 177-190 acetylcholinesterase Rattus norvegicus 146-166 11697469-7 2001 This activity was strongly inhibited by physostigmine, a well-known inhibitor of cholinesterase. Physostigmine 40-53 butyrylcholinesterase Homo sapiens 81-95 11701190-13 2001 Pyridostigmine and physostigmine each decreased blood acetylcholinesterase levels by approximately 50%. Physostigmine 19-32 acetylcholinesterase Rattus norvegicus 54-74 11701190-14 2001 Physostigmine also decreased brain cortical acetylcholinesterase levels by approximately 50%, while pyridostigmine had no effect on cortical acetylcholinesterase activity. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 44-64 11509196-11 2001 We also found that infusions of the acetylcholinesterase inhibitor physostigmine (10 microg/microl) into the dorsal hippocampus, like intraseptal muscimol (20 ng/0.4 microl), increased open-arm exploration in the plus-maze test, and decreased burying behavior in the shock-probe test. Physostigmine 67-80 acetylcholinesterase Rattus norvegicus 36-56 11524148-4 2001 Here we show that systemic administration of physostigmine, an acetylcholinesterase inhibitor, lowers Abeta levels in vivo. Physostigmine 45-58 acetylcholinesterase Cavia porcellus 63-83 11673119-7 2001 Physostigmine, a non-organophosphate cholinesterase inhibitor, was less effective than either chlorpyrifos or diazinon, but still caused significant inhibition of DNA synthesis in C6 cells. Physostigmine 0-13 butyrylcholinesterase Rattus norvegicus 37-51 11517282-4 2001 In the current experiments, elevating endogenous levels of acetylcholine in ovariectomized rats by 3 d of continuous administration of physostigmine, an acetylcholinesterase inhibitor, increased NMDA receptor binding in CA1 as measured by quantitative autoradiography. Physostigmine 135-148 acetylcholinesterase Rattus norvegicus 153-173 11517282-4 2001 In the current experiments, elevating endogenous levels of acetylcholine in ovariectomized rats by 3 d of continuous administration of physostigmine, an acetylcholinesterase inhibitor, increased NMDA receptor binding in CA1 as measured by quantitative autoradiography. Physostigmine 135-148 carbonic anhydrase 1 Rattus norvegicus 220-223 11521162-10 2001 Inhibitors of cholinesterase (physostigmine, neostigmine; 3 microM) facilitated the efflux of acetylcholine about sixfold, and a combination of both (+)-tubocurarine (30 microM) and scopolamine (1 microM) halved the enhancing effect. Physostigmine 30-43 butyrylcholinesterase Homo sapiens 14-28 11337201-6 2001 We found that physostigmine but not PBN significantly reversed the cognitive impairment in scopolamine-challenged rats, prevented the induction of c-fos and c-jun mRNAs by SKF-82958 and attenuated the augmentation of the SKF-82958-induced expression of these genes by scopolamine. Physostigmine 14-27 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 147-152 11408037-2 2001 In contrast, a response was hardly observed in tissues with an intact epithelial layer (674+/-81 mg), which was due to both the synthesis of nitric oxide and the activity of acetylcholinesterase, since the contractions to acetylcholine were significantly enhanced after preincubation with N(omega)-nitro-L-arginine methyl ester (L-NAME) or physostigmine (1374+/-65 and 1120+/-65 mg, respectively). Physostigmine 340-353 acetylcholinesterase Cavia porcellus 174-194 11330337-8 2001 Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent. Physostigmine 99-112 acetylcholinesterase Rattus norvegicus 51-71 11360433-12 2001 Huperzine appears as a selective inhibitor of red cell acetylcholinesterase activity while pyridostigmine or physostigmine additionally inhibit plasmatic butyrylcholinesterase. Physostigmine 109-122 cholinesterase Cavia porcellus 154-175 11325406-3 2001 Oxotremorine, a muscarinic receptor agonist, at the dose of 0.1 mg/kg ip, and physostigmine, a cholinesterase inhibitor, at the dose of 0.1 mg/kg ip, significantly antagonized morphine (10 mg/kg sc)-induced memory impairment in mice. Physostigmine 78-91 butyrylcholinesterase Mus musculus 95-109 11176277-1 2001 [11C]physostigmine, an acetylcholinesterase inhibitor, has been shown to be a promising positron emission tomography ligand to quantify the cerebral concentration of the enzyme in animals and humans in vivo. Physostigmine 5-18 acetylcholinesterase (Cartwright blood group) Homo sapiens 23-43 11893059-2 2001 The earliest known AChE inhibitors, namely, physostigmine and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability). Physostigmine 44-57 acetylcholinesterase (Cartwright blood group) Homo sapiens 19-23 11405996-2 2001 Physostigmine is an AChE inhibitor originally extracted from calabar beans. Physostigmine 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 20-24 11405996-20 2001 The best dose physostigmine (mean 25mg/day) was associated with a 1.75 point improvement on ADAS-Cog score (mean difference -1.75, 95% confidence interval -2.90, -0.60 on an intention-to-treat basis) and a 0.26 point improvement on the CGIC score (treated as a continuous scale) (mean difference -0.26, 95% confidence interval 0.06, 0.46 on an intention-to-treat basis) compared with placebo at 6 weeks. Physostigmine 14-27 alkylglycerone phosphate synthase Homo sapiens 92-96 11405996-22 2001 The best dose physostigmine (mean 27mg/day) was associated with a 2.0 point improvement on ADAS-Cog score (mean difference -2.02, 95% confidence interval -3.59, -0.45 on an intention to treat basis) compared with placebo at 12 weeks. Physostigmine 14-27 alkylglycerone phosphate synthase Homo sapiens 91-95 11514953-4 2000 The purpose of this study is to explain the protective effects of physostigmine against paraoxon toxicity by suppressing CYP3A, and hence, decreasing formation of a toxic metabolite, paraoxon. Physostigmine 66-79 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 121-126 11514953-8 2000 The above data suggested that the formation of paraoxon was inhibited in rats pretreated with physostigmine by inhibiting CYP3A. Physostigmine 94-107 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 122-127 11113581-6 2000 Microinjection of the muscarinic receptor antagonist scopolamine and the cholinesterase inhibitor physostigmine into the RVLM inhibited and potentiated, respectively, the pressor response induced by PVN stimulation. Physostigmine 98-111 butyrylcholinesterase Rattus norvegicus 73-87 10814550-1 2000 We investigated the relative contribution of several cardiorespiratory components to acute lethality produced by N-methylcarbamate cholinesterase (ChE) inhibitors physostigmine, 2-sec-butylphenyl methylcarbamate (BPMC), and 2-isopropoxyphenyl methylcarbamate (PHC) in halothane-anesthetized rabbits. Physostigmine 163-176 cholinesterase Oryctolagus cuniculus 147-150 11190098-1 2000 Statistical analysis of EEG spectra averaged over 10-min periods showed that inhibitor of acetylcholinesterase physostigmine induced the long-term (tens of minutes) characteristic changes in the electric activity of the dorsal hippocampus (CA1 field) and somatosensory cortex of unrestrained rats. Physostigmine 111-124 carbonic anhydrase 1 Rattus norvegicus 240-243 11256231-2 2000 The carbamate derivatives physostigmine and rivastigmine needed preincubation to exhibit appropriate anti-ChE activity. Physostigmine 26-39 butyrylcholinesterase Homo sapiens 106-109 11256231-3 2000 The maximum ChE inhibition by physostigmine developed within 30-60 min, while the inhibitory effect of rivastigmine on AChE and BuChE activities reached its peak after 48 and 6 h, respectively. Physostigmine 30-43 butyrylcholinesterase Homo sapiens 12-15 11256231-4 2000 The order of inhibitory potency (IC50) towards AChE activity under optimal assay conditions for each ChE inhibitor was: physostigmine (0.67 nM) > rivastigmine (4.3 nM) > donepezil (6.7 nM) > TAK-147 (12 nM) > tacrine (77 nM) > ipidacrine (270 nM). Physostigmine 120-133 acetylcholinesterase (Cartwright blood group) Homo sapiens 47-51 11256231-4 2000 The order of inhibitory potency (IC50) towards AChE activity under optimal assay conditions for each ChE inhibitor was: physostigmine (0.67 nM) > rivastigmine (4.3 nM) > donepezil (6.7 nM) > TAK-147 (12 nM) > tacrine (77 nM) > ipidacrine (270 nM). Physostigmine 120-133 butyrylcholinesterase Homo sapiens 48-51 10976649-3 2000 After physostigmine, acetylcholinesterase inhibition averaged 52% in normal cerebral cortex. Physostigmine 6-19 acetylcholinesterase (Cartwright blood group) Homo sapiens 21-41 11040261-2 2000 This experiment determined whether hippocampal or entorhinal infusions of the acetylcholinesterase inhibitor physostigmine would reverse such impairing effects on spontaneous alternation performance, a measure of spatial working memory. Physostigmine 109-122 acetylcholinesterase Rattus norvegicus 78-98 10822160-8 2000 Furthermore, physostigmine treatment from 14th day after the start of TD diet reversed SST fluorescence intensity to the control level by the 25th day. Physostigmine 13-26 somatostatin Rattus norvegicus 87-90 10814550-7 2000 A degree of acute lethality to physostigmine and PHC depended on their anti-ChE activity, whereas BPMC exhibited a low degree of lethality relative to its anti-ChE activity. Physostigmine 31-44 cholinesterase Oryctolagus cuniculus 76-79 10841434-6 2000 The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid. Physostigmine 145-158 butyrylcholinesterase Rattus norvegicus 162-176 10841434-6 2000 The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid. Physostigmine 145-158 butyrylcholinesterase Rattus norvegicus 178-181 10822901-0 2000 Effect of aging on the arginine-vasopressin response to physostigmine and angiotensin II in normal men. Physostigmine 56-69 arginine vasopressin Homo sapiens 32-43 10822901-2 2000 Both drugs induced significant increments in plasma AVP levels in the youngest group, with mean peak levels 4.8 times higher than baseline at 20 minutes after the beginning of physostigmine infusion and 1.5 times higher than baseline at 60 minutes after the beginning of ANG II infusion. Physostigmine 176-189 arginine vasopressin Homo sapiens 52-55 10822901-5 2000 However, the AVP increases induced by physostigmine (mean peak was 9 times higher than baseline) and ANG II (mean peak was 2.2 times higher than baseline) were significantly higher in the oldest group than in the other groups. Physostigmine 38-51 arginine vasopressin Homo sapiens 13-16 10840182-1 2000 The acetylcholinesterase (AChE) inhibitors physostigmine (PHY), tacrine (THA), and heptylphysostigmine (HEP) have been evaluated as potential therapeutics for treatment of Alzheimer"s disease (AD) and as prophylactics against organophosphate (OP) poisoning. Physostigmine 43-56 acetylcholinesterase Rattus norvegicus 4-24 10840182-1 2000 The acetylcholinesterase (AChE) inhibitors physostigmine (PHY), tacrine (THA), and heptylphysostigmine (HEP) have been evaluated as potential therapeutics for treatment of Alzheimer"s disease (AD) and as prophylactics against organophosphate (OP) poisoning. Physostigmine 43-56 acetylcholinesterase Rattus norvegicus 26-30 10840182-1 2000 The acetylcholinesterase (AChE) inhibitors physostigmine (PHY), tacrine (THA), and heptylphysostigmine (HEP) have been evaluated as potential therapeutics for treatment of Alzheimer"s disease (AD) and as prophylactics against organophosphate (OP) poisoning. Physostigmine 58-61 acetylcholinesterase Rattus norvegicus 4-24 10799340-6 2000 Because of the significant implication of these findings, we tested brain cholinesterase (ChE) inhibition following the administration of pyridostigmine, or the tertiary carbamate physostigmine, with or without stress in mice. Physostigmine 180-193 butyrylcholinesterase Mus musculus 74-88 10799340-6 2000 Because of the significant implication of these findings, we tested brain cholinesterase (ChE) inhibition following the administration of pyridostigmine, or the tertiary carbamate physostigmine, with or without stress in mice. Physostigmine 180-193 butyrylcholinesterase Mus musculus 90-93 10799340-9 2000 At the same time, physostigmine induced the expected decrease in brain ChE in all the experiments. Physostigmine 18-31 butyrylcholinesterase Mus musculus 71-74 10768195-1 2000 A concise synthetic route to physostigmine has been developed, where the key step relies on the alkylative cyclization of 1,3-dimethylindole with (Z)-aziridine catalyzed by Sc(OTf)3 and TMSCI in dichloromethane at -30 degrees C, to give 8 in 90% yield, which, in turn, can be readily converted into physostigmine. Physostigmine 29-42 POU class 5 homeobox 1 Homo sapiens 173-181 10780968-6 2000 and the cholinesterase inhibitor physostigmine (0.2 mg kg(-1) s.c.) was observed 24 h after the last i.c.v. Physostigmine 33-46 butyrylcholinesterase Mus musculus 8-22 10637365-3 2000 These data are summarised from nearly all therapeutically important chemical classes of reversible AChE inhibitors, e.g., derivatives of physostigmine, tacrine, donepezil and huperzine A. Interactions observed from X-ray crystallography between these inhibitors and AChE have also been incorporated and compared with modelling and QSAR results. Physostigmine 137-150 acetylcholinesterase (Cartwright blood group) Homo sapiens 99-103 10637367-3 2000 The earliest known AChE inhibitors, namely, physostigmine and tacrine, showed modest improvement in the cognitive function of Alzheimer"s patients. Physostigmine 44-57 acetylcholinesterase (Cartwright blood group) Homo sapiens 19-23 10718513-1 2000 Previously, we have shown that physostigmine, an acetylcholinesterase inhibitor, improved performance on a working memory for faces task, as reflected by reduced reaction time (RT), and reduced task-specific regional cerebral blood flow (rCBF) in right prefrontal cortex and, further, that these reductions in RT and right frontal rCBF were significantly correlated. Physostigmine 31-44 acetylcholinesterase (Cartwright blood group) Homo sapiens 49-69 10718513-1 2000 Previously, we have shown that physostigmine, an acetylcholinesterase inhibitor, improved performance on a working memory for faces task, as reflected by reduced reaction time (RT), and reduced task-specific regional cerebral blood flow (rCBF) in right prefrontal cortex and, further, that these reductions in RT and right frontal rCBF were significantly correlated. Physostigmine 31-44 CCAAT/enhancer binding protein zeta Rattus norvegicus 238-242 10718513-1 2000 Previously, we have shown that physostigmine, an acetylcholinesterase inhibitor, improved performance on a working memory for faces task, as reflected by reduced reaction time (RT), and reduced task-specific regional cerebral blood flow (rCBF) in right prefrontal cortex and, further, that these reductions in RT and right frontal rCBF were significantly correlated. Physostigmine 31-44 CCAAT/enhancer binding protein zeta Rattus norvegicus 331-335 10718513-2 2000 Here we investigated the relation between the effects of physostigmine on task performance and task-specific functional brain response throughout the cortex by examining correlations between physostigmine-related changes in rCBF in all brain areas and changes in RT. Physostigmine 191-204 CCAAT/enhancer binding protein zeta Rattus norvegicus 224-228 10718513-3 2000 In subjects who received an infusion of physostigmine, reduced RT correlated (p<0.001) positively with reduced rCBF in right frontal cortex, left temporal cortex, anterior cingulate, and left hippocampus; and correlated with increased rCBF in medial occipital visual cortex. Physostigmine 40-53 CCAAT/enhancer binding protein zeta Rattus norvegicus 114-118 10718513-3 2000 In subjects who received an infusion of physostigmine, reduced RT correlated (p<0.001) positively with reduced rCBF in right frontal cortex, left temporal cortex, anterior cingulate, and left hippocampus; and correlated with increased rCBF in medial occipital visual cortex. Physostigmine 40-53 CCAAT/enhancer binding protein zeta Rattus norvegicus 238-242 10698015-5 2000 Rivastigmine (0.75 and 1.5 mg/kg) and physostigmine (0.05 mg/kg) caused significantly greater ChE inhibition in females than in males (P<0.01) in the cerebral cortex, hippocampus and striatum, but not in the periphery 30 and 60 min after injection. Physostigmine 38-51 butyrylcholinesterase Rattus norvegicus 94-97 10954048-3 2000 The cholinesterase inhibitor physostigmine ( 1.0 and 3.2 microg/side) and D-cycloserine (0.32 and 1.0 microg/side), the partial agonist at the glycine binding site on the NMDA receptor/channel complex, reduced the increase in working memory errors induced by intrahippocampal 32 microg/side pyrilamine. Physostigmine 29-42 butyrylcholinesterase Rattus norvegicus 4-18 10643873-3 1999 To test the hypothesis of increased cholinergic sensitivity in major depression, physostigmine (PHYSO), a reversible cholinesterase inhibitor, was administered to patients and control subjects at a dose that elevated plasma ACTH, cortisol, and AVP concentrations but produced few or no side effects. Physostigmine 81-94 butyrylcholinesterase Homo sapiens 117-131 11249555-4 1999 It is structurally dissimilar from other established cholinesterase inhibitors, namely THA (an acridine compound) and the carbamates, physostigmine and rivastigmine and has a pharmacokinetic and tolerability profile distinct from these agents. Physostigmine 134-147 butyrylcholinesterase Homo sapiens 53-67 11139819-4 1999 Early acetylcholinesterase inhibitors, such as tacrine and physostigmine, are poorly tolerated and have a short duration of action. Physostigmine 59-72 acetylcholinesterase (Cartwright blood group) Homo sapiens 6-26